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 1 The immune system
The immune system protects the human body from disease. To accomplish this, many cell 
types are involved with different functions and tasks. When bacteria or viruses enter the 
body, the innate immune system first comes into play. 1 This system is non-specific, and 
provides an immediate inflammatory response which is characterized by redness, swell-
ing, pain, heat and dysfunction. Once the innate immune system is activated, cells produce 
several cytokines and chemokines. In response to these secreted factors, other immune 
cells are recruited to the site of inflammation. The innate immune system then activates 
the adaptive immune system, consisting of highly specialized cells, B cells and T cells. 2 
In the absence of antigen, T cells and B cells are naïve. They are activated by the innate 
immune system, when an antigen presenting cell (APC) presents an antigen to the B or T 
cell. Some of these activated B and T cells will become memory cells which provide long-
term immune memory as these cells are able to respond to antigens without the help of the 
innate immune system. This will result in a more rapid and efficient response when the 
immune system encounters an antigen which has been recognized before. 
 1.1  The innate immune system
APCs are the key players of the innate immune system: they sense and process antigens, 
produce cytokines in response to pathogens, and activate the adaptive immune system. 
APCs express several pattern recognition receptor (Prr) molecules to sense pathogens in 
the environment. Two important types of Prrs are membrane-associated toll-like recep-
tors (TLr) and cytosolic nucleotide-binding oligomerization domain (NOD proteins). The 
TLr family includes a family of 10 studied TLrs which all have different specificities for 
various pathogens. When lipopolyssaccharide (LPS, a cell component of Gram-negative 
bacteria and responsible for septic shock) binds to TLr4, the cell starts to produce sev-
eral pro-inflammatory cytokines, among which tumor necrosis factor alpha (TNFα) and 
interleukin-1β (IL-1β). 3 Next, other cells are recruited to the site of inflammation and an 
immune reaction is initiated. NOD2 is located intracellular and recognizes molecules that 
contain muramyl dipeptide (MDP), which is present in several bacteria. 4
Dendritic cells (DCs) are the most specialized APC and are usually one of the first cells that 
come into action once a bacterium or virus enters the body. When a DC senses a pathogen 
by ligation of a Prr, it phagocytoses (“eats”) the potential harmful foreigner, processes it 
inside the cell, and presents pieces of the protein on the cell membrane loaded on MHCII 
molecules. 5, 6 After ligation of Prrs, co-stimulatory molecules like CD80, CD83 and CD86 
are upregulated. The antigen presented on the MHCII molecule is then recognized by the 
T cells receptor complex (TCr) on the T cell, and this provides the first signal to initiate an 
immune response. 7 To achieve a full immune response, additional stimulation is often 
needed; the interaction of costimulatory molecules on DCs and T cells and the presence 
of various cytokines provide the second signal and finally determine the outcome of the 
immune response. 8, 9 
Like DCs, macrophages (Mφ) are part of the innate immune system, derive from monocytes 
and function as APCs. They are present in many tissues and contribute to tissue homeo-
stasis. 10, 11 Mφ are a heterogenous population of cells and have different functions depend-
ing on their differentiation status and the type of cytokines present in their environment. 
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12-14 Type 1 macrophages are typically induced in the presence of LPS or pro-inflammatory 
cytokines. In this setting, Mφ are primed to become effector cells that are highly efficient 
in killing intracellular bacteria and in the production of pro-inflammatory cytokines.  15 In 
contrast to Mφ1, type 2 macrophages (Mφ2, regulatory macrophage or alternatively acti-
vated macrophage) have a more anti-inflammatory phenotype. They are induced by Th2 
cytokines, glucocorticoids or immune complexes. Mφ2 have several characteristics that are 
functionally different from Mφ1: they are able to dampen immune responses by inhibiting T 
cell proliferation, production of anti-inflammatory cytokines and they contribute to wound 
healing. 16-18 In addition, Mφ2 inhibit Th1 responses by skewing the immune response 
towards a Th2 response. 
Figure 1 Innate and adaptive immunity.
nity
APC antigen presenting cell; IL interleukin; PRR pathogen recognition receptor
 1.2  The adaptive immune system
The adaptive immune system consists of lymphocytes, i.e. B cells and T cells. B cells are 
involved in the production of Immunoglobulins (Ig, i.e. antibodies), whereas T cells dif-
ferentiate into helper T cells that further support the ongoing immune response.  After an 
APC has presented an antigen to the T cell, the T cell starts to proliferate, and differentiates 
into one of the known helper T cell lineages: Th1, Th2 or the more recently described Th3 
19 and Th17 (Figure 1). 20, 21 The direction of differentiation is determined by  the inflam-
matory environment and the presence of other factors, like cytokines. A Th1 response is 
characterized by the production of interferon-γ (IFNγ), TNFα and interleukin-2 (IL-2). 
C
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These cytokines stimulate T cell proliferation and activate macrophages. The activated 
ma crophages produce cytokines that further promote Th1 differentiation of T cells. Dur-
ing a Th2 response, IL-4, IL-10 and IL-13 are typically produced, which activate B cells to 
produce immunoglobulines (Ig) and inhibit Th1 responses. Cytokines produced by Th2 
effector cells further augment the differentiation signal towards a Th2 response, thereby 
maintaining the Th2 response. When the cells differentiate into the Th3 lineage, the T cells 
start to produce large amounts of transforming growth factor bèta (TGFβ), a factor which 
is known to be involved in tolerance and for the differentiation of regulatory T cells (Tregs). 
22 Tregs are cells with anti-inflammatory properties; they inhibit activation of the immune 
system and thereby maintain immune homeostasis. 23 A Th17 response is characterized by 
the massive production of interleukin-17 by T cells, which is induced by IL-23, or IL-6 in 
combination with TGFβ. 24, 25 IL-17 induces and promotes pro-inflammatory responses, 26 
and triggers the production of pro-inflammatory cytokines like TNFα and IL-1β. Th1, Th2, 
Th3 and Th17 effector T cells all express CD4 on their membrane, making them CD4+ T 
cells. Another subset of T cells, CD8+ cells, plays an important role in the recognition and 
elimination of intracellular pathogens. 27 CD8+ T cells recognize antigens presented by 
MHCI molecules, and are able to kill infected cells by secreting perforin and enzymes. 28 
Figure 2 The immunological synape.
C
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 1.3 The immunological synapse 
As mentioned before, cytokines present in the inflammatory environment and the inter-
action between the APC and the T cell together determine the outcome of the immune 
response. The immunological synapse (IS) is the initial site of interaction between the DC 
and the T cell. 29, 30 
It is a highly organized structure, with the MHCII-TCr complex in the center, and the co-
stimulatory molecules in the periphery (Figure 2). Importantly, a mature synapse is formed 
only upon recognition of a foreign antigen. When this is the case and an immunological 
synapse is formed, the actin skeleton polarizes towards the synapse. 31 A proper formation 
of the IS is important for an efficient T cell response, as destabilization of the IS has been 
reported to result in decreased T cell signaling. 32 As a consequence, formation of the IS 
plays a crucial role in the activation of T cells, and thereby the outcome of the immune 
response.
 1.4 The immune system and tolerance in the gastrointestinal tract 
The immune system in the gastrointestinal tract has several unique features. In the gut, an 
enormous amount of microorganisms (more than 500 different bacteria species) 33 is pre-
sent that constitutes the gut flora (commensals), and intestinal APCs are constantly exposed 
to these microorganisms and food antigens. An immunologic response to the gut flora or 
other harmless antigens like food antigens would result in the recruitment of immune cells, 
production of cytokines, and consequently in inflammation, tissue damage and dysfunc-
tion. Therefore it is very important that intestinal APCs do not respond to these antigens, a 
process called tolerance. 34 The physical barrier separating the commensals from the under-
lying tissues consists of a single cell layer of epithelial cells and is the first line of defense. 
The presence of a mucus layer, antibacterial molecules (defensins) and IgA further helps to 
protect the invasion of antigens. 35 Since APC are then the first cells to respond to an anti-
gen, Mφ and DCs are the key players of innate immunity and tolerance. 36 To this end, intes-
tinal Mφ lack several innate response receptors, do not produce pro-inflammatory cytokines 
in response to various inflammatory signals, 37 and produce large amounts of IL-10 but no 
IL-12 and IL-23, 38 giving them an Mφ2-like appearance. 39 Loss of tolerance would lead to an 
immune reaction, and subsequently result in autoimmunity. In the absence of inflamma-
tion but in the presence of commensals, a close balance between effector T cells (i.e. Th1, 
Th2 or Th17 T cells) and regulatory T cells is maintained by a complex network of cytokines. 
 2 Inflammatory Bowel Diseases
 2.1  Epidemiology, symptoms and diagnosis
Inflammatory bowel disease (IBD) refers to a chronic inflammation affecting the gastro-
intestinal tract. The highest incidence rates for both Crohn’s disease (CD) and ulcerative 
colitis (UC) are reported in the western world. 40-42 However, the incidence in other parts of 
the world is increasing. In Europe and the US, incidence rates range from 1.5 to 20.3 per 
100.000 person-years for UC, and from 0.7 to 14.6 for CD. The observation that IBD inci-
dence is low in developing countries, suggests that environmental factors and diet play an 
important role in the pathogenesis. 
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Crohn’s disease (CD) is characterized by deep ulcerations that can occur in the entire gas-
trointestinal tract, i.e. from the mouth to the anus. 43, 44 The disease may affect only one area 
in the gut, or several areas with healthy areas in between, so called “skip lesions”. An early 
feature of CD is apthoid ulceration, followed by deep ulcers and fissures in the mucosa at a 
later stage, which makes up the typical cobblestone pattern. Fistulae and abscesses are often 
present in a later stage. The inflammation is transmural (affecting all layers of the bowel), 
and lymphoid hyperplasia, an increase in inflammatory cells and granulomatous lesions 
are often observed. 
Ulcerative colitis (UC) on the other hand, only affects the colon. 43, 44  It can affect the rectum 
alone (proctitis), it may involve the sigmoid and descending colon (left-sided colitis), or it 
may involve the whole colon. Typically, the mucosa has a red appearance, bloods easily and 
is inflamed. The inflammation is restricted to the mucosa, and crypt abscesses and goblet 
cell depletion are common features. 
Typically, a patient presents with abdominal pain, bloody stools, diarrhea and weight loss. 
Some patients may also have complaints of malaise, fever, nausea and vomiting. Also, CD 
can be complicated by anal or perianal disease. 
The diagnosis IBD can usually be made based on clinical, radiographic and histologic data. 
45 The distinct patterns of the two diseases often enable the final diagnosis and differen-
tiation between UC and CD on histologic basis. However, this is not always possible, and 
sometimes the diagnosis interderminate inflammatory colitis is made. In both UC and CD, 
anemia is common, and erythrocyte sedimentation rate (ESr) is often raised. CrP has been 
described as a sensitive marker for CD; elevated CrP levels are detectable in 70 – 100% of 
the CD patients. On the other hand, only 50 – 60% of UC patients have an elevated CrP at 
diagnosis. 46, 47
 2.2  Pathogenesis of IBD
CD and UC are diseases of unknown etiology. The fact that higher incidence rates are 
reported in the Western world compared to developing countries, suggests that environ-
mental factors and nutrition may play a role. However, different incidence rates might 
also result from differences in access to health care and thus lower incidence rates may be 
reported in developing countries. Next to environmental factors, genetic factors and defects 
in innate and adaptive immunity may contribute to inflammatory bowel diseases.  
2.2.1 Genetics 
IBD has a strong genetic component, since a positive family history for the disease is the 
largest independent risk factor. It has been reported that 2.2 – 16.2% of the CD patients 
have a first-degree relative with CD, and in 5.2 – 22% with IBD. For UC, this is 5.7 – 15.5% 
and 6.6 – 15.8% respectively. 48 Moreover, two studies performed in twins show a pooled 
estimated concordance in monozygotic twins of 37.3% for CD, and 10% for UC; 49, 50 pooled 
concordance in dizygotic twins shows 7% for CD and 3% for UC. This suggests that CD 
might have a stronger genetic component than UC. 
However, the disease does not simply result from a single gene defect. Many studies inves-
tigating the contribution of genes have been performed, and several genes that are relevant 
in innate and adaptive immunity have been suggested to be involved in the pathogenesis 
of IBD. First, the involvement of the CARD15/NOD2 gene in CD has been shown and con-
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firmed in several studies. 51-53 Since CArD15/NOD2 is a known Prr, mutations in this gene 
might result in altered sensing of bacterial products. Indeed, several mechanisms linking 
NOD2 dysfunction to CD pathogenesis have been reported, among which enhanced pro-
duction of IL-1β, 54 abnormalities in TLr2 mediated inflammation in intestinal mφ 55 and 
altered NOD2 dependent expression of microbicidal α-defensins. 56, 57 Importantly, NOD2 
knockout mice do not spontaneously develop colitis, indicating that defects in NOD2 only 
are not sufficient to induce inflammation. 58 
SNPs (single nucleotide polymorphisms) in the tumor necrosis factor superfamily 15 
(TNFSF15) gene have also been reported in the pathogenesis of IBD. 59, 60 Briefly, TNFSF15 
is a strong inducer of IFNγ production in T cells and is upregulated in CD4+/CD8+ T cells 
and macrophages in the lamina propria of CD patients. 59, 61 Also, a role for SNPs in the 
IL-23 receptor has been verified in several studies. 62-64 IL-23, together with IL-6 and TGFβ, 
drives the differentiation of naïve T cells towards a Th17 response, thereby initiating an 
immune response. In addition, other genes in the IL-23 pathway have been implicated in 
the pathogenesis of IBD, including IL-12B (encodes the p40 subunit of IL23 and IL12) and 
signals transducer and activator of transcription 3 (STAT3), further suggesting a prominent 
role for this pathway.  65-67
Many other genes have been identified that may play a role in IBD pathogenesis, but a full 
overview of these genetic defects is beyond the scope of this chapter. 
2.2.2 Defects in the immune system in inflammatory bowel diseases
The underlying defect possibly lies in the loss of tolerance towards the mucosal flora, and 
several defects in innate and adaptive immunity have been reported that may play a role in 
the development of IBD.
It has been shown that lamina propria mononuclear cells (LPMNCs) from UC and CD 
patients spontaneously produce large amounts of pro-inflammatory cytokines, thereby trig-
gering an immune response. 68-70 In a mouse model of colitis, increased responsiveness to 
bacterial stimuli has been reported, 71 resulting in aberrant immunity. This suggests that 
Mφ from IBD patients display a more Mφ1 phenotype, while the ability of intestinal Mφ 
to secrete pro-inflammatory cytokines is normally (and preferably) low compared to Mφ1. 
Indeed, lower amounts of Mφ2 were found in mucosal biopsies from active lesions in CD 
patients compared to non-affected colon of the same patient, and compared to healthy con-
trols. 72 In addition, DCs from both UC and CD patients show higher expression of TLr2 
and TLr4 compared to healthy individuals, 73 making them hyperresponsive to bacterial 
antigens. Colonic macrophages from IBD patients have increased expression of the co-stim-
ulatory molecules CD80 and CD86 74 resulting in an increased ability to activate T cells. As 
a consequence of these defects, a Th1 or possibly Th17 response is induced. 
Leaks in the epithelial barrier, which is the first line of defense, also have been reported in 
IBD patients. 75 As a result, pathogens cross the epithelial layer more easily. Interestingly, 
this defect seems to precede the development of CD in individuals with familial risk, 76 sug-
gesting a causal role for this defect. In addition, overgrowth of mucosa-associated Escheria 
coli has been observed in CD patients; adherent-invasive E. coli (AIEC) are found in 36.4% 
of the CD patients with ileal involvement. Although E. coli is considered a commensal, 
some strains acquire virulence factors. AIEC bind to the CEACAM6 receptor, which is over-
expressed in ileal mucosa of CD patients, leading to abnormal colonization. 77 Next, they 
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invade the intestinal barrier, infect and replicate within mucosal macrophages 78 and induce 
production of TNFα. 
Furthermore, defects in the T cell compartment might contribute to the induction and per-
sistence of IBD. It has been shown that IBD patients have increased numbers of activated 
T cells in the circulation, and that activated T cells from CD patients are more resistant to 
apoptosis, 79 a mechanism involved in programmed cell death which takes place after T cell 
activation and thereby contributes to homeostasis. As a result, the balance between effector 
T cells and regulatory T cells is disturbed in IBD patients, followed by uncontrolled inflam-
mation.    
2.2.3 Autophagy
Another interesting but rather unexpected discovery is the contribution of the autophagy-
related 16-like 1 (ATG16L1) and immunity-related GTPase family M (IrGM) genes to CD patho-
genesis, 80-82 two genes that are known to be involved in a process called autophagy (referring 
to the Greek work “autophagos”, i.e. “self-eating”). Autophagy was originally described as a 
cell survival mechanism. When a cell experiences nutrient depletion, autophagy is induced 
in order to remove damaged organelles. 83 Upon induction of autophagy, a membrane is 
formed, creating an autophagosome which surrounds the cellular contents and next fuses 
with lysosomes. 84  More recently, it became clear that autophagy also plays a crucial role 
in the clearance of intracellular bacteria, 85 and in the delivery of cytoplasmic antigens to 
MHCII molecules for antigen presentation to T cells. 86 In an experimental ATG16L1 knock-
down system, cells showed defective autophagy in response to nutrient depletion and infec-
tion, demonstrating the importance of ATG16L1 in the autophagy process. 87 Since ATG16L1 
and IrGM have been confirmed in several Genome Wide Association Studies (GWAS), and 
given the role of autophagy in general and in immunity, it is likely that autophagy plays an 
important role in the development of CD. Several mechanisms have been suggested that 
link defective autophagy to CD. In a DSS colitis model, mice lacking ATG16L1 in hemato-
poetic cells showed increased production of the pro-inflammatory cytokine IL-1β. 88 Further-
more, abnormalities in paneth cells (cells specialized in the secretion of granule contents 
that contain antimicrobial contents) have been reported in ATG16L1 knockout mice and in 
CD patients carrying the risk allele.  89 
In summary, environmental, genetic and immunologic defects all contribute to the devel-
opment of IBD. Likely, the presence of a combination of these factors leads to a loss of 
response towards the mucosal flora, resulting in inflammation in the gut. 
 3 Treatment
The main treatment goals in IBD are improving quality of life, reducing hospitalization, 
surgery and steroid dependency, improving mucosal healing and maintaining clinical 
remission to control the disease while minimizing side effects. Mucosal healing can lead 
to significantly higher steroid-free remission rates and less relapses, 90 and is therefore an 
important goal to achieve in the treatment of CD patients. Induction therapy is concentrated 
on quickly reducing signs and symptoms of acute inflammation. However, the underlying 
disease cause remains unchanged and therefore maintenance therapy is often needed to 
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prevent relapses. relapsing disease frequently leads to surgical interventions and hospi-
talization and for that reason maintaining remission is of great importance. response to 
treatment is defined as a decrease in Crohn’s Disease Activity Index (CDAI) of 70 points 
(70-points response) or 100 (100-points-response) after four weeks from baseline in 
non-fistulizing disease. Here, response is defined as a decrease of 70 points unless stated 
otherwise. In fistulizing disease, response is achieved when a decrease of at least 50% in 
the number of draining fistulas after ten weeks is observed. remission is defined as a CDAI 
score below 150. 91, 92.
The final goal is to understand the course of disease and to finally alter the course towards 
a less aggressive phenotype. Several therapeutics are available with different effects, side 
effects and efficacy profiles to achieve the above described goals. 
 3.1  5-ASA
5-Aminosalicylic acid (5-ASA, mesalazine), a derivate of salicylic acid, is a non-steroidal anti-
inflammatory drug (NSAID). 
Whereas induction with 5-ASA therapy for patients with mild-to-moderate CD seems effec-
tive, 93 it is known that this agent is not effective in inducing remission. 94 In addition, 
patients with ileal disease do not benefit from 5-ASA and side effects occur in about one-
third of the patients. 95  The clinical significance of the CDAI reduction obtained with 5-ASA 
is controversial, and therefore, 5-ASA has limited value in severe disease and in mainte-
nance in CD patients. 
On the other hand, 5-ASA is important in the treatment of UC; the efficacy of 5-ASA in 
severe UC has been shown in several systematic reviews and meta-analyses. 96, 97
 3.2  Steroids
Glucocorticoids are steroid hormones that bind to the glucocorticoid receptor and activate 
or suppress certain target genes. This then results in decreased production of pro-inflam-
matory cytokines and inhibition of T cell proliferation. 98, 99 
Although budesonide is more effective than placebo in inducing remission in acute active 
CD, 100 it is not effective in maintaining remission. 101 Also, systemic corticosteroids are very 
effective in inducing remission in the first place, 102 but do not induce long-term remission, 
103, 104 mucosal healing 105 and do not reduce the risk for surgery. 106 
Similar to CD, corticosteroids are effective in the induction of remission, 107 and are impor-
tant in acute severe UC, 108 but are not useful in maintenance therapy. 109 Furthermore, 
corticosteroids are known to have serious side effects like diabetes mellitus, 110 osteoporosis, 
depression, hypertension, and as a result these agents are associated with increased morbid-
ity and mortality. Therefore, long-term corticosteroid use is discouraged. 
 3.3  Thiopurines
Azahioprine (AZA) and 6-mercaptopurine (6-MP) have been widely used in the treatment 
of IBD. AZA is a pro-drug which is converted to 6-MP, which is then metabolized to 6-thio-
guanine (6-TG). This acts as a DNA synthesis inhibitor, and thereby inhibits proliferation 
of cells, especially lymphocytes. In addition, it has been shown that azathioprine inhibits T 
cell proliferation by inhibiting APC-T cell conjugation 111  and it induces apoptosis in T cells 
by modulating rac1 function. 112 
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Thiopurines play an important role in controlling CD and have long term efficacy, 113, 114 but 
more than half of the patients still depend on corticosteroids. In UC, azathioprine is effec-
tive in inducing clinical and endoscopic remission, and is a drug of first choice in patients 
who are steroid dependent. 115 For maintenance therapy, the evidence for thiopurine in UC 
is weaker than in CD. 
Unfortunately, thiopurine therapy has been associated with myelotoxicity, hepatotoxicity 116 
and lymphoma. 117 
 3.4  Anti-TNF: structure and mechanism of action
Elevated levels of TNFα are detectable in serum and the intestine of IBD patients, 118, 119 and 
therefore, blocking this cytokine would potentially alleviate the disease. The introduction of 
anti-TNF agents during the late ‘90s has proven to be an effective instrument to achieve the 
above described treatment goals. Anti-TNF agents induce mucosal healing, reduce steroid 
dependency, reduce the risk for surgery and hospitalization and improve the patient’s qual-
ity of life. 91, 120, 121 In addition, healing of endoscopic lesions 121, 122 and reduction of chronic 
inflammatory infiltrates 122, 123 was achieved. 
Figure 3 Different anti-TNF agents.
Anti-TNF agents are designed to neutralize soluble TNF-α, 124  an essential Th
1
 cytokine 
produced by monocytes and T cells. 125 Several anti-TNF agents are available nowadays, and 
all of them have different structures and properties (Figure 3). Infliximab (remicade®), is a 
chimaeric monoclonal antibody, and the first anti-TNF antibody on the market for CD. Ada-
limumab (Humira®), is a completely humanized anti-TNF antibody, and was designed in 
the hope to reduce immunogenicity. Adalimumab and infliximab are quite similar in struc-
ture; both have an Fc region and a Fab region. Certolizumab (Cimzia®) is different from 
infliximab and adalimumab, since it does not contain an Fc region and thus can not interact 
with Fc receptors. Whereas certolizumab was approved by the FDA for the treatment of 
moderate-to-severe CD, it has not been approved by the EMEA. Etanercept (Enbrel®), a 
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soluble TNF receptor fusion protein, is an effective drug for the treatment of rheumatoid 
arthritis and also efficiently neutralizes TNF-α. 124, 126, 127 Surprisingly, etanercept is not ben-
eficial in CD, 128 implicating that neutralizing soluble TNF-α is not the only mechanism 
of action of anti-TNF agents responsible for their efficacy in CD. One of the differences 
between infliximab and etanercept is that infliximab induces apoptosis in lamina propria 
T cells, 129 but etanercept does not. 130 Infliximab, but not etanercept, binds to membrane 
bound TNF-α (mTNF), which can be cleaved by TNF-α-converting enzyme (TACE) to gen-
erate soluble TNF-α. Upon binding to mTNF, infliximab induces antibody dependent cyto-
toxicity (ADCC) and cell lysis. 131 Mitoma et al. described reverse signaling through mTNF 
induced by infliximab and adalimumab (but not etanercept), leading to cell cycle arrest 
in Jurkat T cells. 132, 133 Certolizumab does not induce apoptosis, but, like infliximab and 
adalimumab, inhibits LPS-induced IL-1β production by monocytes. 124 In addition, inflixi-
mab induces apoptosis in monocytes from CD patients with active disease. 134 Furthermore, 
infliximab reduces VCAM-1 (vascular cell adhesion molecule-1) and CD40 expression on 
mucosal endothelium, thereby disrupting the CD40-CD40L dependent interaction between 
T cells and endothelium. 135 Infliximab also acts on wound healing: infliximab increases tis-
sue inhibitor of metalloproteinases-1 (TIMP-1) production and reduces matrix metallopro-
teinase (MMP) activity, and enhances myofibroblast migration in vitro. 136 
 3.5  Anti-TNF therapy efficacy in clinical trials
The efficacy and safety of anti-TNF therapy has been widely evaluated in clinical studies 
Targan et al. reported response rates at week 4 of overall 65% in patients treated with inflixi-
mab vs. 17% in the placebo group. 91 In the ACCENT I trial,  58% responded to infliximab at 
week 2. 137 In another study, much higher response rates were observed in patients naïve to 
immunomodulators and biologics with short duration of disease. 138 response rates of anti-
TNF-naïve patients treated with adalimumab were assessed in the CLASSIC-I trial. After 4 
weeks, 54% (adalimumab 40/20 mg) to 59% (adalimumab 80/40 and 160/80) showed a 
clinical response. 92 Clinical response rates of patients receiving certolizumab pegol were 
evaluated in the PrECISE-1 trial and were 44% at week 4 139. The 100-points response at 
week 6 (primary end point) after full induction therapy was 35%. Both response rates did 
not reach statistical significance. Patients who received anti-TNF therapy within the previ-
ous three months, or had a hypersensitivity or lack of response to a first anti-TNF dose were 
excluded. Infliximab, adalimumab, as well as certolizumab appeared safe. 
Altogether, around one-third of patients treated with infliximab, 45% of patients treated with 
adalimumab and 56% of patients receiving certolizumab fail to show a clinical response at 
week 4 or week 6 after full induction therapy. Because there are no head-to-head trials, it is 
complex to directly compare the results of different studies. It is not known whether these 
primary non-responders represent a specific group of patients. Patients who do not show a 
response after a first infusion of infliximab, also fail to show response after subsequent infu-
sions, 91, 140 suggesting that lack of response is stable over time. In general, although many 
clinical trials have shown the efficacy and safety of anti-TNF therapy, there is a relatively 
large group of patients displaying lack of response after 4 weeks (primary non-responders). 
In addition to lack of response, a considerable group of patients lose response following an 
initial response after several months of treatment. Loss of response is generally defined as a 
history of initial response and lack of improvement or worsening of symptoms, including: 
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increased stool frequency, fever, rectal bleeding, daily abdominal pain and recurring drain-
age from a previously non-draining fistula. 141 Furthermore, a significant number of patients 
become intolerant to anti-TNF, which is characterized by acute (during or within 24 h post 
treatment) or delayed (occurring 24 h – 15 days post treatment) infusion reactions. 
Lack and loss of response to anti-TNF therapy is an obstacle in the treatment of CD. Predic-
tive factors for lack and loss of response are needed to select patients for a certain approach. 
This may improve treatment, reduce side-effects and reduce morbidity. Many studies have 
been done to identify factors for lack and loss of response. Genetic, clinical and demo-
graphic factors have been described to play a role in lack of response. FcγrIIIa, 142 TACE 
143 and LTA 140 might be possible genetic factors, and young age, 144, 145 luminal CD, 145 short 
duration of disease 146  and concurrent immusuppression 145, 147-150 possible clinical factors. 
Patients with lack of response can switch to another anti-TNF, or to a biologic with another 
mechanism of action. Though controversial, the formation of antibodies against antibodies 
has been associated with loss of response. The use of concurrent immunosuppressive drugs 
may reduce the formation of antibodies against antibodies. Dose intensification in patients 
with low drug through levels or switching to another anti-TNF might be a good option in 
patients with loss of response. 
Also, side effects might complicate anti-TNF treatment. Anti-TNF use is associated with an 
approximately 21-fold increased risk of tuberculosis (TB) without appropriate safety meas-
ures. 151 The TB incidence has been reported to decrease with 78% when suitable safety 
measures where undertaken. Most cases are presented during the first three months of 
treatment and have an atypical presentation, which makes the diagnosis more complica-
ting. 152 For that reason, international guidelines advise to assess the risk of TB before start-
ing treatment with an anti-TNF agent, including an X-ray, tuberculin skin testing (depend-
ing on national guidelines) and careful evaluation of the TB history. 153 Latent TB may be 
suspected in case of a positive initial tuberculin skin test and when the patient has recently 
been exposed to the disease. Physicians should be aware of the possibility of false-negative 
skin tests, especially when patients are immunocompromized.
Next to reactivation of mycobacterium tuberculosis, the use of immunosuppressive agents is 
associated with opportunistic infections. The risk of opportunistic infections in anti-TNF 
treated patients is estimated between 0.3 and 0.9%, 154 and an increased risk is observed in 
patients treated with concommittant immunosuppressives. 155 Indeed, in a large meta-analy-
sis of 21 placebo-controlled trials including 5356 anti-TNF treated patients, the increased risk 
of opportunistic infections was likely due to disease severity and prednisone use, instead of 
merely anti-TNF. 156 In line with this observation, no increased risk was found in infections 
and mortality in 734 anti-TNF treated patients compared to controls, with a median follow-
up of 58 months. 149
Finally, the development of malignanies, and especially lymphomas, is a major concern. 
Whereas some studies do not show an increased risk, 157-160 other studies do find a moder-
ately elevated risk, especially in patients on thiopurine therapy. 117, 161, 162 Lethal hepatosplenic 
T cell lymphoma has been reported in young patients on azathioprine/infliximab combina-
tion therapy, 163-166 and therefore long-term combination therapy in younger patients is not 
recommended. Still, the absolute risk appears to be low and should be weighed against the 
beneficial effects of immunomodulator therapy. In addition, differences in study design 
and patient recruitment complicate the interpretation of these data. Furthermore, in the 
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meta-analysis including 21 placebo-controlled trials, 156 no increased risk of malignancy was 
observed. These data were supported by another study 149 including 734 anti-TNF treated 
patients. However, long-term safety data are not available yet and therefore awareness of 
(serious) side effects is warranted.
 3.6  Other therapies
There is not much data on the efficacy of methotrexate in UC, but the only randomized pla-
cebo-controlled trial did not show any benefit. 167 In contrast, methotrexate efficacy has been 
shown CD patients. 168 and at the present time, methotrexate therapy is used in patients with 
active or relapsing CD who are refractory or intolerant to thiopurine therapy or anti-TNF 
agents. 169 Other immunosuppressives, like ciclosporin or tacrolimus, may be of benefit in 
patients with severe UC who are intolerant to i.v. corticosteroids. 109 Ciclosporin is of limited 
value in CD, 45 but data are lacking on the efficacy of tacrolimus in CD. 
 3.7  Future treatment 
Unfortunately, the medication used to control CD is not without risk. Although substantial 
progression has been made with regard to treatment, there is still no cure for IBD. In addi-
tion, side effects like lymphoma, Mycobacterium tuberculosis and opportunistic infections 
further complicate treatment. Moreover, lack and loss of response to anti-TNF therapy are 
problems in daily practice that are even now unsolved, and surgery is then often the only 
option left. 
Our understanding of the mechanism of action and side effects of several therapies is still 
incomplete. In an ideal situation, it would be possible to select patients based on genotype 
or disease phenotype, age or other yet undefined factors for a certain therapeutic strategy. 
To accomplish this, a better understanding of the pathogenesis of CD and the complex 
mechanism of action of anti-TNF therapy is warranted in order to tailor therapy. In that way, 
it is possible to reduce side effects, surgery and chronic use of corticosteroids. In addition, 
therapy risks need to be re-assessed at any given time point, and if necessary, the therapeutic 
approach should be re-adjusted. Finally, we have to continue exploring new therapies with 
less side effects and high efficacy profiles. One interesting development in the treatment 
of inflammatory disorders, is the administration of mesenchymal stem cells (MSC). MSC 
are cells with immunosuppressive properties 170, 171 and have been studied in various fields 
of medicine. Administration of MSCs to patients with severe steroid-refractory graft-versus-
host disease (GvDH), including GvDH of the gut, has been shown to be effective. 172, 173 This 
may be a promising strategy in the treatment of CD.  
 4 Scope of the thesis
In chapter 2, we give an overview of current treatment strategies for CD, especially the top-
down approach. Since CD typically progresses from an inflammatory to a fibrotic pheno-
type, it may be beneficial to interfere in an early disease stage in patients with high risk at 
developing complicated disease.
In chapter 3, we demonstrate the role of autophagy in DCs in regulation of the immuno-
logical synapse and CD pathogenesis. We show that decreased levels of autophagy lead to 
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hyperstabilization of the immunological synapse. This results in increased interaction dura-
tion between DCs and T cells and increased T cell activation and IL-17 production. Also, 
we demonstrate that autophagosomes contain components of the synaps, suggesting that 
autophagy might be involved in the synaptic breakdown, and thereby plays a role in con-
trolling T cell responses. In addition, we found the same results in patients carrying the 
ATG16L1 risk allele, indicating a novel role for autophagy in CD pathogenesis by modulat-
ing adaptive immune responses. 
In chapter 4, we further dissect the mechanism of action of anti-TNF agents in vitro. We 
describe the Fc-receptor dependent induction of Mφ2 upon infliximab therapy and their 
immunosuppressive phenotype. Since loss of tolerance and hyperresponsiveness contri-
bute to IBD, the induction of Mφ2 by infliximab might restore the dysbalance. 
The induction of Mφ2 in vivo is shown in chapter 5, and a significant relation between 
response to infliximab and induction of Mφ2 is described. Also, we show the wound healing 
capacity of infliximab-induced macrophages, further supporting their role in mucosal heal-
ing. Furthermore, we show an enhanced induction of Mφ2 upon infliximab/azathioprine 
combination treatment, and that Mφ2 induced by combination treatment have a stronger 
immunosuppressive phenotype. This might explain the superiority of infliximab/azathio-
prine combination treatment observed in patients. 
In chapter 6 a Phase I study investigating the safety and feasibility of MSC therapy in ster-
oid-refractory CD patients is described. We show the immunosuppressive properties of 
MSCs in vitro and that MSC therapy in CD patients is safe and feasible. Importantly, no 
serious side effects were reported during the study period. The efficacy of MSC therapy in 
CD patients should be further assessed in Phase II/III trials. 
In chapter 7 we further examine the safety profile of common IBD drugs in relation to lym-
phoma development. In a cohort of approximately 18000 patients, no increased risk was 
found compared to the general population, but a clear association was observed between 
thiopurine therapy and EBV positive lymphoma, especially in younger patients. These data 
give more insight in the risks in specific patient groups. 
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During recent years, the treatment for patients with Crohn’s disease has changed substan-
tially. With the introduction of anti-TNFα antibodies, the treatment goals have been more 
ambitious. Today, upon diagnosing Crohn’s disease, clinicians are able to use predictors 
of a complicated disease course and act accordingly when designing an individual medical 
strategy. 
Crohn’s disease typically progresses from an inflammatory disease phenotype in the early 
stage of the disease to a more severe complicated disease phenotype, characterized by fibro-
sis and stenoses. At this point, the disease is difficult to treat and fibrotic lesions are often 
irreversible. Therefore, intensive therapy in an early disease stage, within the so-called ‘Win-
dow of Opportunity’, is favorable in patients who are likely to develop a complicated disease 
phenotype. This disease-modifying strategy is aimed at avoiding late stage disease-related 
complications and at inducing steroid-free remission as soon as possible. Indeed, with this 
approach, higher response rates, higher rates of mucosal healing, and a higher percentage 
of patients achieving steroid-free remission is observed. However, not all patients will need 
this early intensive approach, and long-term safety is one of the concerns. 
In this chapter, we discuss which patients can be selected for an early intervention approach, 
which safety measures should be undertaken, how patients should be monitored, and how 
therapy might be de-escalated once remission has been achieved. 
35Early intensive treatment for Crohn’s disease
  Introduction
In recent years, the medical care for patients suffering from Crohn’s disease (CD) has 
changed considerably. Nowadays, clinicians are equipped with a robust set of tools, sup-
ported by a substantial body of literature, on how to act upon diagnosing Crohn’s disease for 
the first time. There seems general consensus on the diagnostic process, using a full endo-
scopic work-up in combination with radiologic and histopathologic assessments. 1 Once 
diagnosed, it is up to the team of IBD health professionals to fully inform and educate the 
patient and his/her relatives, and to install and monitor a vigorous medical regime.
The main treatment goals are 1) to achieve clinical remission of steroids as soon as possible 
2) to achieve endoscopic remission 3) to avoid hospitalization and surgery 4) to improve the 
quality of life. Indeed, today we are able to monitor the success of each of the treatment goals 
very effectively: ad 1) monitoring the rate of clinical remission in daily practice can be per-
formed on a week to week basis by, for example, a specialized IBD nurse, using well defined 
and validated parameters of general well being, abdominal pain, stool frequency, extra intes-
tinal manifestations and general symptoms like fever and weight. More and more, IBD 
centers are establishing remote care delivery systems for monitoring disease activity indices 
on a regular basis and thus partly allowing self-management. 2 Next to clinical parameters, 
a defined set of laboratory values like CrP is recommended nowadays for monitoring. In 
addition, most steroid tapering schedules can be completed within 8 weeks. Intervention is 
required much sooner than 8 weeks should patients continue to have active disease. Ad 2) 
the paradigm of mucosal healing has been well accepted upon publication of a large num-
ber of studies showing the relevance of endoscopic assessments for the prediction of clinical 
remission. 3-5 Alternative biomarkers for mucosal healing, for instance fecal calprotectin and 
fecal lactoferrin, are under development since endoscopy remains an invasive procedure. 6-8 
Again, these fecal tests could also be very well for home monitoring of mucosal healing. Ad 
3) it has also been shown that induction of clinical and endoscopic remission decreases the 
number of hospitalizations and surgeries in CD patients. 9 Ad 4) Similar to clinical remis-
sion, the quality of life of CD patients dramatically improves upon reaching the previously 
discussed treatment goals. 4, 10, 11
In summary, today’s physicians are able to act immediately upon diagnosing CD with effec-
tive and safe drugs. This chapter clarifies i) why there is this ‘Window of Opportunity’ the first 
years after the diagnosis of CD ii) why intensive treatment (also referred to as Top Down) 
is superior in selected cases iii) which safety measures should be taken to prevent (serious) 
adverse events during intense therapy iv) how to optimally monitor patients and lastly v) the 
possibilities for de-escalating therapy once deep remission is achieved.
  Window of opportunity in Crohn’s disease
When a patient is diagnosed with CD, it is an important and challenging issue how to 
optimally treat the patient and at which point a certain therapy should be initiated. In estab-
lished CD, early disease should be distinguished from late disease, since CD is character-
ized by progression of inflammatory disease (early disease) to a more complicated stric-
turing, penetrating and fibrotic disease (late disease). 12 Fibrostenosis and perforations are 
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not per se associated with early CD, usually patients with recently diagnosed CD have pure 
inflammatory lesions (Figure 1). However, when the disease evolves, the number of com-
plications increases and many patients will develop strictures or fistulae formation. In this 
stage, complications caused by tissue remodeling and fibrosis following long-standing dis-
ease are irreversible and difficult to treat with the anti-inflammatory agents. Often, surgery 
can’t be avoided at this stage. The progression from early to late disease is accompanied 
by a change in mucosal cytokine profiles. Early CD is characterized by a pronounced Th1 
response, whereas in late disease Th2 cytokines are predominating. 13 The concept that 
mucosal T cell regulation is different in early and late disease, suggests that patients with 
late disease respond different to therapies. Indeed, superior therapy efficacy is observed in 
patients with newly diagnosed CD compared to patients with a longer disease duration. 14-17 
The progression from early to complicated late disease course has also been reported in 
rheumatoid arthritis (rA). 18, 19 In rA patients, therapy is aimed at preventing late disease 
when complications and bone destruction are irreversible. In this light, intervening in an 
early stage of the disease has proven to be very effective and superior to treatment in a late 
disease stage. 19-21
Figure 1 Inflammation (left panel) and fibrostenosis (right panel).
The fact that disease progresses to complicated disease suggests that there is a particular 
time window at which therapy is most effective and favorable. In order to prevent progres-
sion to a complicated phenotype, it is of great importance to intervene in an early stage of 
the disease, the so-called “Window of Opportunity” (Figure 2). At this point, it is most likely 
still possible to change the course of the disease towards a less aggressive phenotype, to 
control symptoms, induce mucosal healing and to induce and maintain clinical and endo-
scopic remission. 
C
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Figure 2 Window of opportunity.
Adapted with permission from Cosnes et al. Inflamm Bowel Dis. 2002
  Early intensive treatment (“Top-Down”)
  Selecting patients for early intensive treatment
The window of opportunity is especially important for patients who are likely to develop 
a disabling disease course. risk factors that predict a disabling disease course have now 
been identified and confirmed in several studies (Figure 3). Although “disabling disease” 
has various definitions in different studies, clinical factors predicting the course of disease 
have been independently verified. In a retrospective study involving 1188 patients, disabling 
disease was defined as more than 2 steroid courses, hospitalization, immunomodulators or 
surgery within the first 5 years of diagnosis. 22 Young age at diagnosis, presence of perianal 
disease at diagnosis and initial need for corticosteroids were found to be predictive factors for 
disabling disease. In addition, when 2 of these factors were present at diagnosis, 84% of the 
patients developed disabling disease within 5 years; when 3 factors were present, 91% devel-
oped a disabling disease course. These factors were all independently confirmed in another 
study. In this study, disabling disease was defined as complex perianal disease, colonic 
resection, ≥ 2 small bowel resections or a definitive stoma, also within the first 5 years of 
diagnosis. 23 Using one definition or the other, several factors that are present at diagnosis 
have been identified and confirmed that predict a disabling disease outcome, including a 
young age (≤ 40 y), presence of perianal disease, stricturing disease and the initial need for 
steroid therapy. 22-24 Patients with these symptoms at diagnosis are at high risk for a compli-
cated disease course. Therefore, early intensive treatment in selected patients could prevent 
the development of complicated disease, and thereby prevent hospitalization and surgery.
C
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Figure 3 Predictive factors at diagnosis for selection of high-risk patient.
Biomarkers predicting disease outcome in CD are currently lacking. Serological- genetic- 
and immunological factors are being studied and would be helpful to further adequately 
select patients for a certain therapy strategy. Elevated levels of CrP correlate with more 
severe clinical, endoscopic and histologic disease. 25 However, CrP did not very well pre-
dict milder disease, and some patients with severe disease have normal CrP levels. Con-
sequently, additional markers are needed. Positive anti-Saccharomyces cerevisiae antibody 
(ASCA) status has been associated with early surgery, 26 ileal disease 27 and poor outcome 28 
and might therefore be a useful marker in the selection of patients. In another study, a well 
defined correlation was found between triple positive status for ASCA, anti-OmpC as well 
as anti-I2 and small bowel surgery. 29 Furthermore, mutations in NOD2 30 and CArD15 31 
increase the risk for surgery in patients with pediatric-onset CD.
Large trials should further confirm the value of these markers in predicting disease course. 
When combining these factors, a profile can be established including phenotypic, genetic 
and serologic markers to facilitate the selection of patients. 
  Early intensive strategy in Crohn’s disease
The benefit of the disease-modifying strategy has been shown in several studies. The first 
clues pointing towards the benefit of so-called early intervention strategies in CD, result 
from retrospective analyses from large randomized, placebo-controlled trials. In a study 
evaluating the maintenance of response and remission of adalimumab, a clear difference 
was observed in patients with different disease durations. 32 The rate of patients with remis-
sion maintenance at week 26 was 56% in patients with a disease duration less than 2 years, 
35% in patients with a disease duration of 2 – 5 years and 37% in patients with a disease 
duration more than 5 years. 
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In a prospective, randomized controlled trial, including 130 patients with newly diagnosed 
CD naïve to corticosteroids, immunomodulators or anti-TNF agents, efficacy of step-up ver-
sus top-down therapy was evaluated. 33 The top-down approach involved a treatment algorithm 
starting with infliximab 5 mg/kg at weeks 0, 2 and 6 and azathioprine 2.5 mg/kg/d. Patients 
randomized to the step-up treatment algorithm were initially treated with cortico steroids 
(current standard around 1999), followed by azathioprine in case the corticosteroids were 
not able to control disease activity. Should this combination fail to avoid relapse, infliximab 
treatment was initiated. The co-primary endpoint in this study was clinical remission off 
steroids and without surgery at weeks 26 and 52. At both time points, a significant greater 
proportion of patients in the early combined intervention group met this endpoint com-
pared to the conventional therapy group. At week 26, 39 (60.0%) of 65 patients in the 
top-down group were in remission without corticosteroids and without surgical resection, 
compared with 23 (35.9%) of 64 step-up patients, with an absolute difference of 24.1% (95% 
CI 7.3 - 40.8, p = 0.0062). Corresponding rates at week 52 were 40/65 (61.5%) and 27/64 
(42.2%) (absolute difference 19.3%, 95% CI 2.4 - 36.3, p = 0.0278). Furthermore, after two 
years, mucosal healing was observed in 73% of the patients in the early intervention group, 
whereas mucosal healing was seen in only 30% of the patients in the conventional treat-
ment group. Importantly, 19% of the patients in the step-up group were still on steroids at 
this time point, whereas 0% of the patients in the early intervention group were receiving 
steroids. Also, it has been shown that complete mucosal healing in patients with early-stage 
Crohn’s disease is associated with significantly higher steroid-free remission rates 4 years 
after therapy began. 3 Complete mucosal healing, defined as a Simple Endoscopic Score of 0 
after 2 years of therapy, was the only factor that predicted sustained, steroid-free remission 
3 and 4 years after therapy was initiated; it was observed in 17 of 24 patients (70.8%) vs 6 
of 22 patients with lesions detected by endoscopy (27.3%, Simple Endoscopic Score >0) (p = 
0.036; odds ratio = 4.352; 95% confidence interval, 1.10-17.220). Fifteen of 17 patients with 
mucosal healing at year 2 maintained in remission without further infliximab infusions 
during years 3 and 4 (p = 0.032; odds ratio = 4.883; 95% confidence interval, 1.144 - 20.844).
Finally, in this step-up versus top-down study, the number of side effects did not differ 
significantly between the two groups. Obviously, remission rates in the two groups did not 
differ significantly after 1 year since the two treatment algorithms were both designed to 
control disease, and allowed intensification when disease activity persisted.
Effective early intervention has also been reported in children. Twenty-nine patients receiv-
ing infliximab in either step-up (11 patients) or top-down (18 patients) regimen where evalu-
ated 8 weeks after initiation of treatment. 34 remission was achieved in 3/11 patients in 
the step-up group and in 15/18 in the top-down group. In the top-down group, significant 
improvement was observed in PCDAI score and perianal fistula status. Furthermore, in a 
retrospective study of 36 pediatric CD patients, 35 relapse rate after 24 months was signifi-
cantly lower in the early intervention group than in the conventional therapy group. 
Finally, the SONIC trial evaluated the efficacy of infliximab monotherapy, azathioprine 
monotherapy, and the two drugs combined in 508 adults with moderate-to-severe Crohn’s 
disease who had not undergone previous immunosuppressive or biologic therapy. 15 Patients 
were randomly assigned to receive an intravenous infusion of 5 mg of infliximab per kilo-
gram of body weight at weeks 0, 2, and 6 and then every 8 weeks plus daily oral placebo cap-
sules; 2.5 mg of oral azathioprine per kilogram daily plus a placebo infusion on the standard 
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schedule; or combination therapy with the two drugs. Of the 169 patients receiving com-
bination therapy, 96 (56.8%) were in corticosteroid-free clinical remission at week 26 (the 
primary end point), as compared with 75 of 169 patients (44.4%) receiving infliximab alone 
(p = 0.02) and 51 of 170 patients (30.0%) receiving azathioprine alone (p < 0.001 for the 
comparison with combination therapy and p = 0.006 for the comparison with in fliximab). 
Similar numerical trends were found at week 50. At week 26, mucosal healing had occurred 
in 47 of 107 patients (43.9%) receiving combination therapy, as compared with 28 of 93 
patients (30.1%) receiving infliximab (p = 0.06) and 18 of 109 patients (16.5%) receiving 
azathioprine (p < 0.001 for the comparison with combination therapy and p = 0.02 for the 
comparison with infliximab). Thus, infliximab plus azathioprine was shown to be the supe-
rior combination for inducing remission.
In conclusion, early intensive treatment, consisting of the combination of a thiopurine with 
an anti-TNF, should be considered in all patients who have a high risk for a complicated dis-
ease course, i.e. young age at diagnosis, presentation with peri-anal or stricturing disease, 
or initial needs of steroids.
  Safety measures for early intensive treatment
An important issue related to early intensive treatment is the safety of long-term use of bio-
logics and immunomodulators. Patients are exposed to potentially toxic agents, and there-
fore appropriate safety measures should be undertaken before immunomodulators and bio-
logicals are initiated (Figure 4). Safety measures are aimed at prevention of infections and 
awareness of several rare complications. 
It appears that patients treated with immunomodulators have an increased risk for influ-
enza infections, pneumococcal infections, and Salmonella supp. infections. 36 Therefore, 
influenza vaccination, pneumococcal vaccination and appropriate food hygiene (avoiding 
raw eggs, unpasteurized milk, raw meet) is recommended. Also, reactivation of latent HBV 
is considered a serious risk, and therefore all IBD patients should be tested to exclude HBV. 
36 Patients with active chronic infection should be treated according to standard antiviral 
therapy. Nucleoside/nucleotide analogues are preferred since IFN therapy might exacerbate 
the colitis. Seronegative patients should receive HBV vaccination, patients might need a 
higher dose of immunizing antigen since vaccination efficacy is affected by the number of 
immunomodulators. 
Screening for cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes simplex virus 
(HSV) before starting immunomodulator therapy is not recommended. In case of severe 
EBV infection, immunomodulator therapy should be discontinued. Latent subclinical CMV 
infection is also no contra-indication for starting immunomodulators. However, CMV coli-
tis should be excluded in refractory IBD cases and in case of systemic CMV, immunomodu-
lator therapy should be discontinued. 36
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Figure 4 Safety measures.
Anti-TNF use is associated with an approximately 21-fold increased risk of tuberculosis (TB) 
without appropriate safety measures. 37  The TB incidence has been reported to decrease 
with 78% when suitable safety measures where undertaken. Most cases are presented dur-
ing the first three months of treatment and have an atypical presentation, which makes the 
diagnosis more complicating. 38 For that reason, international guidelines advise to assess 
the risk of TB before starting treatment with an anti-TNF agent, including an X-ray, tubercu-
lin skin testing (depending on national guidelines) and careful evaluation of the TB history. 
36 Latent TB may be suspected in case of a positive initial tuberculin skin test and when the 
patient has recently been exposed to the disease. 
Physicians should be aware of the possibility of false-negative skin tests, especially when 
patients are immunocompromised. When the patient is diagnosed with latent TB, treat-
ment with the full therapeutic antituberculous regimen should be initiated and it is advised 
to delay anti-TNF treatment with at least 3 months. The full anti-TB regimen consists of 
isoniazid (INH) for 6 to 9 months. An association between isoniazid related hepatoxicity 
and methotrexate and sulphasalazine has been reported in the rheumatology setting, but 
this is not clear for IBD. When active TB is diagnosed, anti-TNF treatment is ideally delayed 
until anti-TB treatment is completed. However, solid data on the ideal timing during anti-
TB treatment are lacking and in case of medical urgency, physicians may consider to start 
anti-TNF therapy despite positive TB diagnosis. Advice from a TB expert is in that case rec-
ommended. When TB is diagnosed during anti-TNF treatment, the anti-TNF agent should 
be discontinued and TB therapy should be started. Anti-TNF therapy can be resumed if 
needed after 2 months. In any event, supervision of a thoracic physician or infectious dis-
ease specialist is advised. 5-ASA, azathioprine, methotrexate and steroids can be continued 
during anti-TB therapy. All patients should be monitored carefully for signs of cough, fever 
and weight loss and treating physicians should be aware of uncommon extrapulmonary TB 
as well as the more common lung disease. 
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  How to optimally monitor patients
 1 Disease activity 
Prior to installing a medical strategy, it is essential to discuss the monitoring scenario with 
each patient. Monitoring of both disease activity and drug safety is mandatory, irrespec-
tive of early- or late stage disease. Although guidelines discuss monitoring practices, the 
evidence in the literature is currently lacking. Optimally, the clinical monitoring of Crohn’s 
disease activity should be done in a standardized manner using for instance the Crohn’s 
Disease Activity Index (CDAI), the Harvey Bradshaw Index (HBI) or other validated indices. 
However, for routine clinical practice this is usually not accepted. Using simple Physician 
Global Assessments is very simple and easy to do, and a reasonable alternative. These clini-
cal assessments are required on a weekly basis once remission induction is initiated, and 
less often once remission is achieved. In addition to monitoring clinical disease activity, 
clinicians should also monitor CrP each time a clinical assessment is made. Finally, the cor-
rect monitoring strategy of early intensive treatment also involves assessment of mucosal 
healing. It has been shown that, following surgical remission, Crohn’s ulceration can be 
detected within 3 to 6 months following surgery preceding clinical symptoms. 39 Mucosal 
healing predicts long-term outcome and is associated with less surgery and hospitaliza-
tion.4, 40 In a retrospective study, it has been shown that patients with severe ulcerations 
at colonoscopy are more likely to have a complicated disease course, 41 and in an ongo-
ing study, a strong association was found between mucosal healing and decreased risk of 
relapse. 42 Therefore, assessing mucosal healing is a useful tool to predict the course of 
disease, to monitor disease activity and to further optimize treatment. 
Non-invasive fecal markers such as fecal lactoferrin and calprotectin are currently being 
evaluated for their usefulness to measure disease activity. Increased levels of calprotectin 
and lactoferrin have been shown to correlate with CDEIS scores 7, 43 and therefore these 
markers might be useful tools to assess disease activity. In addition, it has been shown 
that lactoferrin and calprotectin are valuable markers to predict relapse. 44 In patients with 
high (>150 microgr/gr) calprotectin levels or positive lactoferrin, a higher risk for relapse 
was observed.  The value of lactoferrin and calprotectin as markers for disease activity has 
also been demonstrated in paediatric disease. 45 However, it has been suggested that these 
markers may be less valuable in patients with ileal CD, 46 since the disease location might 
interfere with accurate fecal detection. Future studies are needed to further confirm the 
value of these markers in daily practice, define clear cut-off values and to finally identify a 
combination of markers with higher sensitivity and specificity. 
 2 Side effects
In order to evaluate the risk benefit of the early intensive treatment, a careful monitor-
ing of potential, and sometimes avoidable adverse events is mandatory (Figure 5). Patients 
on immunosuppressive therapy and with malnutrition are at risk for opportunistic infec-
tions. 47 For that reason, patients with fever, cough and systemic illness should be carefully 
examined. In case of an active infection, it is advised to withdraw immunomodulators until 
the resolution of infection. In case of persistent fever and when the patient is treated with 
an anti-TNF agent, mycobacterium tuberculosis (TB) should be excluded. Patients diagnosed 
with pneumonia should be treated with an antibiotic covering S. pneunomiae. 36 
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Figure 5 Monitoring strategies for patients with early intensive therapy.
Furthermore, about 60 – 80% of the European population has latent JC virus, which can 
cause progressive multifocal leukoencephalopathy (PML) upon reactivation. Since reactiva-
tion of the JC virus is associated with systemic immunosuppression, treating physicians 
ought to be aware of this rare situation, especially in patients presenting with new onset 
neurological symptoms, in which case the patient should receive an MrI scan and lumbar 
puncture. 
Studies show divergent data on the occurrence of malignant lymphoma in IBD patients 
receiving immunomodulators. Whereas some studies do not show an increased risk, other 
studies do find a moderately elevated risk, especially in patients on thiopurine therapy. 48-50 
Still, the absolute risk appears to be low and should be weighed against the beneficial effects 
of immunomodulator therapy. On the other hand, awareness is advised. Lethal hepato-
splenic T cell lymphoma has been reported in young patients on azathioprine/infliximab 
combination therapy, 51-54 and therefore long-term combination therapy in younger patients 
is not recommended. 
After all, when taking appropriate safety measures, anti-TNF and immunomodulator ther-
apy appears to be relatively safe. Safety data from referral centers and randomized con-
trolled trials do not show an increased risk of malignancies or infections in anti-TNF treated 
patients. In a large meta-analysis of 21 placebo-controlled trials including 5356 patients, no 
increased risk of death, serious infection or malignancy compared to controls was reported. 
55 In line with this observation, no increased risk was found in infections, mortality or malig-
nancy in 734 anti-TNF treated patients compared to controls, with a median follow-up of 
58 months. 11 In addition, no increased risk of malignancy was observed in patients treated 
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with anti-TNF in a large cohort of CD patients. 56 However, long-term safety data are not 
available yet and therefore awareness of (serious) side effects is warranted. 
  Possibilities for de-escalating therapy once remission is achieved
Once remission is achieved, it is important to know if, when and how to de-escalate therapy. 
Although severe adverse events are rare, especially when appropriate safety measures are 
undertaken and patients are correctly monitored, they can occur and therefore establishing 
an individualized risk-benefit ratio is encouraged. The disadvantages of discontinuation 
of therapy should be taken into account, including relapse, possibly lower response to re-
induction therapy, infusion reactions and surgery. Particularly important when considering 
de-escalation is the earlier pattern of the disease and response to therapies. In addition, 
several factors may predict relapse, including smoking, previous steroid use and elevated 
fecal calprotectin and CrP. 
  Anti-TNF and anti-TNF/azathioprine combination therapy 
The question how and when to de-escalate infliximab therapy is of great interest. Trials 
investigating this matter are currently ongoing, and therefore there is not much data and 
consensus on this topic yet. 
The proportion of patients with infliximab-induced remission that relapsed after discontin-
uing infliximab was assessed in a prospective single-center study. 57 In this study, infliximab 
was stopped in patients who were treated with infliximab for at least one year, and who were 
in steroid-free remission for 6 months. After the median follow up time of 12 months, about 
50% of the patients relapsed. On the other hand, 35% of the patients were still doing well up 
to the end of the follow-up time (nearly 7 years). Therefore, it seems that the patients that 
are still doing well after 7 years represent a specific group of patients. Age, gender, number 
of infliximab infusions and disease location were all excluded as predictors for relapse in 
this study.  These results were supported by data from an observational study evaluating 
the long-term effects of infliximab. 11 In this study, 20% of the patients who experienced a 
sustained clinical response to infliximab, maintained remission after infliximab discontinu-
ation. 
Interim results of the STOrI (infliximab discontinuation in Crohn’s disease patients in 
stable remission on combined therapy with immunosuppressors) showed similar results. 
58 In this prospective study, relapse was assessed in patients on combination therapy for 
more than 1 year and in stable remission for ≥ 6 months after stopping infliximab therapy. 
About 50% of the patients relapsed within 1 year of discontinuation; patients retreated with 
infliximab after relapse responded well.  In addition, risk factors that predict relapse were 
detected. A univariate analysis revealed current smoking, previous steroid treatment, lower 
haemoglobin, higher CDAI, ultrasensitive C reactive protein and faecal calprotectin as pre-
dictive markers. In a multivariate analysis, CDEIS ≥ 2, usCrP > 5 mg/dl, haemoglobin ≤ 
14.5 g/dl and infliximab trough levels ≥ 2 μg/ml were found to predict relapse.  Further-
more, the risk of relapse increased as the number of risk factors increased. 42
In a study investigating the ability to stop immunosuppressives in patients treated with 
combination therapy, an enduring response was observed after withdrawal of immunosup-
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pressives. 59 Importantly, they reported low infliximab trough levels before immunosuppres-
sive withdrawal as a predictor for surgery. risk factors for relapse after azathioprine with-
drawal in patients treated with infliximab/azathioprine combination therapy were identified 
in another study. 60 Infliximab/azathioprine exposure duration ≤ 811 days, CrP ≥ 5 mg/L 
and platelet count ≥ 298 x 109 were found to predict infliximab failure, which was defined 
as disease flare, hypersensitivity reactions leading to infliximab discontinuation or surgery. 
After 12 and 24 months, resp. 85% and 41% of the patients were infliximab-failure free. 
In summary, it appears from these preliminary data that there is a distinct group of patients 
that does well after de-escalation therapy.  It is of great interest to identify the factors that 
discriminate patients with sustained remission from the patients that relapse, in order to 
further tailor therapy and to prevent unnecessary side effects. Studies are currently ongoing, 
and the preliminary data need to be confirmed in large cohorts. 
  Thiopurines 
Furthermore, there are conflicting data with regard to discontinuation of thiopurine ther-
apy once a patient is in remission. In a large randomized, placebo-controlled double blind 
trial, azathioprine discontinuation was associated with a 50% relapse rate after 54,5 months, 
regardless of the duration of remission. 61 
In a study evaluating disease recurrence after azathioprine withdrawal, a lower rate of 
relapse was seen in patients who received azathioprine ≥ 4 years than in patients treated 
with azathioprine ≤ 4 years. 62 
  Concluding remarks
Early intervention therapy in CD is beneficial in selected patients who are likely to develop 
a severe disease course. Young age at diagnosis, the presence of perianal disease, stricturing 
disease and the initial need for corticosteroids are factors predicting a complicated disease 
course. When taking appropriate safety measures, this approach appears to be relatively 
safe. However, treating physicians should be aware of opportunistic infections and other 
rare complications, and patients should be monitored carefully on a regular basis. The value 
of serological, immunologic and genetic markers in monitoring and predicting disease are 
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Autophagy-related gene variants are associated with the development of Crohn’s disease, 
an aberrant inflammatory response to the intestinal flora. How autophagy is linked to 
the loss of immune tolerance has not been established. We demonstrate that autophagy 
regulates the stability of the immunological synapse in dendritic cells (DC). Autophagy is 
induced upon formation of the immunological synapse, and autophagosomes preferentially 
localize to the site of interaction. Autophagosomes engulf synaptic components such as 
MHCII and ICAM-1, targeting them for degradation. Knockdown of the autophagy-related 
genes ATG16L1 and IRGM in DC results in hyperstable DC-T cell interactions, leading to 
increased T cell signaling and Th17 differentiation. Similar aberrations were observed in DC 
obtained from patients with Crohn’s disease carrying the disease associated polymorphisms 
in ATG16L1. Our findings show that autophagy is induced upon formation of the immuno-
logical synapse and acts as a negative regulator of T cell activation and Th17 differentiation.
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  Introduction
A number of genome-wide association studies have associated autophagy-related genes 
ATG16L1 and IRGM with the development of Crohn’s disease, an inflammatory bowel dis-
ease. 1-3 During autophagy, the cell envelops damaged or excess proteins with a lipid bilayer, 
thus creating an autophagosome. The autophagosome then fuses with a lysosome, result-
ing in the degradation of the protein and the release of free amino acids. Although the 
pathway was initially described as a cell survival mechanism during nutrient depletion, 4 
more recent studies show that the process is also involved in the proper function of various 
immune cells, including pathogen degradation and antigen processing by phagocytes. 5-7 
The Crohn’s disease risk alleles result in decreased autophagic function, suggesting that 
autophagy is required to limit the intestinal immune response. Mice expressing a hypomor-
phic variant of ATG16L1 display aberrant Paneth cell morphology and decreased secretion 
of anti-microbial proteins into the intestinal lumen. 8 Additionally, autophagy is involved in 
the killing of intracellular pathogens by phagocytes, including Salmonella enterica and Myco-
plasma tuberculosis. This suggested that the effects of autophagy on intestinal inflammation 
are secondary, as impaired autophagy leads to hampered innate immune responses and 
microbial overgrowth, which in turn results in hyperstimulation of the intestinal immune 
system. However, we hypothesized that autophagy also has a direct effect in the regulation 
of immunity.
Dendritic cells (DC) are key players in the maintenance of immune homeostasis, as they 
link the innate and the adaptive immune system and can drive both immunogenic and 
tolerogenic responses. The mechanisms by which DC can dampen immune responses 
include secretion of cytokines which induce Foxp3+ regulatory T cells and skew the T cell 
response to a less damaging subtype. 9, 10 Additionally, a lack of costimulatory molecules or 
expression of inhibitory proteins such as IDO and PD-L1 can lead to T cell anergy and thus 
also limit immunogenic responses. 11, 12 In contrast to the volume of data on these topics, the 
involvement of the immunological synapse in the regulation of immune responses by DC 
has been studied to a limited degree.
The immunological synapse is the site of contact between DC and T cells and is character-
ized by a highly organized structure containing molecules involved in antigen recognition 
such as MHC class II and the T cell receptor and adhesion molecules ICAM-1 and LFA-1. 
13 The proper formation is important for the efficacy and outcome of the ensuing immune 
response, and synaptic destabilization has been shown to result in decreased T cell sign-
aling. 14 Although the formation of the immunological synapse as well as the signaling 
pathways involved have been described in some detail from the T cell side, the regulation of 
synapse formation in DC has remained largely unexplored. 
Given the pivotal role of DC and DC-T cell interactions in immunity and the role of 
autophagy in the control of intestinal inflammation, we studied the role of autophagy in 
DC, in particular during cell-cell interactions. We report here that autophagy is induced in 
DC upon formation of an immunological synapse. Autophagosomes localize preferentially 
towards the site of interaction and engulf components of the synapse. DC in which expres-
sion of the autophagy-related genes ATG16L1 or IRGM is decreased show increased stability 
of the immunological synapse, enhanced stimulation of T cell proliferation and increased 
Th17 activation. Our data suggest that autophagy acts as a negative feedback mechanism in 
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DC-T cell interactions and that a loss of this negative feedback mechanism may be a con-
tributing factor in the pathogenesis of Crohn’s disease.
  Material and methods
  Mice
C57BL/6-Tg(TcraTcrb)425Cbn/J (OT-II) mice carrying the OVA
323-339
 specific T cell receptor 
were obtained from Jackson Laboratories (Bar Harbor, ME) and supplied with water and 
standard chow ad libitum. Experimental procedures were approved by the local Animal 
Ethics Committee in accordance with national guidelines.
  Antibodies, immunofluorescence and flow cytometry
Anti-IFNγ, anti-IL-17 and anti-IL-4 were obtained from Miltenyi Biotec (Bergisch Gladbach, 
Germany). Anti-CD40, CD80, CD83, CD86, CD209, anti-HLA-Dr-FITC and isotype con-
trols were obtained from BD Biosciences (San Jose, CA). Anti-HLr-Drbeta and anti-LAMP2 
were obtained from Abcam (Cambridge, MA), anti-GFP, anti-mouse AlexaFluor 546, anti-
rat AlexaFluor 568 and anti-rabbit-AlexaFluor 488 from Invitrogen (Carlsbad, CA). For 
immunofluorescence, cells were adhered to poly-L-lysine (Sigma Aldrich, Deisenhofen, 
Germany) coated coverslips, fixed in 4% paraformaldehyde, stained in permeabilisation 
buffer (PBS containing 0.05% Triton X-100) and embedded in SlowFade Gold (Invitrogen). 
Images were obtained on a Leica TCS SP2 confocal system equipped with 488 nm argon 
and 543 HeNe lasers (Leica, Mannheim, Germany) and processed using ImageJ software.    
For flow cytometry of surface markers, cells were washed and stained in PBS/0.5% BSA, 
washed again and fixed in 2% PFA. For cytokine staining, cells were washed in PBS, fixed 
in 2% PFA, permeabilized and stained in 0.5% saponin and washed in PBS/0.5% BSA. All 
samples were analyzed using a FACSCalibur (BD Bioscience) and FlowJo Software (Tree-
star, Ashland, Or). 
For immunoblotting the following antibodies were used: anti-human p62 lck ligand (BD), 
anti-GFP serum (Invitrogen), anti-pLAT Tyr191 (Cell Signaling, Beverly, MA).
  Cell isolation and generation of dendritic cells
Monocytes and lymphocytes were isolated from buffy coats using Ficoll and Percoll den-
sity gradients according to a previously described protocol. 15 For generation of human DC, 
monocytes were then cultured for 6-8 days in AIM-V culture medium (Invitrogen) in the 
presence of recombinant human GM-CSF and IL-4 (both 100 ng/ml, rnD Systems, Inc. 
Minneapolis, MN). 
For patient studies, Crohn’s disease patients were genotyped for rs_2241880 (ATG16L1) 
and rs_5743293 (NOD2) using polymerase chain reaction restriction fragment length poly-
morphisms. Inclusion criteria were homozygosity for either the risk or wild type allele of 
ATG16L1 and homozygosity for the wild type allele of NOD2. Venous heparinized blood was 
obtained and monocytes were isolated using Ficoll density gradient followed by magnetic 
bead isolation (Miltenyi). Monocytes were then used for further analysis and culture. All 
patients gave informed consent and the study was approved by the Ethical review Commit-
tee.
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For generation of mouse dendritic cells (BMDC), bone marrow was isolated from femur 
and cultured in rMPI 1640 culture medium (Invitrogen), in the presence of 10% FCS and 
20 ng/ml recombinant mouse GM-CSF (rnD Systems Inc.) for 7-9 days.
  Transfection of dendritic cells
ON-TargetPlus ATG16L1, IrGM and NOD2 specific sirNA pools were obtained from Dhar-
macon (Epsom, United Kingdom), and control non-specific sirNA from Ambion (Austin, 
Texas). All were transfected using Dharmafect 4 (Dharmacon) reagent according to the 
manufacturer’s protocol. Plasmid encoding eGFP-LC3 fusion protein was described previ-
ously (Addgene plasmid 11546 16). To generate the plasmid encoding the SNAP-ICAM-1 
fusion protein, human ICAM-1 was amplified by PCr from Addgene plasmid 8632 17 using 
targeted primers (forward CAGGCGCGCCAGCTCCCAGCAGCCCCCGG, reverse CAG-
GATCCTCAGGGAGGCGTGGCTTG) containing BamHI and ASCI restriction sites and 
cloned into the pSNAP-Tag vector (New England Biolabs, Ipswich, MA). All plasmids were 
transfected using Lipofectamine 2000 reagent (Invitrogen). Surface expression of SNAP-
ICAM was visualized by staining of transfected DC with SNAP-Surface 549 cell imper-
meant fluorescent dye (New England Biolabs) according to the manufacturer’s suggestions.
  RNA isolation and quantitative pcr
rNA was isolated using the rNAeasy mini kit (Qiagen, Hilden, Germany) and cDNA was 
generated using revertAid reverse transcriptase (Fermentas, St Leon-rot, Germany) and 
random hexamer primers (Promega, Leiden, The Netherlands). Quantitative pcr reactions 
were carried out using Quantitekt primer assays and SybrGreen PCr Kit (both Qiagen). 
For relative expression, all data was normalized against expression of the household gene 
GAPDH.
  DC-T cell cluster formation and analysis
DC-T cell clusters were induced as described previously. 14 Briefly, DC and T cells were cen-
trifuged together at 50xg in a 15 ml conical tube and incubated at 37oC for times indicated. 
Where indicated DC were pre-treated with 10 mM 3-methyladenine (Sigma Aldrich, Deisen-
hofen, Germany) for 2 hours at 37 oC after which cells were washed carefully. For antigen 
specific interactions, OVA
323-339
 and control OVA
257-264
 peptide (2 μg/ml, both AnaSpec Inc, 
San Jose, CA) were added. For Western Blot analysis cells were then lysed in lysisbuffer 
(Cell Signaling Technology, Beverly, MA) containing Protease Inhibitor Cocktail (MP Bio-
medicals Inc., Solon, OH), and homogenized by ultrasound sonication. Samples were run 
on SDS-PAGE gels under reducing conditions and transferred to an Immobilon-P mem-
brane (Millipore, Billerica, MA). Membranes were blocked by incubation in 5% blocking 
powder (Bio-rad, Hercules, CA) and incubated with primary and secondary antibodies in 
1% blocking powder (Biorad). Expression was detected by Lumilight Plus (roche, Woerden, 
The Netherlands) and image analysis was performed using ImageJ software.
For analysis of cytoskeletal polarization, clusters were plated on Poly-L-lysine (Sigma) coated 
slides and fixed in 4% paraformaldehyde. Polarization of the cytoskeleton was visualized 
using phalloidin-AlexaFluor 488 (Invitrogen) and scored on a three point scale by two inde-
pendent observers.
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  Mixed lymphocyte reaction and Th subset induction
For mixed lymphocyte reactions, DC were co-cultured with allogeneic lymphocytes for 72 
hours. For OVA specific reactions, BMDC were cocultured with isolated OTII splenocytes in 
the presence of OVA
323-339
 peptide for 72 hours. Proliferation was measured by 3H-thymidine 
incorporation assay.
For analysis of Th subset induction, CD45rO+ T cells were isolated from peripheral blood 
using magnetic beads (Miltenyi Biotec) and co-cultured with autologous DC in the pres-
ence or absence of anti-IFNγ (10 μg/mL, rnD Systems) for 4 days and restimulated during 
4-6 hours using Phorbol Myristate Acetate and ionomycin (both Sigma) in the presence of 
Golgistop (BD Biosciences).
  Time lapse analysis
DC were plated on glass bottom microwell dishes (MatTek Corp. Ashland, MA) and allowed 
to adhere for 2 hours at 37oC. When appropriate, OVA peptide was added during adhesion. 
Supernatant was removed and lymphocytes (human: peripheral blood lymphocytes, mouse: 
OT-II spleen cells) were added to the plates and allowed to settle for 1 minute. Sequential 
images were then taken every 20 seconds for 30 minutes using a Zeiss Axiovert 200M 
inverted microscope and processed using OpenLab 3.09 software (Perkin Elmer, Waltham, 
MA). The resulting image sequences were analysed by two independent observers.
  Statistics
Statistical analyses were performed using SPSS (SPSS Inc., Chicago, IL) or GraphPad 
(Graphpad software Inc., La Jolla, CA). Analyses included Mann-Whitney U test (non paired 
data), Wilcoxon square rank test (paired data), Kruskall Wallis test followed by Dunn’s mul-
tiple comparisons (multiple comparisons) and Spearman’s rho (correlations). Data was 
considered significant if p<0.05.
  Results
  Decreased DC autophagy results in increased T cell stimulatory capacity
Expression of ATG16L1 was decreased in human DC using sirNA technology and con-
firmed by quantitative PCr and immunoblotting for the autophagy target p62 (Supplemen-
tary Figure 1A/B). Although autophagy has been described as a cell death pathway, under 
our experimental (nutrient sufficient) conditions cell viability was not altered in ATG16L1low 
DC (Supplementary Figure 1C).
ATG16L1low DC induced significantly more proliferation in allogeneic lymphocytes than 
control DC (Figure 1A). To verify that the increased stimulatory capacity of ATG16L1low cells 
was due to diminished autophagy rather than an unknown function of ATG16L1, results 
were confirmed by inhibition of a second autophagy related protein, IrGM (Figure 1A). 
Additionally, autophagy knockdown in murine BMDC resulted in increased proliferation of 
ovalbumin-specific T cells in the presence of their cognate antigen (Figure 1B), suggesting 
the mechanism also operates in antigen specific responses and is conserved across species.
Expression of activation markers including HLA-Dr, CD80, CD86 and CD83 was not altered 
after knockdown, neither before nor after co-culture with lymphocytes (Figure 1C and data 
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Figure 1 Decreased DC autophagy results in increased T cell proliferation without phenotypic 
maturation.
(a) Inhibition of autophagy genes ATG16L1 or IRGM in DC results in increased allogeneic T cell stimulation 
in an MLR culture. Cells were co-cultured for 72-96 hours, data normalized against proliferation in the con-
trol sample of the same donor, n=10 and n=9 respectively. (b) Decreased autophagy in BMDC pulsed with 
OVA results in increased OTII proliferation. Cells were co-cultured for 96-120 hours, data normalized against 
control sample, mean and s.e.m. of three independent experiments shown. (c) Inhibition of ATG16L1 expres-
sion does not alter DC maturation. DC were treated with ATG16L1 (green line) or control (red line) siRNA 
for 48 hours and analyzed by flow cytometry, blue lines indicate control staining. Data is representative of 
four independent experiments. (d) Inhibition of ATG16L1 expression does not alter DC cytokine secretion. 
Cyokine secretion of DC co-cultured with allogeneic lymphocytes (ratio 1:5) was determined in supernatants 
by cytometric bead array. Data normalized against control of the individual donors. Mean and s.e.m. of three 
individual experiments shown. (a,b) * indicates p<0.05, ** p<0.01
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not shown). Furthermore, decreased expression of ATG16L1 did not affect the secretion 
of proinflammatory cytokines IL-1β, IL-6 and TNF-α, nor of the regulatory cytokine IL-10 
(Figure 1D), suggesting that the immunogenic phenotype was not due to increased DC 
maturation. 
  Decreased autophagy increases interaction strength in DC – T cell interactions
Interestingly, knockdown of ATG16L1 and IrGM gene expression resulted in a change in 
the gross morphology of DC, in that cells showed a more elongated phenotype (Figure 2A). 
This suggests that autophagy affects the cytoskeletal organization of DC. As polarization 
of the actin cytoskeleton is a key feature of DC-T cell interactions, we reasoned that such 
cytoskeletal effects may also affect DC mediated immune responses. Upon antigen recogni-
tion, DC and T cells form an immunological synapse, a highly organized molecular struc-
ture at the site of contact between the two cells. 13 One characteristic of the immunological 
synapse is the polarization of the actin skeleton towards the site of interaction. The rele-
vance of this polarization is shown by the fact that inhibition of cytoskeletal rearrangements 
results in decreased T cell activation. 18 We hypothesized that autophagy knockdown would 
alter polarization of the DC actin skeleton. Therefore, allogeneic DC-T cell interactions were 
induced in vitro and the level of polarization was measured. Significantly stronger actin 
polarization was seen in DC in which autophagy was inhibited either by ATG16L1 or IrGM 
knock-down (Figure 2B). Again, this finding was consistent in OVA-specific murine BMDC-
T cell interactions (Supplementary fig. 2A).
We further confirmed the role of the autophagy pathway as a whole using the autophagy 
inhibitor 3-methyladenine (3-MA). Since it has been shown previously that T cells require 
some level of autophagy to prevent activation induced cell death, 19 it was not possible to 
add 3-MA directly to the cultures. Instead, DC were pre-incubated with 3-MA for two hours. 
Cells were than washed carefully, and used in subsequent polarization experiments. Indeed, 
pharmacological inhibition of autophagy also resulted in increased cytoskeletal polarization 
(Figure 2C), suggesting a role for the pathway as a whole.
The outcome of immune responses is not only determined by the polarization and recruit-
ment of molecules, but also by the duration of the interaction. 20, 21 As has been described 
previously, inhibition of proper immunological synapse formation by the myosin II inhibi-
tor blebbistatin resulted in decreased duration of DC-T cell interactions and decreased T cell 
activation (data not shown). To measure the effect of decreased autophagy on the duration of 
DC-T cell interactions, we performed time lapse experiments. Both ATG16L1low and IrGM-
low DC engaged in more prolonged interactions with allogeneic T cells (Figure 2D, left). 
In accordance with a conserved role for autophagy in immune regulation, similar results 
were obtained for the interaction between murine BMDC loaded with cognate antigen and 
OTII splenocytes (Figure 2D, right). Together this data suggests that in DC, autophagy is a 
regulatory mechanism, controlling the strength and duration of DC-T cell interactions and 
thereby the ensuing immune response. 
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Figure 2 Decreased autophagy leads to increased cytoskeletal rearrangements in DC and 
prolonged DC-T cell interactions. 
(a) DC generated from siRNA treated monocytes show an elongated phenotype. Representative light microscopy 
image of each condition (magnification 200x, left). Cell length was measured by image analysis in arbitrary units 
(right). Mean and s.e.m. of >50 cells per condition is shown. (b,c) DC-T cell clusters were generated by centrifuga-
tion at 50g and maintained for 30 min. Actin skeleton was visualized by phalloidin staining and scored for actin 
polarization on a three point scale (0-2). Bars represent mean and s.e.m., representative figure of three indepen-
dent experiments. (c) DC were pre-treated with 3MA for 2 hours and washed carefully prior to clustering with T 
cells. (d) Time lapse analysis of DC-T cell interactions. Allogeneic T cells were added to adherent siRNA treated 
human DC (ratio 5:1, left panel) and OTII cells were added to adherent siRNA treated BMDC in the presence of 
cognate antigen (OVA323-339 peptide, 1 μg/ml, ratio 1:5, right panel). All samples were analyzed for 30 minutes 
by time lapse microscopy and total duration of individual interactions were calculated in duplicate samples. Inter-
actions were categorized as short (< 3 minutes, black)), intermediate (3-15 minutes, white) or long >15 minutes, 
grey). Results are representative of five independent experiments. * indicates p<0.05, ** p<0.01
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  Decreased DC autophagy results in Th17 polarization
One important function of DC in the regulation of immune responses is the skewing of 
T cells. Although the sharp distinction between Th1, Th2 and Th17 cells has proven less 
obvious in humans than in rodents, human T cell subsets also produce varying degrees of 
the effector cytokines IFNγ, IL-4 and IL-17. The stability of DC-T cell interactions has been 
shown to influence the Th1/Th2 balance, 22 but data regarding the effect on Th17 has not 
been available thus far. Given the potential role of the Th17 axis in inflammatory bowel 
disease, 23, 24 we tested the effect of decreased autophagy on the polarization of Th17 cells. 
To this end, DC were co-cultured with CD45rO+ T cells without the addition of exogenous 
cytokines. Both ATG16L1low and IrGMlow DC induced significantly more IL-17 producing 
cells in an array of donors (Figure 3A). In contrast, the level of IFNγ producing cells was not 
altered (Figure 3A). 
Figure 3 Immunological synapse hyperstability results in increased Th17 polarization.
(a,b) Isolated CD45RO+ T cells were co-cultured with autologous siRNA treated DC for 4 days, restimulated by 
PMA/ionomycin and analyzed by flow cytometry (a), quantitative pcr or ELISA (b). (a) Left panel shows repre-
sentative data, bars represent mean (normalized against control sample in each donor) and s.e.m. of duplicate 
experiments in five different donors. (b) Bars represent mean relative mRNA expression and s.e.m. (left and right 
panel, n=3 and n=4 respectively) normalized against GAPDH and CD11c expression in each individual donor. Mid-
dle panel represents mean protein level and s.e.m. of four individual donors. (c) Isolated CD45RO+ T cells were 
co-cultured with autologous siRNA treated DC for 4 days in the presence of blebbistatin (5 μM) or vehicle control 
(DMSO), restimulated by PMA/ionomycin and analyzed by flow cytometry. Data are normalized against vehicle 
control for each donor and represent mean and s.e.m. (n=5). * indicates p<0.05, ** p<0.01
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Various cytokines have been implicated in the development of Th17 cells in vitro, including 
IL-23, IL-6 and TGF-β. However, IL-23 mrNA levels were unaltered and protein levels were 
decreased rather than increased in ATG16L1 sirNA treated DC (Figure 3B). Furthermore, 
DC production of TGFβ1 and IL-6 was also comparable in autophagylow and control cells 
(Figure 3B and Figure 1D), suggesting that increased secretion of Th17 inducing cytokines 
is not the mechanism underlying the T cell skewing observed. To further analyze the role 
of synaptic stability in the activation of Th17 responses, we used the myosin II inhibitor 
blebbistatin. Complete myosin inhibition would quench all cellular interactions and be toxic 
in long term cultures, such as those required for induction of Th17 responses. Therefore, we 
used a relatively low dose in order to destabilize but not completely abolish immunological 
synapse formation. Interestingly, we found that in the presence of blebbistatin polarization 
towards the Th17 phenotype was decreased, whereas the induction of Th1 was not signifi-
cantly affected (Figure 3C). This results in a decreased Th17/Th1 balance, suggesting that 
Figure 4 ATG16L1 Crohn’s disease susceptibility allele induces DC hyperpolarisation and tilted 
Th17/Th1 balance.
(a) Monocyte-T cell clusters were induced by centrifugation at 50g, actin was stained using phalloidin and actin 
polarization was scored on a three point scale (0-2, n=9). (b) Monocytes isolated from peripheral blood were 
cultured in the presence of GM-CSF and IL-4 for six days, two images were taken from each well at random loca-
tions and processed by image analysis (n=9), right panel shows representative images from 2 donors . (c) DC 
were co-cultured with allogeneic T-cells for 96 hours. Supernatant was then collected for cytokine measurements 
by ELISA (d) Cell length as measured in section (a) was correlated to IL-17 concentration in supernatants using 
Spearman’s Rho. * indicates p<0.05
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the stability of the immunological synapse itself may be involved in determining the polari-
zation of the immune response.
  ATG16L1 risk allele carrier DC display hyperpolarization and increased Th17 induction
To confirm the physiological relevance of autophagy-based immune regulation, we 
recruited Crohn’s disease patients homozygously carrying either the wild type or the 
T300A risk allele for ATG16L1. 1 Since protein interactions between ATG16L1 and NOD2 
have been described previously, we excluded carriers of the NOD2 3020insC risk allele to 
avoid confounding by this polymorphism. In accordance with our previous data, mono-
cytes obtained from ATG16L1 risk allele carriers exhibited significant hyperpolarization 
of the actin cytoskeleton, indicating more stable synapses (Figure 4A). Furthermore, DC 
generated from patients carrying the risk allele were significantly longer than DC from 
patients expressing the wild type allele, similar to the data obtained using gene knock-down 
(Figure 4A). Furthermore, co-culture of CD45rO+ T cells and T300A expressing DC resulted 
in a trend towards increased levels of IL-17 but not IFNγ secretion compared to wild type DC 
(Figure 4B). Strikingly, the level of IL-17 secretion was strongly correlated to DC length, but 
not to activation marker expression (Figure 4C and data not shown), further supporting the 
link between the cytoskeletal aberrancies and the increased presence of Th17 cells.
  Immunological synapse formation induces autophagy in DC
To further decipher the mechanism by which autophagy regulates stability of the immuno-
logical synapse, we evaluated whether autophagy is upregulated by synapse formation. Dur-
ing autophagy, the autophagosomal protein LC3 is converted from 18 kD (LC3 I) to 16 kD 
(LC3 II), leading to an increased LC3 II/ LC3 I ratio. 25 This ratio can therefore be used as a 
measure of the level of autophagy. GFP-LC3 transfected DC were incubated in the presence 
or absence of allogeneic T cells, and the LC3 II/I ratio was determined by immunoblotting 
against GFP. Indeed, DC co-incubated with allogeneic T cells for more than 30 minutes 
showed autophagic processing compared to DC alone (Figure 5A).
This finding was further confirmed by quantification of GFP-LC3 puncta (which are formed 
upon induction of autophagy, Figure 5B) in single and clustered DC in the same image 
field. The number of LC3 puncta was increased significantly in clustered DC compared to 
single DC, suggesting the induction of autophagy (Figure 5C). To verify that autophagy is 
induced by the actual formation of the immunological synapse rather than the mere prox-
imity of a lymphocyte, we compared allogeneic and autologous DC-T cell clusters. In allo-
geneic clusters, a real synapse is formed, including polarization of the actin cytoskeleton, 
while in an autologous setting, clusters are formed, but these do not lead to the formation 
of a full synapse. 14 Again, in the allogeneic setting, a significantly higher level of autophagy 
was present in clustered cells compared to single DC. However, in autologous interactions 
the number of puncta in clustered DC was not increased compared to the number of LC3 
puncta in single DC, indicating that under these conditions, autophagy was not induced 
(Figure 5C). Similarly, a significant increase in autophagy occurred in BMDC-OTII spleno-
cyte clusters when DC presented the cognate OVA
323-339
 peptide resulting in a full synapse. 
However, when DC were loaded with the control OVA
257-264
 peptide (Figure 5c) autophagy 
remained unaltered, emphasizing the fact that it is not the mere clustering of DC and T cells 
that leads to autophagy, but the actual cognate interaction.
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Figure 5 Immunological synapse formation induces autophagy in DC.
(a) GFP-LC3 transfected DC were incubated in the absence (black bars) or presence (white bars) of allogeneic lym-
phocytes (times indicated above lanes), samples were then blotted for GFP and LC3II/LC3I ratio was calculated by 
image analysis. Western blot representative of three independent experiments. Data normalized against control 
samples, bars represent mean and s.e.m. of duplicate experiments. (b) GFP-LC3 transfected DC were treated with 
rapamycin (right, 20 μg/ml) and analyzed by immunofluorescence. (c) Clusters were induced between GFP-LC3 
transfected DC and autologous or allogeneic T cells (left), or between BMDC and OTII cells in the presence of 
control or cognate antigen (right). Number of LC3 puncta/DC were then scored in unconjugated DC (black bars) 
and DC conjugated to T cells (white bars) in the same image fields. Data representative of three individual experi-
ments, bars represent mean and s.e.m. (d) Clusters were induced between GFP-LC3 transfected DC and alloge-
neic T cells and maintained for indicated periods. Cells were then imaged by confocal microscopy and relative 
distance was calculated as (distance of LC3+ spot to contact site / maximum width of the cell at site of synapse). 
Spot size was measured by image analysis. * indicates p<0.05, ** p<0.01
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To further establish whether this autophagy induction was related to stability of the immu-
nological synapse, we measured the relative distance between the autophagosome and the 
synapse (that is, the distance between the LC3+ spot and the site of cell-cell contact rela-
tive to the maximum width of the cell). If the autophagosomes are distributed randomly 
throughout the cell, this relative distance would have an average of 0.5. However, when 
measuring the relative distance over a large number of clusters, the average distance is 
significantly below 0.5, suggesting a preferential localization towards the immunological 
synapse (Figure 5D). 
Figure 6 Autophagosomes are involved in degradation of synaptic components.
(a) Clusters of GFP-LC3 transfected DC and allogeneic T cells were induced for 60 minutes and stained for expres-
sion of HLA-DR (red). Subcellular localization of positive staining was determined by confocal imaging. Three 
individual clusters are shown, arrows indicate position of T cell in cluster. (b) Position of LC3+/MHC+ and LC3+/
MHC- spots were calculated as relative to maximum width of the cell. Data representative of three independent 
experiments in four donors. (c) Clusters of GFP-LC3 transfected DC and allogeneic T cells were induced for 60 
minutes and stained for expression of HLA-DR (red) and LAMP2 (blue). Arrows indicate location of T cell in 
cluster. Arrowheads indicate line of analysis shown in line graphs. Graphs show relative signal intensity along the 
same line for all three stainings. Data representative of three individual experiments in different donors. (d) GFP-
LC3 and SNAP-ICAM transfected DC were surface stained for ICAM (red). ICAM localized around phagocytic cups 
(indicated by arrows) and co-localized with LC3. Picture representative of two independent experiments. (a,c,d) 
All images magnification 630x and taken at a single Z-stack level in each cell
C
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  Autophagosomes close to the immunological synapse contain synaptic components
When we analyzed the formation of autophagosomes during formation of the immunologi-
cal synapse, we not only observed a preferential localization towards the contact site, but 
also an increase in the size of autophagosomes between 30 minutes and 2 hours of DC-T 
cell interactions (Figure 5D). Given that autophagy is mainly involved in the degradation 
of cellular components, we hypothesized that these growing structures are sites of degra-
dation of synaptic components, thereby destabilizing the synapse. To test this, clusters of 
GFP-LC3 transfected DC and allogeneic T lymphocytes were induced as described before, 
and localization of the central immunological synapse component MHC II was determined 
by confocal imaging. In line with our hypothesis, clustered DC showed clear colocaliza-
tion of autophagosomes and MHC II (Figure 6a). Furthermore, distance measurements 
revealed that while autophagosomes in general are localized somewhat preferentially near 
the synapse, LC3+ spots containing MHC II molecules are localized significantly closer to 
the synapse (Figure 6B). To exclude the possibility that the MHC II/LC3 colocalization was 
caused by fusion of autophagosomes and late endosomes/lysosomes, 6 samples were also 
stained for the endo/lysosomal marker LAMP2. Although the majority of spots stained posi-
tive for all three markers, puncta positive for LC3 and MHCII but negative for LAMP2 were 
also observed, showing these spots are in fact autophagosomes containing non-lysosomal 
derived MHCII (Figure 6C). To further confirm this data, colocalization of the immunologi-
cal synapse component ICAM-1 was determined using SNAP-tag technology. After expres-
sion in the cell of interest, the SNAP-tag can be labeled fluorescently using a cell non-per-
meable dye, resulting in the selective staining of proteins present on the outside of the cell 
membrane. We created an SNAP-ICAM-1 fusion construct, and labeled membrane ICAM-1 
during formation of the immunological synapse. Similar to MHC II, ICAM-1 colocalized 
with LC3 puncta close to the synapse (Figure 6D). Since ICAM-1 staining was only possible 
at the cell surface these ICAM-1 molecules have to be membrane derived. The presence of 
immunological synapse derived molecules in autophagosomes close to the synapse strongly 
suggests that these autophagosomes play an active role in degradation and thereby regula-
tion of the synapse. 
  Discussion
We demonstrate that cognate interactions between DC and T cells induce autophagy 
which in turn negatively regulates the interaction. Decreased autophagy in DC resulted in 
increased formation of the immunological synapse, prolonged DC-T cell interactions and 
increased T cell activation and Th17 polarization.
Autophagy was first described over three decades ago, but was initially only considered 
a cell survival mechanism. The identification of several autophagy genes as susceptibility 
genes for Crohn’s disease has lead to renewed attention for the field, in particular its role 
in the immune system. Autophagy contributes to innate immunity through degradation 
of intracellular pathogens, including Mycoplasma Tuberculosis, Listeria Monocytogenes and 
Salmonella Enterica. 26, 27, 28 Diminished autophagy may therefore result in defective innate 
immunity, excessive microbial expansion and unbalanced adaptive immune activation. This 
mechanism, known as the theory of innate immunodeficiency, has been proposed to be 
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responsible for the elevated immune activation seen in Crohn’s disease patients carrying 
these SNP. However, although impaired clearance of intracellular pathogens may contrib-
ute to the excessive immune responses seen in Crohn’s disease, our study shows that a 
deficient autophagy can also directly hyperactivate T cell responses. 
Previous studies into formation of the immunological synapse mainly focused on the T cell. 
The ‘other side’ of the synapse (ie, the DC) has received relatively little attention, leading to 
a void in the knowledge on this topic. However, inhibition of actin polarization specifically 
in DC hampers the formation of a proper synapse and significantly decreases T cell activa-
tion and proliferation. 14 Additionally, a recent study showed recruitment of the signaling 
molecule phosphatidylinositol-4,5-biphosphate to the synapse as well as local activation of 
Akt1 in DC suggesting active signaling in DC. 29 Our study further confirms the active 
participation of DC in immunological synapse formation, as autophagy knockdown specifi-
cally in DC results in altered synapses. This effect appears to be part of a negative feedback 
mechanism, as autophagic activity increases upon formation of a mature immunological 
synapse. Dendritic cells have a basal level of constitutive autophagy, which is increased 
upon synapse induction. Most likely only part of these autophagosomes are involved in 
regulation of the immunological synapse, whereas others play a role in cellular homeo-
stasis. This may explain why localization of autophagosomes is somewhat polarized to the 
synapse, but still displays a relative big spread. Synaptic components such as MHCII and 
ICAM-1 are engulfed by autophagosomes, targeting them for degradation. Although no data 
is available on the relationship between the number of molecules present and the strength 
of the immunological synapse, it is not hard to imagine that a decrease in the number of 
interacting molecules leads to a relative destabilization of the synapse. Previously, it has 
been shown that membrane expression of MHCII is regulated through ubiquitination of 
the molecule and that ubiquitination can target proteins to the autophagosomes. 30-32 There-
fore, ubiquitination of synaptic components may be the mechanism behind the trafficking 
observed. Interestingly, ubiquitination-related polymorphisms have recently been associ-
ated with the development of Crohn’s disease. 33, 34 Whether these polymorphisms have 
similar consequences for the regulation of cell-cell interactions as autophagy related defects 
would be an interesting topic of investigation.
Interestingly, a recent study shows that the protein encoded by another Crohn’s disease 
susceptibility gene, NOD2, is necessary for proper localization of ATG16L1 at the cell mem-
brane. 35 The susceptibility variant of NOD2 lacks this function, resulting in abnormal cyto-
plasmic ATG16L1 distribution. Given the important role of the membrane in cell-cell inter-
actions, it is tempting to speculate that membrane localization of ATG16L1 is also neces-
sary for proper regulation of DC-T cell interactions. Indeed, in our experiments, decreased 
expression of NOD2 resulted in a DC hyperpolarization similar to that observed in autopha-
gylow DC (Supplementary Figure 2B). This suggests that NOD2 and ATG16L1 risk alleles 
can independently lead to decreased pathogen degradation as well as increased adaptive 
immune activation, thus explaining why the risks carried by these alleles appear to be inde-
pendent rather than cumulative.
Several studies have highlighted the importance of autophagy in the antigen presentation 
by MHC class II molecules. When influenza matrix antigen was targeted to the autophago-
some, increased presentation and T cell activation was observed. 6 More recently, Atg5loxCD-
11ccre mice lacking autophagy specifically in DC show decreased MHC II antigen presenta-
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tion due to decreased autophagosomal-lysosomal fusion. 36 Consequently, these DC were 
less capable of inducing T cell activation and mice showed impaired immune responses. 
The different results in this study compared to ours may be explained by the fact that the pre-
vious study used a complete knockout model, whereas in our model DC display decreased 
autophagy levels, but not a complete deficiency. Differential levels of autophagy may be 
required for regulation of antigen processing versus regulation of immunological synapse 
stability. Whereas the complete knockout is a relevant model to study if a specific gene 
plays any role in a given process, our model may be more reflective of the effect of hypo-
morphic alleles as seen in Crohn’s disease patients. Indeed, several of the effects seen in 
our autophagylow DC are mirrored by results in DC generated from Crohn’s disease patients 
carrying the ATG16L1 risk allele, confirming the physiological relevance of our findings.
The role of the immunological synapse in the polarization of T helper responses has been 
investigated previously in the context of Th1/Th2 skewing. For example, synapses result-
ing in Th1 polarization contain a clear ICAM-1 ring structure and exclusion of CD45 from 
the central synapse, while synapses resulting in Th2 skewing contain more phosphotyro-
sines.37 To the best of our knowledge, no data are available on the role of the synapse in 
the induction or activation of Th17 cells. In our experiments, secretion of the Th17 induc-
ing factors IL-23, IL-6 and TGF-β 38 was not increased in autophagylow DC, indicating that 
the Th17 polarization observed is not due to altered cytokine secretion. Although we can 
not formally exclude that the increase in Th17 is the result of alterations in DC other than 
increased immunological synapse formation, we have not observed any such alterations. 
Furthermore, destabilization of the synapse using blebbistatin resulted in a decreased Th17 
skewing, further supporting our hypothesis that hyperstability of the immunological syn-
apse positively correlates with the induction of Th17 responses.
Our results demonstrate a novel role for autophagy in the regulation of immunologi-
cal synapse stability and subsequent strength and polarization of the adaptive immune 
response. The clinical implications of these findings are shown by the fact that Crohn’s dis-
ease patients carrying polymorphisms in ATG16L1 display similar alterations in their DC, 
including hyperpolarization and a tendency towards increased induction of IL-17 produc-
ing T cells. Interestingly, azathioprine, a frequently used therapy for Crohn’s disease, has 
been shown to destabilize DC-T cell interactions through inhibition of the rac pathway. 39 
Our data suggest that this may in fact be a therapeutic mechanism for this drug in Crohn’s 
disease. Additionally, other medications interfering with immunological synapse formation 
may be new candidates for Crohn’s disease treatment.
In summary, this study shows that upon formation of the immunological synapse, 
autophagy is induced, which then acts as a negative feedback regulator of DC-T cell interac-
tions by destabilizing the synapse. In Crohn’s disease patients carrying the ATG16L1 risk 





  Supplementary figures
Supplementary figure 1.
(a) DC were treated with specific or control siRNA for 48 hours and analyzed by quantitative PCR. All data was 
normalized against GAPDH. Bars indicate mean expression and s.e.m., representative of >10 experiments. (b) 
siRNA treated DC were stimulated with rapamycin for 12 hours (20 μg/ml) and immunoblotted for expression 
of p62. Data representative of three donors. (c) siRNA treated DC were cultured for three days in RPMI culture 
medium containing 10% FCS and tested for viability by MTS assay. Bars represent mean and s.e.m. of three 
individual donors
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Supplementary figure 2.
Clusters were formed between T cells and DC (a) pre-treated with 3MA (1 mM, 2 hours) or (b) transfected using 
NOD2 siRNA. Data representative of three individual experiments. Actin skeleton was visualized by phalloidin 
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Anti-TNFα antibodies are effective in Crohn’s disease whereas soluble TNFα receptors have 
failed to show clinical efficacy. The molecular mechanism that underlies the differences 
between these compounds has not been elucidated. Here we aimed to examine the mecha-
nism of action of the immunosuppressive effect of anti-TNFα antibodies on activated T 
cells.    
We studied the effect of anti-TNFα antibodies infliximab and adalimumab, the soluble 
TNFα receptor etanercept, pegylated F(ab’) fragment certolizumab and certolizumab-IgG 
on primary activated T cells. T cells were grown in isolation or in a mixed lymphocyte reac-
tion (MLr). Proliferation was measured by 3H thymidine incorporation and apoptosis was 
examined using Annexin V labeling and a colorimetric assay for activated caspase-3. Mac-
rophage phenotype was assayed by flow cytometry and cytokine secretion. 
Infliximab and adalimumab reduced proliferation in an MLr, whereas etanercept and cer-
tolizumab did not. This effect was completely abolished after blocking Fc receptors. Inflixi-
mab F(ab’)2 fragment failed to inhibit proliferation whereas certolizumab-IgG gained the 
ability to inhibit proliferation. In the MLr anti-TNFs induced a new population of mac-
rophages in an Fc region dependent manner. These macrophages were found to have an 
immunosuppressive phenotype, in terms of their capacity to inhibit proliferation of acti-
vated T cells, production of anti-inflammatory cytokines and the expression of the regula-
tory macrophage marker CD206. 
regulatory macrophages have immunosuppressive properties and play an important role 
in wound healing. Our data show that anti-TNFs induce regulatory macrophages in an Fc 
region dependent manner. This mechanism of action of anti-TNFs may contribute to the 
resolution of inflammation. 
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  Introduction
Crohn’s disease (CD) is a chronic inflammatory bowel disease that results from a dysregu-
lated immune response of unknown aetiology. 1-3 Tumour necrosis factor alpha (TNFα), a 
cytokine produced by activated macrophages, monocytes and T cells, 4 is a key mediator in 
immune responses and is increased in serum and intestine in CD and synovium in rheu-
matoid arthritis (rA). 5-7
Since their introduction in the ’90s, anti-TNFα antibodies are commonly used for the treat-
ment of Crohn’s disease. Various classes of anti-TNFs have been introduced, and although 
all classes efficiently neutralize TNFα, they show different efficacy profiles. The antibodies 
infliximab 8, 9 and adalimumab 10, 11 were shown to be effective in both inducing and main-
taining remission in CD patients. On the other hand, two soluble receptors; etanercept and 
onercept were ineffective in inducing remission in CD patients. 12, 13 Also, the humanized 
anti-TNFα antibody CDP571 which was designed as an IgG
4
 to reduce interaction with Fc 
receptors in the hope to reduce side effects also failed to show effectiveness in CD. 14 These 
clinical data strongly suggest that neutralizing TNFα may not be the sole mechanism of 
action of anti-TNFα treatment in Crohn’s disease. 
Several effector mechanisms of anti-TNFα treatment have been proposed that are independ-
ent of TNFα neutralizing activity.  Examples are the induction of apoptosis in T cells and 
monocytes via binding of membrane bound TNFα (mTNFα), 15-17 antibody-dependent-cell-
mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity. 18, 19 Furthermore, a 
role for Fc receptors has been proposed based on the association between a polymorphism 
in the Fc gamma receptor IIIa and the biological response to infliximab. 20 Fc receptors 
bind the Fc region of an antibody or antibody-complex, resulting in myeloid cell activation, 
phagocytosis and cytokine secretion. The importance of Fc receptors in the mechanism of 
action of other antibody therapies such as anti-CD20 and anti-Human Epidermal growth 
factor receptor 2 (Her2) has been described before. 21, 22 In Fcγ-/- mice which are unable to 
bind Fc regions, both anti-CD20 and anti-Her2 lost their efficacy in reducing tumor size, 
demonstrating a key role for the Fc receptor in the mechanism of action of these antibodies. 
Although a number of mechanisms have been suggested, it is still unclear why certain 
anti-TNFs are effective in Crohn’s disease and other anti-TNFs are not. Many studies on 
the mechanism of action of anti-TNFα focus on binding to mTNFα  and reverse signaling 
in T cells, 18, 23 whereas the effect and importance of binding to Fc receptors has not been 
established thus far. 
In this study, we found that in order for an anti-TNFα to inhibit T cell proliferation in vitro, 
the compound needs to bind to mTNFα on activated T cells and posses an Fc region to 
interact with the Fc receptor on antigen presenting cells. Upon this binding, a distinct mac-
rophage subset is induced with immunosuppressive capacities, including the production of 
anti-inflammatory cytokines and inhibition of T cell proliferation.  
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  Material and methods
  Antibodies and Reagents
Infliximab, certolizumab, adalimumab and etanercept were prepared according to manu-
facturers’ recommendations. Certolizumab-IgG was obtained from UCB (UCB, Belgium), 
and IgG
1k
 was obtained from Sigma. 
  Cell isolation and culture
Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were isolated by Ficoll 
Paque density-gradient centrifugation. After washing, monocytes were isolated by Percoll 
density-gradient centrifugation. CD3 positive T cells were isolated from PBMCs using nega-
tive magnetic bead separation (Invitrogen). For T cell activation, cells were activated with 
αCD3/αCD28 antibodies (Sanquin) at the indicated concentration or αCD3/αCD28 beads 
(Invitrogen) (1 bead/5 cells). PBMCs and T cells were cultured in rPMI 1640 containing 
10% heat-inactivated FCS. 
Dendritic cells (DCs) were obtained by culturing monocytes with GM-CSF (50 ng/mL, 
r&D), IL-4 (50 ng/mL, r&D) for 7 days in AIM-V medium. To generate macrophages, 
monocytes were cultured in 6 wells plates for 5 days. 
Infliximab induced macrophages (Mφ
ind)
 were isolated from MLr cultures using CD14 
microbeads according to manufacturer’s protocol (Miltenyi). Next, cells were cultured in 
rPMI 1640, containing 10% heat-inactivated FCS. For light microscopy, cells were adhered 
to poly-L-lysine coated coverslips and stained using DiffQuick. 
  Binding to membrane TNFα 
For mTNFα binding assays, infliximab, certolizumab, adalimumab, etanercept and control 
IgG were labeled with a fluorescent dye using a commercially available kit according to the 
manufacturers’ instructions (Alexa Fluor 647 protein labeling kit, Pierce). CD3 positive T 
cells were activated with αCD3/CD28 antibodies for 48 hours. Cells were collected, washed 
three times in FACS buffer (PBS containing 1% BSA) and incubated with various amounts 
of labeled anti-TNFα compound or IgG control for 30 minutes on ice. Binding of inflixi-
mab F(ab’)2 fragment was assessed in a competition assay; activated T cells were incubated 
with labeled infliximab (10 μg/mL) and increasing concentrations of unlabeled infliximab 
F(ab’)2 fragment at the same time.  After washing, binding to mTNFα was analyzed by flow 
cytometry. 
  Allogeneic mixed lymphocyte reaction (MLR)
PBMCs from two healthy donors were cultured in a 1:1 ratio in rPMI 1640 culture medium. 
After 48 hours of activation, cells were treated with the indicated compound (infliximab, 
adalimumab, certolizumab, etanercept, Certolizumab-IgG or IgG control, all at 10 μg/mL) 
for up to 7 days where indicated. When appropriate, Fc receptors were saturated by treating 
MLrs with IgG (10 μg/mL, Sigma) for 6 – 16 hours and next treated with anti-TNF com-
pound or IgG control for 2 days. Finally, proliferation was measured using a 3H-thymidine 
incorporation assay. 
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  Assays for apoptosis
PBMCs or isolated T cells were activated in an MLr or with CD3/CD28 antibodies for 48 hr, 
and treated with anti-TNF compound or control (10 μg/mL). Cells were collected, washed 
three times, and stained with Annexin V and Pi and analyzed by flowcytometry. 
For measurement of caspase-3 enzymatic activity, a colorimetric assay was used as described 
before. 24 Cell lysates were generated from MLr cultures and protein concentration was 
determined by BCA analysis (Pierce). Lysates were incubated with a saturating concen-
tration of 25μM specific enzyme substrate Ac-Aps-Glu-Val-Asp-AMC (Ac-DEVD-AMC, 
Bachem, Germany) in 100mM HEPES buffer with 10% sucrose, 10mM dithiothreitol and 
0.1% Nonidet-P40. Samples were incubated at 37°C and fluorescent AMC release was moni-
tored (Fluostar Optima plate reader). 
  FACS analysis 
Human monocytes and DCs were plated in 6 well plates (2 x 106 cells/well) and cultured 
with or without LPS (Sigma, 100 ng/mL) for 16 hours, and treated with anti-TNFα com-
pound or IgG control (Sigma, 10 μg/mL) for 25 – 48 hours. Cells were harvested, washed, 
and stained for αCD14-FITC, αCD40-FITC, αCD80-Pe, αCD83-APC, αCD86-APC, αHLA-
Dr-FITC and appropriate controls (all BD) for 30 minutes on ice. For analysis of marker 
expression on monocytes, macrophages and Mφ
ind
, cells were cultured in 6 wells plates and 
stained for αCD14-FITC, αCD16-FITC, αCD32-APC, αCD40-FITC, αCD80-Pe, αCD83-
APC, αCD86-APC, αCD206-APC, αCD209-Pe or αHLA-Dr-FITC (all BD). Finally, expres-
sion was analyzed by flow cytometry using a FACS Calibur (BD) and FlowJo software (Tree-
star Inc, Ashland, Or). Expression was calculated as MFI specific staining – MFI control.
  Generation of Infliximab F(ab’)2 fragment
Infliximab F(ab’)2 fragments were generated using a Fab Preparation Kit according to the 
manufacturers protocol (Pierce). Purity of the resulting fraction was analyzed by SDS-PAGE 
followed by Coomassie Blue staining and showed no remaining intact antibodies.
  Cytokine detection by cytokine beads array (CBA)
DCs, Mφ1 or Mφ
ind
 were treated or untreated with LPS for 24 hours, supernatants were 
collected and stored at -20 until use. A CBA was performed according to manufacturer’s 
protocol. Data were analyzed with FlowJo (Treestar). 
  Statistical analysis 
results are representative for at least three independent experiments and show means ± 
SEM unless otherwise indicated. For statistical analysis, one way ANOVA was used followed 
by Bonferroni post test. results were considered significant when p < 0.05. 
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  Results
  Anti-TNFα compounds bind TNFα on activated T cells to varying degrees
To assess binding of compounds to mTNFα, anti-TNFα compounds and IgG control were 
labeled with a fluorescent dye, and binding of fluorescent labeled compounds to activated 
T-cells was compared to binding to non-activated cells. Binding of infliximab and adali-
mumab to mTNFα was highly efficient, binding of certolizumab was intermediate and 
binding of etanercept was low compared to the IgG control (Figure 1).
Figure 1 Anti-TNF compounds bind to mTNF in varying degrees.
Naïve or CD3/CD28 activated T cells were labeled with a fluorescent dye (Alexa Fluor). Next, cells were incubated 
with different labeled anti-TNF compounds or IgG control for 30 minutes and binding to activated or non-acti-
vated T cells was analyzed by flow cytometry. Data are shown as means ± SD from 3 independent experiments 
  Anti-TNFα compounds with an Fc region suppress T cell activation but only in an MLR 
We examined the effect of various anti-TNFα compounds on the proliferation of activated 
T cells and found that all anti-TNFα agents slightly inhibited T cell proliferation although 
this did not reach statistical significance (Supplementary Figure 1A). This minor effect was 
similar for all anti-TNFα compounds and irrespective of their capacity to bind mTNFα, sug-
gesting it may be due to the neutralizing effect on soluble TNFα. 
As it has previously been described that anti-TNFs can induce apoptosis in T cells, we exam-
ined effects on apoptosis of T cells cultured in isolation or in an MLr. No apoptosis was 
induced in CD4+ cells treated with anti-TNFs as detected by Annexin V/Pi staining (Sup-
plementary Figure 1B). Also, no apoptosis was observed at increasing concentrations, or 
when we used other cell types or different detection methods (Jurkat cells, lymphocytes, 
monocytes, Annexin V staining, Caspase 3 activity assay; data not shown). As a result, we 
hypothesized that anti-TNFs do not have a direct effect on T cells grown in isolation and we 
established a mixed lymphocyte reaction as a model to further elucidate their anti-inflam-
matory properties. Again, in this model, no apoptosis was observed (Supplementary Figure 
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1C). In addition, no differences were observed in caspase 3 activity whether we used heat 
inactivated serum or serum without heat inactivation (Supplementary Figure 1D). How-
ever, a reproducible effect on T cell proliferation was observed with some of the anti-TNFα 
compounds in the MLr. We found that infliximab and adalimumab inhibit proliferation 
in this model, whereas etanercept and certolizumab do not (Figure 2A). The suppressive 
effect was much stronger than the effect observed in T cells alone (up to 50% inhibition in 
an MLr vs 15% inhibition in T cells alone (Supplementary fig 1A). These findings suggest 
that the various anti-TNFα compounds have distinct properties that may result in differ-
ent pharmacological behavior. To further elucidate the cell types involved in this observed 
effect, we established an MLr containing purified CD14+ cells and CD4+ T cells. In this 
assay, infliximab strongly inhibited proliferation compared to the untreated or IgG treated 
condition (Figure 2B). These data show that CD4+ T cells and CD14+ cells are sufficient to 
induce inhibition of proliferation. 
Figure 2 Anti-TNFs differ in their capacity to inhibit proliferation in an MLR.
(A) MLR cultures were treated with anti-TNF compound or IgG control (all 10 μg/mL) for 36 - 48 hours. Prolifera-
tion was measured by thymidine incorporation. Only infliximab and adalimumab significantly inhibited prolifera-
tion (** P < 0.01 and *** P < 0.001). (B) CD14+ cells and CD4+ cells from two healthy donors were cocultured 
for 48 hours. Next, cultures were treated with infliximab or IgG control (10 μg/mL) for 72 hours. Proliferation was 
measured by thymidine incorporation. Data show means ± SD from 2 independent experiments
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The main difference between the two assays we used is that an MLr contains not only T 
cells, but also antigen presenting cells (APCs). As these cells may also express low levels of 
mTNFα, binding of the anti-TNF compounds may affect the activation of the APC and thus 
decrease its T cell stimulatory capacity. To test this hypothesis, we incubated monocytes and 
dendritic cells with anti-TNFα compounds in the presence or absence of LPS and analyzed 
the expression of costimulatory molecules. No effect was found for any of the anti-TNFα 
compounds tested, either on the expression of costimulatory molecules or on the expression 
of HLA-Dr (Supplementary Figure 2), indicating that infliximab does not affect the activa-
tion of APCs.  
  Inhibition of proliferation is abolished when binding to Fc receptors is inhibited 
We found that only infliximab and adalimumab (Figure 2) were effective in the MLr, and 
both of these agents are characterized by efficient binding to mTNFα on the T cells and the 
presence of an Fc region. In contrast, certolizumab does not contain an Fc region whereas 
etanercept does, but does not bind efficiently to membrane bound TNFα. We hypothesized 
that the combination of efficient binding to T cells and the ability to bind and activate an Fc 
receptor plays an important role in the immunosuppressive function of these compounds 
in our system. To examine the contribution of the Fc receptor, the ability to inhibit MLr 
responses was tested after blocking Fc receptors with IgG. Indeed, we found that the inhibi-
tion of proliferation by infliximab was completely abolished after saturation of Fc receptors 
(Figure 3A). 
To further examine the role of the Fc receptor, infliximab F(ab’)2 fragments were generated 
from infliximab. This compound is identical to the structure of infliximab, except for the 
fact that it does not contain an Fc region. Successful digestion was confirmed by Coomassie 
Blue staining (data not shown). To confirm that infliximab F(ab’)2 fragment remained capa-
ble of binding to mTNF, a competition assay was performed. In this assay, infliximab was 
labeled with a fluorescent dye, and activated T cells were incubated with a constant concen-
tration of labeled infliximab and increasing concentrations of either infliximab F(ab’)2 frag-
ment or infliximab at the same time. Binding of fluorescent infliximab to mTNFα decreases 
in the presence of a competitor, in this assay infliximab itself or infliximab F(ab’)2 fragment. 
The experiment showed that infliximab F(ab’)2 fragment competes with fluorescent inflixi-
mab to the same extent as infliximab itself (Figure 3B and Supplementary Figure 3), demon-
strating that infliximab F(ab’)2 fragment binds to mTNF to the same degree as infliximab. 
In contrast, infliximab F(ab’)2 fragment did not inhibit proliferation in an MLr, (Figure 
3C). This effect was also absent at higher concentrations. These data further support a cru-
cial role for the Fc region in the effects of infliximab and adalimumab on T cells in the MLr. 
The previous results indicated that binding to the Fc receptor is necessary for the immuno-
suppressive effect of anti-TNFα; however, Fc receptor binding alone is not sufficient since 
IgG and etanercept do not inhibit proliferation although these compounds do contain an Fc 
region. Therefore, we hypothesized that both binding the Fc receptor and binding mTNFα 
is required to inhibit T cell proliferation. As shown in figure 1, certolizumab binds to mTNF, 
albeit at an intermediate level. However, certolizumab does not contain an Fc region and 
does not inhibit proliferation in an MLr (Figure 2). Strikingly, certolizumab-IgG, a com-
pound containing the mTNFα binding region of certolizumab as well as an Fc region does 
inhibit proliferation to the same extent as infliximab and adalimumab (Figure 3D), fur-
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ther confirming that both binding Fc receptor and binding to mTNF is responsible for the 
immunosuppressive effects of anti-TNF. 
  Only infliximab, adalimumab and certolizumab-IgG induce a distinct CD14+ and HLA-DR+ 
cell population in an MLR which correlates with inhibition of T cell activation
To further investigate the mechanisms involved in the inhibition of T cell activation in an 
MLr, we evaluated the cells by flowcytometry after one week of treatment. We noticed a 
distinct cell population characterized by high forward scatter and intermediate side scatter 
upon treatment with infliximab, adalimumab or certolizumab-IgG, which was absent when 
cells were untreated or treated with certolizumab or IgG (Figure 4A). Importantly, the pres-
ence of these cells correlates with the degree of inhibition of proliferation induced by the 
Figure 3 Infliximab induced T cell proliferation is completely abolished when binding to Fc 
receptors is inhibited.
(A) Fc receptors were saturated by treating MLRs with IgG (10 μg/mL) for 6 – 16 hours following activation. 
Next, cells were treated with the indicated compound. Proliferation was measured using a 3H-thymidine incorpo-
ration assay. *** p ≤ 0.001 (B) T cells were activated for 48 hours with CD3/CD28 beads. Infliximab was labeled 
with a fluorescent dye (Alexa Fluor 647). Cells were incubated with infliximab Alexa Fluor (70 nM) and different 
concentrations of infliximab and infliximab F(ab’)2 fragment. Fluorescence was measured with Flow Cytometry. 
(C, D) Cells in an MLR were treated with the indicated compound for 48 hours. Next, proliferation was measured 
by thymidine incorporation
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compounds in the MLr, indicating their involvement in the inhibition of T cell activation 
(Figure 4B). Based on the cell size and the position of the cells in the FSC/SSC plot, we 
hypothesized that these cells might be macrophages. This idea was further supported by the 
fact that the population expressed the macrophage marker CD14 as well as HLA-Dr (Figure 
4C). This finding also facilitated the isolation of the cell population based on the expression 
of CD14. Since this induced cell population (further referred to as Mφ
ind
) was absent when 
cells were treated with certolizumab or IgG, and present upon treatment with infliximab, 
adalimumab and certolizumab-IgG, this effect seems to be mediated by the Fc region. The 
characteristics of the different anti-TNFα agents are summarized in Table 1. 
Figure 4 Only infliximab, adalimumab and certolizumab-IgG induce a distinct CD14+ and 
HLA-DR+ population in an MLR.
(A) Cells in an MLR were treated with anti-TNF compound or IgG control (all 10 μg/mL) for 7 days. Cells were 
analyzed on the FSC/SSC. (B) Correlation between the presence of myeloid cells analyzed on the FSC/SSC and 
proliferation. (C) Cells in an MLR were treated with anti-TNF compound or IgG control (all 10 μg/mL) for 7 days, 
stained for HLA-DR and CD14 and analyzed on the FACS. Cells were gated as in 4A. Graphs show MFI ± SD 
and representative histograms of CD14 and HLA-DR expression of an untreated or infliximab-treated MLR are 
shown. Grey = isotype, white = expression. (D) T cells are required for the differentiation of Mφ
ind
. CD14+ cells 
were treated with infliximab in the presence or absence of CD4+ T cells, and CD206 expression was analyzed by 
flowcytometry. CD206 expression was upregulated only when CD14+ cells were cocultured with CD4+ cells. A 
representative graph is shown from 2 independent experiments. Upper panel: MFI ± SD. Lower panel: histogram 
plots. Black = isotype control, grey = CD206 expression
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Figure 5 Characterization of Mφind.
(A) Mφ
ind
 have a macrophage like appearance (40x magnification) Macrophages (Mφ
ind
: left panel, Mφ1: right 
panel) were stained using DiffQuick (B) Mφ1, monocytes, DCs or Mφ
ind
 were stained for different markers and 
expression was measured on the FACS. (C) Cells in an MLR were treated with anti-TNF compound or IgG control 
(all 10 μg/mL) for 7 days and stained for CD206 or isotype control
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Finally, we examined whether the presence of T cells was required for the differentiation 
of Mφ
ind. 
To address this question, we isolated CD14+ cells and cultured these cells in the 
presence or absence of CD4+ T cells, treated the cells with infliximab and analyzed CD206 
expression by flowcytometry. We found an upregulation of CD206 when CD14+ cells were 
cocultured with CD4+ cells. This upregulation was absent when CD14+ cells were cultured 
without T cells (Figure 4D). These data show that T cells are required for the infliximab-




express costimulatory molecules, Fc receptors and the regulatory macrophage marker 
CD206 
Since the cell population induced by some anti-TNFs expresses CD14 and HLA-Dr and 
looks like macrophages (Figure 5A), we sought to further characterize the phenotype of 
these cells. Therefore we isolated Mφ
ind 
based on CD14 expression and compared the expres-
sion level of different markers with the levels on monocytes, DCs and macrophages. Den-
dritic cells were cultured in the presence of IL-4 and GM-CSF, macrophages in the presence 
of IFN-γ (further referred to as Mφ1)
 
and monocytes were freshly isolated from blood. Mφ
ind 
express CD40, CD80, CD83 and CD86 comparable to the expression of these markers on 
Mφ1, as well as CD16 (FcγrIII, activating Fc receptor) and CD32 (FcγrIIb, inhibitory Fc 
receptor) (Figure 5B). Furthermore, Mφ
ind 
express CD206 (mannose receptor), a commonly 
used marker for regulatory macrophages (alternatively activated macrophages, type 2 mac-
rophages or Mφ2), which was absent on Mφ1. We confirmed the presence of this marker 
in the primary MLr and found CD206 expression only in the infliximab, adalimumab or 
certolizumab-IgG treated conditions (Figure 5C). Therefore, we hypothesized that Mφ
ind 
are 






 are only present in the conditions where inhibition of T cell proliferation was 
observed, we hypothesized that Mφ
ind
 inhibit T cell responses. To test this hypothesis, we 
isolated the Mφ
ind 
from an MLr and co-cultured these cells with pre-activated isolated T cells 
from a third donor (secondary MLr). Indeed, we found a strong immunosuppressive effect 
that was induced by Mφ
ind
 and not by Mφ1. In addition, this effect was absent when activated 
T cells were co-cultured with the CD14 negative fraction of the MLr, indicating that Mφ
ind
 
mediate the immunosuppressive effect (Figure 6A).
To further characterize Mφ
ind
, we evaluated the cytokine profile of these cells in the pres-
ence and absence of LPS, and compared this to the cytokine production by DCs and Mφ1. 
In accordance with their regulatory properties, Mφ
ind
 produce large amounts of IL-10 in 
response to LPS (figure 6B). Also, Mφ
ind
 secrete less IL-1β in response to LPS compared to 
Mφ1. The secretion of TNFα was comparable to that produced by DCs. Taken together, these 
data indicate that Mφ
ind
 induced by infliximab, adalimumab or certolizumab-IgG have anti-
inflammatory properties. 
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Figure 6 Mφind have anti-inflammatory properties.
(A) Isolated CD3/CD28 activated T cells from a third donor were co-cultured with Mφ
ind
, Mφ1, or the CD14 nega-
tive fraction of the MLR. Proliferation was measured by thymidine incorporation. (B) Mφ
ind
, Mφ1 and DCs were 
cultured in the presence or absence of LPS. Supernatants were collected after 24 hours and cytokine production 
was measured by CBA. Data are shown as means ± SD from 3 independent experiments. * p ≤ 0.05, *** p ≤ 0.001, 
ns = not significant
  Discussion
In the present study, we find that drugs used to target TNFα have different functional prop-
erties. The anti-TNFα antibodies bind to mTNFα on activated T cells and inhibit their pro-
liferation but only in the presence of antigen presenting cells. In contrast, a soluble TNFα 
receptor or F(ab’)2 fragments of the anti-TNFα antibodies do not affect T cell proliferation 
under the same circumstances.  Our experiments show that the immunosuppressive prop-
erties of the anti-TNFα antibodies are dependent on their Fc region. We find that the anti-





 have anti-inflammatory properties since they inhibit proliferation of activated T cells, 
produce IL-10 and express the regulatory macrophage marker CD206. 
It was previously described that infliximab may induce low levels of apoptosis in T cells as 
determined by TUNEL staining of cytospins of infliximab treated activated Jurkat cells, a 
lymphoblastoid T cell line. 15 Also, others found that anti-TNFα antibodies induce apoptosis 
in Jurkat cells that stably overexpress a non-cleavable form of mTNFα using Annexin V-PI 
staining as a read out. 18, 23 Additionally, apoptosis was described in primary lymphocytes 
isolated from the lamina propria of CD patients. 16 These data are in contrast to our current 
results, where none of the anti-TNFα compounds affected either apoptosis or proliferation 
of Jurkat cells or primary T cells grown in isolation despite extensive attempts. The differ-
ence between the previous studies and ours most likely lies in the use of endogenous levels 
of mTNFα expression in contrast to overexpression and the use of highly viable peripheral 
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blood lymphocytes rather than lamina propria lymphocytes which had undergone extensive 
isolation procedures. In line with this is the study by Bedini et al, 25 who described that anti-
TNFα antibodies suppress activation of T cells in the presence of either immature dendritic 
cells or monocytes. Indeed, we find similar properties of the anti-TNFα antibodies but not 
of the other anti- TNFα compounds in the presence of monocytes in an MLr. The results 
we obtained in this assay are robust and reproducible.
In contrast to some earlier studies, we did not detect binding of etanercept to mTNFα. 
Importantly, binding of etanercept to mTNFα has only been described in experiments in 
which a non-cleavable mTNFα was stably overexpressed. 18, 26 In untransfected activated pri-
mary lymphocytes it was found that etanercept has weak mTNFα binding activity 16 similar 
to the results of our current experiments. Thus strong binding of etanercept to mTNFα may 
only occur in situations in which a non cleavable mTNFα is artificially overexpressed. 
An important role for Fc receptor binding has been shown for the mechanism of action of 
other antibody therapies. Fc receptor binding of rituximab (a chimaeric monoclonal anti-
CD20 antibody) was found to be indispensable for the clearance of B cells. 27 In addition, 
the FcγrIIIA-158V allotype has a higher affinity for binding to IgG
1 
than the FcγrIIIA-158F 
allotype and an association between the FCGR3A genotype and clinical response to rituxi-
mab was observed in several studies. 27, 28 The FCGRIIIA genotype has also been associated 
with outcome in other antibody therapies, such as cetuximab (chimaeric monoclonal anti-
EGFr antibody). 29 In line with this, antibodies with higher Fc receptor affinity have been 
developed to augment antibody efficacy in animal models. 22, 30 The same polymorphism 
has been associated with response to infliximab, however with conflicting results. 20, 31 In 
addition, CDP571, an IgG
4
 antibody against TNFα, was found to be ineffective for steroid-
sparing in CD. 14 Interestingly, IgG
4
 has very low affinity for binding Fc receptors 32 and our 
data suggest that this could play a causal role in the disappointing performance of CDP571 
in the treatment of Crohn’s disease.
The effects observed with various anti-TNFs in the MLr may have implications for our 
understanding of the clinical activity of the compounds in patients with Crohn’s disease. 
It is tempting to speculate that Fc receptor dependent differentiation of alternatively acti-
vated macrophages plays a role in mucosal healing in patients with Crohn’s disease, since 
alternatively activated macrophages play a major role in wound healing. 33 recently, it has 
been shown that regulatory macrophages cultured in vitro reduce colonic inflammation in 
mice and that patients with active CD have reduced numbers of these cells compared to 
patients with inactive CD. 34 Also, lamina propria macrophages produce large amounts of 
IL-10 and have anti-inflammatory properties, indicating that these cells are involved in gut 
homeostasis. 35 Thus far, our data has been limited to in vitro experiments, and it would be 
highly informative to verify the generation of regulatory macrophages in vivo in patients 
receiving anti-TNF therapy. Furthermore, although we have shown in vitro that an Fc region 
is required for inhibition of proliferation and the induction of regulatory macrophages, 
the in vivo clinical benefit of certolizumab has been shown in several studies. 36, 37 Certoli-
zumab was found to be more effective than placebo to induce and maintain remission in 
CD patients and anti-TNFs are likely to exert their effects through multiple mechanisms. 
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The anti-TNFα antibodies and soluble receptors not only differ in their clinical efficacy in 
Crohn’s disease but it has also been reported that the risk of tuberculosis with infliximab or 
adalimumab was 13 to 17 times higher than with etanercept. 38 Interestingly, mycobacteria 
such as M. Tuberculosis bind stronger to Mφ2 than to Mφ1, and have a prolonged survival in 
Mφ2. 39 In this light it is interesting to note that Mφ2 are strongly induced by infliximab and 
adalimumab in our experiments but significantly less by etanercept (data not shown). In 
addition, the mannose receptor plays an important role in the phagocytosis of mycobacteria 
40 and we found that the mannose receptor CD206 is upregulated on Mφ
ind
. Therefore it is 
tempting to speculate that the increased risk of tuberculosis in patients treated with inflixi-
mab or adalimumab is at least partly mediated by the induction of Mφ
ind
. 
In conclusion, our data show that the anti-TNFα antibodies have immunosuppressive prop-
erties that are distinct from those of the soluble TNFα receptor etanercept and F(ab’)2 frag-
ments of anti-TNFα. These distinct properties may have implications for both the effects 
and side effects of anti-TNFα compounds in patients in vivo. This finding sheds more light 
on the complex mechanism of action of infliximab and anti-TNFα therapies in general and 
gives new directions for the future development of new antibody based therapy for CD.
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  Supplementary Figures 
Supplementary Figure 1 Anti-TNFs do not induce apoptosis in activated T cells or an MLR, and 
do not inhibit proliferation in isolated T cells. 
(A) T cells were isolated from PBMCs using negative magnetic bead separation (Invitrogen) and activated with 
CD3/CD28 antibodies for 48 hr. Next, cells were treated with anti-TNF or IgG control (10ug/mL) for 48 hrs. Finally 
proliferation was measured by thymidine incorporation. (B) T cells were stained with annexin V and Pi and fluo-
rescence was measured on the FACS. (C) MLR cultures were stained with annexin V and Pi and fluorescence was 
measured on the FACS. (D) Apoptosis in an MLR with heat inactivated serum and serum without heat inactiva-
tion was measured in a caspase 3 activity assay. All data are shown as means ± SD
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Supplementary Figure 2 Infliximab has no effect on costimulatory molecules on DCs and 
monocytes.  
MoDCs (A) or monocytes (B) were activated with 100 ng/mL LPS for 16hr, and treated with anti-TNF for 24 hr. 
Cells were stained with αHLA-DR, αCD40, vCD80, αCD83, αCD86 and isotype control and analyzed by flowcy-
tometry. All data are shown as means ± SD
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Supplementary Figure 3 Infliximab F(ab’)2 fragment binds to activated T cells.
K
T cells were activated for 48 hours with CD3/CD28 beads. Infliximab was labeled with a fluorescent dye (Alexa 
Fluor 647). Cells were incubated with infliximab Alexa Fluor (70 nM) and different concentrations of infliximab 
and infliximab F(ab’)2 fragment. Fluorescence was measured with Flow Cytometry
C
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  Abstract
regulatory macrophages play an important role in wound healing and gut homeostasis 
and have anti-inflammatory properties. Induction of this cell type (Mφ
ind
) by the anti-TNF 
antibodies, infliximab and adalimumab, has recently been shown in vitro. Also, the superi-
ority of infliximab/azathioprine combination therapy over infliximab or azathioprine mono-
therapy has recently been established, but the mechanism behind this remains unclear. The 
aim of this study is to examine the induction of regulatory macrophages in patients with 
and without mucosal healing in response to infliximab. In addition, we studied the effect 
of infliximab/azathioprine combination treatment on the differentiation and function of 
regulatory macrophages.
IBD patients (n=10) underwent endoscopy before and after first infliximab treatment. 
Immunohistochemical staining of CD68 and CD206 was performed in all patients. Mixed 
lymphocyte reactions (MLr) were treated with infliximab, azathioprine or both. Macrophage 
phenotype was evaluated by flow cytometry and inhibition of T cell proliferation was meas-
ured in a secondary MLr containing macrophages and third party lymphocytes. 
A significant induction of regulatory macrophages was observed in patients with mucosal 
healing after treatment with infliximab, this induction was absent in patients without 
mucosal healing. In addition, Mφ
ind
 have the ability to induce wound healing in an in vitro 
model, further suggesting a key role for infliximab induced macrophages in mucosal heal-
ing. Upon infliximab/azathioprine combination treatment, an increased number of regula-
tory macrophages was observed. These macrophages also displayed stronger immunosup-
pressive properties than macrophages induced by infliximab monotherapy. 
These data show that regulatory macrophages may be involved in mucosal healing, and 
provide a rationale for the superiority of infliximab/azathioprine combination treatment 
observed in the clinic. 
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  Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases 
(IBD) of unknown etiology resulting in loss of tolerance towards the mucosal flora. Tradi-
tionally, therapy to control IBD was aimed at reducing symptoms, but at the present time 
treatment is more and more focused on inducing mucosal healing and altering the disease 
course. The introduction of anti-TNF agents in the ‘90’s has been an important break-
through to accomplish this. Anti-TNF agents have been shown to induce mucosal healing, 
reduce steroid dependency, reduce the risk for surgery and hospitalization, and to improve 
the patient’s quality of life. 1-5 However, not all anti-TNF agents that have been introduced in 
the clinic appeared effective. For instance, the TNF receptor fusion protein etanercept 6 and 
the IgG
4
 anti-TNF antibody CDP571 7 lacked clinical efficacy although these agents have the 
ability to neutralize soluble TNF. This observation raised the question why some anti-TNF 
agents are effective and others are not. We have recently shown that in order for an anti-TNF 
to inhibit T cell proliferation in vitro, the compound needs to bind to membrane bound TNF 
on activated T cells and posses an Fc region to interact with Fc receptors. 8 Upon this bind-
ing, a distinct macrophage subset is induced (Mφ
ind
) with immunosuppressive capacities, 
including the production of anti-inflammatory cytokines and inhibition of T cell prolifera-
tion.  Furthermore, it has been shown that in vitro derived regulatory macrophages reduce 
colonic inflammation in mice, 9 and inhibit proliferation of activated T cells. 10 On top of 
this, regulatory macrophages play a crucial role in wound healing, 11 and therefore the induc-
tion of this cell type may be of particular interest in the treatment of IBD and induction of 
mucosal healing. 
recently, a large randomized, placebo-controlled trial demonstrated the superiority of 
in fliximab/azathioprine combination treatment over infliximab or azathioprine monother-
apy in inducing and maintaining remission and mucosal healing in patients with CD. 12 The 
exact mechanism underlying this effect is unknown, but it likely results from the additional 
effect of a second immunosuppressive. Also, it is possible that azathioprine suppresses 
infliximab induced immunogenicity, thereby increasing infliximab efficacy.  However, the 
specific mechanisms involved in this superiority and in mucosal healing in general are so 
far not completely understood. 
In this study, we aimed to investigate the induction of regulatory macrophages in patients 
responding to infliximab therapy versus those who did not respond. Also, we examined the 
wound healing capacity of infliximab-induced regulatory macrophages in vitro. In addition, 
we examined the effect of infliximab/azathioprine combination treatment on the induction 
and function of regulatory macrophages in vitro.
  Materials and methods
  Patients
The patient material used in this study was obtained from University Hospital Gasthuisberg 
in Leuven (ClinicalTrials.gov number NCT00639821). All patients gave written informed 
consent. Ten patients with active IBD (4 UC, 6 CD), refractory to corticosteroids and/or 
immunosuppression, were examined. The patients underwent endoscopy with biopsies 
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from affected bowel (colon for UC and colonic CD, and ileum for ileal CD) within a week 
prior to the first infliximab infusion of 5 mg /kg body weight. Patients received a second 
endoscopy with biopsies at week 4 - 6.  The biopsies were taken at sites of active inflam-
mation but at a distance of ulcerations. When healing was observed at the second endo-
scopy, biopsies were obtained in the areas where lesions were present before therapy. The 
endoscopist was not blinded to treatment.
Next, biopsies were fixed in Carnoy’s fixative for up to 5 hours and then dehydrated, 
cleared and paraffin-embedded for histological examination and/or immunohisto-
chemistry. Haematoxylin-eosin stained slides from the paraffin block of each patient 
were used to score chronic intestinal inflammation using a previously reported scor-
ing system for UC 13 and for CD. 14 The pathologists were blinded to treatment. 
response to infliximab was assessed 4-6 weeks after the first infliximab treatment and clas-
sified as has been described before. 15 Briefly, for colonic CD, a response was defined as 
complete mucosal healing with a decrease of at least 3 points on the histological score. 14 
For UC, a response consisted of a decrease to a Mayo endoscopic subscore of 0 or 1 with a 
decrease to grade 0 or 1 on the histological score. 13 For ileal CD (3 patients), patients with a 
clear improvement of the ulcerations and a decrease on the histological score 14 were consid-
ered responders. Patients who did not achieve this healing were considered non-responders 
although some of them showed an improvement on the histologic or endoscopic score. 
  Immunohistochemistry
For immunohistochemistry, Mφ2 cells were defined as CD206+/CD68+ cells. Mφ2 were 
detected using an anti-human CD206 goat polyclonal antibody (AF2534, r&D systems, 
Abingdon, UK) and anti-human CD68 mouse monoclonal antibody (clone KP1, M0814, 
Dako Belgium NV, Heverlee, Belgium). Briefly, 5 μm-thick sections were cut from the paraf-
fin blocks of Carnoy-fixed endoscopic biopsies from the patients. After drying, deparaffini-
zation and rehydration, epitope retrieval was performed at high pH (Dako PT Link machine, 
Dako Belgium NV, Heverlee, Belgium). Sections were then washed 3 times 5 min (Envision 
Flex wash buffer, Dako) and Envision Flex Peroxidase-Blocking reagent (Dako) was applied 
for 10 min at room temperature. After a second wash step, sections were incubated with the 
anti-human CD206 antibody (r&D Systems, dilution 1:40) or with the anti-human CD68 
antibody (Dako, dilution: 1:2000) for 30 min at room temperature. Following a third wash 
step, bound primary antibody was visualized by incubating the slides for 30 min with Envi-
sion Flex/HrP (Dako) and application of the Envision DAB+ Chromogen (Dako) for 10 
min at room temperature. After rinsing, the slides were counterstained with haematoxylin, 
dehydrated, cleared and mounted. Negative controls (no application of primary antibody) 
were run together with the test samples. All the stains were evaluated by an experienced 
pathologist (GDH). Finally, the stains were analyzed using ImageJ software. 
  Cell isolation and culture
Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were isolated by Ficoll 
Paque density-gradient centrifugation. Mϕ1 macrophages were generated as described pre-
viously. 10 Briefly, monocytes were isolated by Percoll density-gradient centrifugation and 
cultured in rPMI 1640 containing 10% heat-inactivated FCS for 5 days. CD3 positive T cells 
were isolated from PBMCs using negative magnetic bead separation (Invitrogen, Paisley, 
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UK). Where appropriate, T cells were activated with αCD3/αCD28 beads (Invitrogen) (1 
bead/5 cells). 
  Allogeneic mixed lymphocyte reaction (MLR)
PBMCs from two healthy donors were cultured in a 1:1 ratio in rPMI 1640 culture medium 
to establish a mixed lymphocyte reaction (MLr). After 48 hours of activation, cells were 
treated with infliximab (10 μg/ml), azathioprine (1 μM) or a combination, for 5 days. Were 
indicated, cells were treated with 10 μg/ml certolizumab. Finally, proliferation was meas-
ured using a 3H-thymidine incorporation assay. 
  Isolation of infliximab-induced macrophages (Mφ
ind




Infliximab induced macrophages (Mφ
ind
) and infliximab/azathioprine induced macrophages 
(Mφ
ind/AZA
) were isolated from MLr cultures from healthy volunteers. We have previously 
shown that upon infliximab treatment, a distinct cell population occurs on the FCS/SSC, 
which is strongly positive for several markers, among which CD206 (a commonly used 
regulatory macrophage marker) and CD14, and that these cells have immunosuppressive 
properties. The induction, phenotype and isolation of this cell subset have been extensively 




were isolated from the MLr based on the 
expression of CD14 using CD14 microbeads according to manufacturer’s protocol (Milte-
nyi, Bergisch Gladbach, Germany). Next, cells were counted and cultured in rPMI 1640, 
containing 10% heat-inactivated FCS.
  In vitro wound healing assay
The wound healing scratch assay was performed as previously described with a few modi-
fications. 16 HCT116 colon epithelial cells were cultured to approximately 70% confluence 
in 6 wells plates under standard culture conditions. The plates were marked in order to 
create a reference point to identify the wound at the same place at different time points. 
Next, a wound was created using a plastic tip, and pictures were taken at a phase-contrast 
microscope. Mφ
ind
 and pro-inflammatory type 1 macrophages from healthy volunteers were 
added to the cell culture (100.000 cells/well). To quantify the degree of wound healing, pic-
tures were taken again after 24 hrs, and the percentage closure was calculated using Image 
J software. 
  FACS analysis of regulatory macrophages
MLr were treated with infliximab, azathioprine, or a combination. After 5 days, cells were 
harvested, washed with FACS buffer, and stained for CD206 or isotype control. Finally, 
expression was analyzed by flow cytometry using a FACS Calibur (BD) and FlowJo software 
(Treestar Inc, Ashland, Or) 
  Statistical analysis 
results are representative for at least three independent experiments and show means ± 
SEM unless otherwise indicated. For statistical analysis, one way ANOVA was used followed 
by Bonferroni post test. results were considered significant when p < 0.05. Paired t test 
was used to calculate statistical significance in patients before and after infliximab therapy. 
results were considered significant when p < 0.05
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Figure 1 Infliximab induces regulatory macrophages in responders but not in non-responders. 
A) Representative pictures of CD206/CD68 stainings in a patient responding to infliximab (left panel) and a non-
responder (right panel). Pictures of stained biopsies before and after infliximab induction therapy are shown. B). 
Induction of CD206/CD68 regulatory macrophages per patient. A significant induction of CD206/CD68+ cells 
is observed in patients responding to infliximab (left panel), whereas this induction is absent in non-responders 
(right panel). The red line represents a patient with a partial response observed during endoscopy. C). Non-
responders have lower amounts of CD206/CD68+ cells at baseline. ** p ≤ 0.01 Data were analyzed using paired 
t test 
C
101Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro
  Results
  Infliximab induces regulatory macrophages in responders but not in non-responders
We have shown previously that anti-TNF antibodies induce regulatory macrophages in vitro  
8  and this cell type plays an important role in wound healing. 11 Now, we aimed to investi-
gate whether the induction of regulatory macrophages is also observed in vivo in patients 
responding to infliximab therapy.  Biopsies were obtained from six CD patients (3 respond-
ers, 3 non-responders) and 4 UC patients (2 responders, 2 non-responders) before (week 0) 
and after (week 4 - 6) first infliximab treatment. Patient characteristics are shown in table 1. 
Slides from each patient before and after therapy were stained for CD68 and CD206 (also 
called MrC1 or MMr). CD206 is a commonly used marker for regulatory macrophages, 
and CD68 is a macrophage marker. Since patients with a response to infliximab usually 
have a decrease in the number of CD68+ cells, we used the ratio CD206+/CD68+ to iden-
tify the induction of regulatory macrophages. 
A clear and significant increase was observed in the percentage of CD206+ macrophages 
in patients responding to infliximab induction therapy, indicating that regulatory mac-
rophages were induced (Figure 1A and 1B). This induction was observed in each individual 
responding to infliximab therapy Figure 1B, left panel). Importantly, induction of CD206+/
CD68+ cells was absent in patients not responding to infliximab therapy (Figure 1B, right 
panel). One patient (Figure 1b, right panel, red line) was considered a non-responder on 






















1 UC r 5.4 0.3 3 1 19,7 66,8
2 UC r 5.2 0.1 2 0 47,6 91,6
3 UC Nr 5.4 5.3 3 3 16,7 22,8
4 UC Nr 5.1 5.3 2 3 30,5 42
5 CDc r 14/16 6/16 Active colitis healing 26,8 60,1
6 CDc Nr 16/16 16/16 Active colitis Active colitis 8,4 9,6
7 CDc Nr 10/16 10/16 Active colitis Incomplete 
healing
7,2 32,8
8 CDi r 10/16 3/16 Active colitis healing 31,5 45,5
9 CDi r 12/16 5/16 Active ileitis Incomplete 
healing
44,5 71,8
10 CDi Nr 7/16 8/16 Active ileitis Active ileitis 26,2 16,9
Biopsies were obtained before (week 0) and after (week 4 - 6) infliximab therapy. Histologic and endoscopic 
scores and the percentage of CD206/CD68+ cells  at 0 and 4 weeks are shown. Pathologists who scored histology 
were blinded to treatment, endoscopists were not blinded to treatment, and the percentage CD206/CD68+ was 
calculated using Image J software. 
UC Ulcerative colitis, CDc colonic Crohn’s disease, CDi ileal Crohn’s disease, R responder, NR non-responder
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histological basis, but did show a partial response on endoscopy.  An increase of CD206+/
CD68+ cells was observed in this patient. 
Taken together, these data show that regulatory macrophages similar to those induced by 
infliximab in vitro, are induced in vivo in patients responding to infliximab therapy. 
Figure 2 Mφ
ind
 induce wound healing in vitro. 
A) Mφ
ind
 induce wound healing in vitro B) representative pictures of the wound healing assay. Data are repre-
sentative of at least three independent experiments. Data were analyzed using one-way ANOVA and bonferroni 
post-test. * p ≤ 0.05
  Infliximab-induced regulatory macrophages induce wound healing in vitro 
It has been shown previously that regulatory macrophages generated in vitro by addition of 
IL-4 and IL-13 exhibit wound healing capacities. The data described above show an increased 
presence of macrophages displaying a regulatory phenotype after infliximab therapy. How-
ever, the presence of CD206+/CD68+ cells in patients presenting with mucosal healing does 
not discriminate between infliximab-mediated effects and wound healing effects induced by 
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another mechanism such as immunosuppression in general. Therefore, we aimed to assess 
specifically the wound healing capacity of macrophages induced by infliximab treatment. 
To this end, macrophages were isolated from MLr cultures treated with infliximab (regula-
tory Mφ
ind
) or generated from monocyte cultures (inflammatory Mφ1). HCT116 colonic epi-
thelial cells were cultured and a wound was created in the monolayer. Mφ1, Mφ
ind
 or control 
medium was added to the wells and images were taken at t=0 and t=24 hours.  As expected, 
Mφ1 did not induce wound healing above the level of control (Figure 2). In contrast, Mφ
ind
 
showed a clear capacity to enhance wound healing up to two-fold compared to Mφ1 or 
medium alone. These data are in line with the results observed in patients responding to 
infliximab therapy, and further suggest that regulatory macrophages induced by in fliximab 
induce wound healing.
  Enhanced induction and function of regulatory macrophages upon infliximab/azathioprine 
combination treatment in vitro
Since the induction of Mφ
ind
 correlates with response to infliximab (Figure 1), and higher 
response rates are observed in patients receiving infliximab/azathioprine combination 
treatment compared to either monotherapy, 12 we hypothesized that infliximab/azathioprine 
combination treatment might enhance the induction of Mφ
ind
 in vitro. To answer this ques-
tion, we treated mixed lymphocyte cultures with infliximab, azathioprine or a combination. 
Azathioprine and infliximab monotherapy inhibited T cell proliferation in an MLr to the 
same extent (Figure 3A). As expected, when cells in an MLr were treated with a combina-
tion of infliximab and azathioprine, T cell proliferation was further inhibited. To investi-
gate whether this observation was a cumulative effect of a second immunosuppressive or 
whether another mechanism was involved, we studied the effect of combination treatment 
on the induction of regulatory macrophages. As shown previously, 8 anti-TNF antibodies 
induce a distinct subset of cells, characterized by high forward and high side scatters and 
expression of CD14 and CD206 when analyzed by flowcytometry. When cells were treated 
with azathioprine monotherapy, no induction of regulatory macrophages was observed. 
Strikingly, we found a significantly increased induction of this CD206+ subset upon com-
bination treatment (Figure 3B/C). 
We have previously shown that anti-TNF agents induce regulatory macrophages in an Fc 
region dependent manner, 8 and that agents lacking the Fc fragment, do not induce this cell 
type. Therefore, we also evaluated the combination azathioprine/certolizumab (lacking the 
Fc fragment) to examine whether the observed effect of enhanced Mφ
ind/AZA
 was induced by 
infliximab in particular or a general effect of TNFα neutralization. Indeed, the effect was 
specific for the combination treatment of azathioprine/infliximab, since the induction was 
absent upon azathioprine/certolizumab or azathioprine/IgG treatment (Figure 3D). 
To further examine the properties of regulatory macrophages induced by infliximab/aza-
thioprine combination treatment (Mφ
ind/AZA
), we aimed to investigate their immunosuppres-
sive function.  Therefore, we isolated regulatory macrophages based on CD14 expression, 
and co-cultured equal numbers of these cells with activated T cells from a third donor. 
Striking ly, Mφ
ind/AZA
 displayed a stronger immunosuppressive phenotype, since Mφ
ind/AZA
 
showed enhanced ability to inhibit T cell proliferation compared to Mφ
ind
 (Figure 3E). 
These data show that combination treatment is superior to monotherapy in vitro with 
respect to the induction of regulatory macrophages. Not only the number of regulatory mac-
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Figure 3 Enhanced induction of regulatory macrophages upon infliximab / azathioprine combina-
tion therapy. 
A). Infliximab and azathioprine inhibit T cell proliferation in an MLR to the same extent, but stronger inhibition is 
observed upon infliximab/azathioprine combination therapy. B) Enhanced induction of regulatory macrophages 
in an MLR. C) Enhanced number of CD206+ cells upon infliximab/azathioprine combination therapy. This induc-
tion is absent when cells are treated with azathioprine monotreatment. D) The enhanced induction of regula-
tory macrophages is specific for infliximab, and is absent when co-treated with certolizumab or control IgG. E) 
Mφ
ind/AZA
 are superior to Mφ
ind
 in inhibiting T cell proliferation. 20.000 macrophages were plated and cocultured 
with 100.000 T cells. All figures are representative figures of at least three independent experiments. Data were 
analyzed using one-way ANOVA and bonferroni post-test *p ≤ 0.05, **p ≤ 0.01,  ***p ≤ 0.001
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rophages is increased, but the macrophages also display a stronger immunosuppressive 
phenotype. These findings may provide a partial explanation for the superiority of inflixi-
mab/azathioprine combination therapy observed in patients with CD. 
  Discussion
The data presented here show the induction of regulatory macrophages after infliximab 
treatment in IBD patients. Patients responding to infliximab showed a significant induction 
of CD206+/CD68+ cells, whereas this induction was absent in non-responders. Since we 
used endoscopic and histologic healing as a definition of response, these data suggest that 
the induction of regulatory macrophages may be involved in the process of mucosal healing. 
The fact that we observe increased numbers of CD206+/CD68+ cells in patients respond-
ing to infliximab therapy does not prove directly that this effect is mediated by infliximab. 
However, we have previously shown induction of CD206+ macrophages by infliximab in 
vitro. 8 Additionally, we now show here that CD206+ macrophages induced by infliximab in 
vitro have wound healing capacity, similar to what has been described for IL-4/IL-13 induced 
regulatory macrophages previously. 17 Together these data suggests that the induction of 
regulatory macrophages by infliximab may contribute to mucosal healing in patients clini-
cally responding to the treatment.
A recent clinical trial has shown that combination treatment of azathioprine and inflixi-
mab is superior to monotreatment in the induction of remission and mucosal healing in 
CD patients. 12 In our in vitro system, azathioprine did not induce significant numbers of 
macrophages. However, in combination with infliximab, azathioprine potentiated both the 
number and immunosuppressive capacity of CD206+ macrophages. Although the supe-
riority of combination treatment in vivo probably results at least in part from the additive 
effects of two immunosuppresives, our data suggest an additional layer of actual synergism 
which may also contribute to the increased mucosal healing observed in patients.
In order to maintain tolerance, lamina propria macrophages normally display a type 2 mac-
rophage (Mφ2) phenotype. Mφ2 are functionally different from type 1 macrophages (Mφ1), 
since they have minor ability to respond to bacterial stimuli, and produce anti-inflammatory 
cytokines rather than pro-inflammatory cytokines. 18, 19 In IBD patients, lamina propria mac-
rophages have a more Mφ1 phenotype, as lamina propria mononuclear cells (LPMNCs) 
from IBD patients spontaneously produce large amounts of pro-inflammatory cytokines 
and are hyperresponsive to bacterial stimuli. 20-22 In line with this, lower amounts of Mφ2 
were found in mucosal biopsies from active lesions in CD patients compared to non-affected 
colon of the same patient, and compared to healthy controls. 9 This suggests that lamina 
propria macrophages from CD patients are skewed towards an Mφ1 phenotype, thus con-
tributing to the defect in tolerance. Since regulatory macrophages contribute to tolerance 
towards the mucosal flora and CD patients have decreased numbers of this cell type, the 
induction of Mφ2 might be an interesting target in restoring the disturbed balance. 
In conclusion, our data demonstrate the induction of regulatory macrophages in IBD 
patients responding to infliximab therapy. In addition, we show that infliximab induced 
macrophages indeed have wound healing capacity, suggesting a potential role in mucosal 
healing. Finally, we show that infliximab/azathioprine combination treatment potentiates 
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the induction of regulatory macrophages, thus providing a new rationale for the superiority 
of infliximab/azathioprine combination treatment observed in the clinic.
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Background and aim: Mesenchymal stromal cells (MSCs) are pluripotent cells that have 
immunosuppressive effects both in vitro and in experimental colitis. Promising results of 
MSC therapy have been obtained in patients with severe graft versus host disease of the gut. 
Our objective was to determine the safety and feasibility of autologous bone marrow derived 
MSC therapy in patients with refractory Crohn’s disease (CD).
Patients and intervention: Ten adult patients with refractory CD (8 females/2 males) under-
went bone marrow aspiration under local anesthesia. Bone marrow MSCs were isolated and 
expanded ex vivo. MSCs were tested for phenotype and functionality in vitro. Nine patients 
received 2 doses of 1-2x10^6 cells/kg bodyweight, intravenously, 7 days apart. During follow 
up, possible side effects and changes in patients’ Crohn’s disease activity index (CDAI) scores 
were monitored. Colonoscopies were performed at week 0 and 6, and mucosal inflamma-
tion was assessed by using the Crohn’s disease endoscopic index of severity (CDEIS).
Results: MSC isolated from CD patients showed similar morphology, phenotype and growth 
potential compared to MSCs from healthy donors. Importantly, immunomodulatory capac-
ity was intact, as CD MSCs significantly reduced peripheral blood mononuclear cell pro-
liferation in vitro. MSC infusion was without side effects, besides a mild allergic reaction 
probably due to the cryopreservant DMSO in one patient. Baseline median CDAI was 326 
(224-378). Three patients showed clinical response (CDAI decrease ≥70 from baseline) 6 
weeks post treatment, conversely three patients required surgery due to disease worsening.
Conclusions: Administration of autologous bone marrow derived MSCs appears safe and 
feasible in the treatment of refractory CD. No serious adverse events were detected during 
bone marrow harvesting and administration. 
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  Introduction
Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the gastro-intes-
tinal tract, including Crohn’s disease (CD) and ulcerative colitis (UC). Despite the improve-
ments in IBD management with the introduction of anti-TNF compounds, remission often 
remains difficult to maintain. Many patients suffer from a poor quality of life due to disease 
relapse, repeated surgeries, extra intestinal manifestations and drug side-effects. Therefore, 
novel therapeutic approaches need to be explored.
Mesenchymal Stromal Cells (MSCs) are nonhematopoietic stromal cells exhibiting multi-
lineage differentiation capacity and the ability to mediate immunosuppressive and anti-
inflammatory effects. 1-3 MSCs are easily isolated from various tissues, 4-6 including the bone 
marrow, and are capable of ex vivo expansion. Moreover, MSCs can be cryopreserved with-
out loss of phenotype or differentiation potential. 7 Systemic infusion of MSCs ameliorated 
the clinical and histopathologic severity of experimental colitis, abrogating body weight loss, 
diarrhea, and inflammation and increasing survival. 8, 9 Furthermore in humans, transplan-
tation of bone marrow (bm) derived MSCs has led to improvement of corticoid refractory 
graft versus host disease (GvHD), including GvHD of the gut 10, 11 and MSCs obtained from 
adipose tissue induced healing in complex perianal fistulas in patients with CD. 12 Although 
the mechanisms underlying these effects are not fully elucidated, it has been shown that 
both cell-cell contact and the secretion of growth factors and cytokines are involved. 13, 14 The 
potential role of MSCs in the modulation of immune responses and tissue regeneration 
aroused interest to use MSCs as a novel cellular therapy to treat Crohn’s disease. 15
In this clinical phase I study, we evaluated the safety and feasibility of intravenous infu-
sion of autologous bmMSC in refractory CD patients. Additionally the functionality of the 
bmMSCs of the CD patients was studied focusing on culture potential, morphology, cell 
surface marker profiling, differentiation potential and immunosuppressive properties. 
Finally, the effect of bmMSCs on various drugs used to treat Crohn’s disease was assessed.
  Methods
  Patient selection
On January 14th 2008, the Medical Ethical Committee of the Leiden University Medical 
Center (LUMC) and the Central Committee on research involving Human Subject (CCMO, 
The Hague, the Netherlands) approved this phase I study on autologous bmMSCs in the 
treatment of refractory CD (registered in the Netherlands National Trial register under 
study number NTr1360 www.trialregister.nl). All patients gave written informed consent. 
Criteria for patient inclusion were that patients were at least 18 years of age and had mod-
erate to severe CD, as defined by a baseline Crohn’s Disease Activity Index (CDAI) score 
between 220 and 450. Furthermore, patients had to be refractory to the standard treat-
ment options for CD. We defined refractory patients as patients that, at some time dur-
ing the course of the disease, must have received steroids, immunosuppressive agents (for 
example, azathioprine, 6-mercaptopurine or methotrexate) or anti-TNF therapy which did 
not result in an adequate response to treatment. The following medications were allowed: 
5-aminosalicylates and corticosteroids (at a stable dosage regimen for at least 4 weeks) and 
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methotrexate, azathioprine, or 6-mercaptopurine (at least 12 weeks, with stable dosage regi-
men for at least 8 weeks). Infliximab was discontinued at least 8 weeks prior to enrolment. 
All patients continued current treatment at the time of infusion. Before bone marrow har-
vest for MSC isolation and expansion, patients were thoroughly screened including medical 
history, physical examination, standard laboratory investigations and chest x-ray to rule out 
tuberculosis. Each patient was also screened for human immunodeficiency virus (HIV), 
syphilus, hepatitis B and C virus. Patients were excluded if they had a history of lymphopro-
liferative disease or malignancy within the past five years, when they exhibited serious infec-
tions or when in need of immediate surgery. Colonoscopy was performed at baseline to 
confirm disease activity.
  Laboratory methods for clinical expansion of MSCs
MSC isolation and expansion
MSCs were expanded according to a common protocol devised by the European Group 
for Blood and Bone Marrow Transplantation developmental committee, as previously 
described. 10 Bone marrow was harvested by aspiration from the iliac crest from patients 
under local anesthesia in the outpatient clinic. Bone marrow mononuclear cells (MNC) 
were isolated by Ficoll density gradient (density 1.077 g/cm3) centrifugation. Washed cells 
were resuspended in Dulbecco’s modified Eagle’s-low glucose medium (Invitrogen, Pais-
ley, UK) supplemented with penicillin and streptomycin (Lonza, Verviers, Belgium) and 
10% fetal bovine serum (FBS, HyClone, Logan, UT), without any additional growth fac-
tors. MNCs were plated at a density of 160.000 cells per cm². Cultures were maintained at 
37ºC in a humidified atmosphere containing 5% CO2 in 175 cm² flasks (Greiner Bio-One, 
Frickenhausen, Germany). When the cultures reached near confluence (>80%), the cells 
were detached by treatment with trypsin/ EDTA (Lonza, Verviers, Belgium) and replated 
at a density of 4000 cells per cm². MSCs were passaged up to a maximum of three times. 
When sufficient MSCs were expanded, cells were harvested and cryopreserved in isotonic 
buffered salt solution supplemented with 10% dimethyl sulphoxide (LUMC Pharmacy, the 
Netherlands). Data on MSCs obtained from healthy donors matched for age and gender, 
was obtained from previous studies. 10, 16, 17 MSCs for these studies were sourced either from 
a family or non-related (third party) donor. Donors were informed about and consented to 
the possibility of the use of their MSCs for preclinical studies/analysis. All donors under-
went routine donor control examination and screening tests, according to the standard pro-
cedures required for bone marrow donors. Following eligibility, donors donated 50-100cc of 
bone marrow under local anesthesia as described above.
  Characterization of MSC products
Morphology was monitored twice a week throughout the culture period by light microscopy. 
Cell viability was determined at each passage and harvest procedure by trypan blue stain-
ing in a Bürker chamber. Immunophenotyping of cultured MSCs was performed using flow 
cytometry. The following markers were analyzed: HLA II (Dr), CD73, CD90, CD31, CD34, 
CD45, CD80 (Becton Dickinson, Franklin Lakes, NJ, USA) and CD105 (Ancell, Bayport, 
MN, USA). The samples were analyzed on a FACSCalibur™ using CellQuest Pro software 
(Becton Dickinson). Absence of contamination by pathogens was tested at culture initiation 
and harvest of the MSC product by aerobic and anaerobic cultures (Becton Dickinson, Bac-
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tec plus aerobe/F and Bactec plus anaerobe/F). Genetic stability of the expanded MSCs was 
tested by karyotype analysis using a standard G-banding procedure.
  Clinical application of MSC products
release criteria for clinical use of MSCs included product sterility, absence of visible 
cell clumps, spindle-shape morphology, expression of CD73, CD90, and CD105 surface 
mo lecules (>90%) and a normal karyotype in at least 20 observed metaphases.
  Laboratory methods for supportive research
In vitro differentiation
MSCs were plated at 5x10^4 cells/cm2 in 24-well culture plates and kept in complete 
medium until 80-90% confluency was reached. For osteogenic differentiation cells were 
stimulated for 21 days in standard medium supplemented with 50 μg/mL ascorbic acid, 10 
mM β-Glycerolphosphate and 10−8M dexamethasone and were stained with fast blue  for 
alkaline phosphatase. For adipogenic differentiation, cultures were stimulated for 21 days 
with complete medium supplemented with 0.5 mM 3-isobutyl-1-methylxanthine, 100 μM 
indomethacin, 5 μg/ml insulin and 10-6 M dexamethasone. Lipid droplets were revealed by 
staining with Oil red O. Control MSCs were grown in non-conditioned medium. All chemi-
cals were from Sigma-Aldrich (St Louis, Missouri, USA)
  MSC/peripheral blood mononuclear cell (PBMC) proliferation assay
Cultured MSCs from Crohn’s disease patients were plated in flat bottom 96 well plates 
(Costar, Zwijndrecht, the Netherlands) and allowed to attach overnight. PBMCs were iso-
lated from whole blood of CD patients before MSC infusion. PBMCs were stimulated anti-
CD28/anti-CD3 coated Dynabeads (1 bead/5 cells, Invitrogen) per 1x10^6 cells and were 
seeded in IMDM with 5% human serum (Sanquin, Amsterdam, the Netherlands), 5% FBS 
and 100 IU/mL IL-2 (LUMC Pharmacy, Leiden, the Netherlands) per well. Proliferation 
was measured by 3H-thymidine incorporation. In order to test the effect of Crohn’s disease 
medication on the immunosuppressive properties of MSCs, the proliferation assay was also 
performed in the presence of indicated medications: 10 μg/mL infliximab, 10ug/mL adali-
mumab, 10 μM dexamethasone (Sigma-Aldrich), 1μM azathioprine (Sigma-Aldrich), 4um 
6-mercaptopurine (Sigma-Aldrich), and 100 μg/ml methotrexate (Pharmachemie BV Haar-
lem, the Netherlands) performed as described above.
  Cell bead array cytometric assay
Production of TNF-α, IL-1b, IL-10, and IL-6 in MSC/PBMC supernatants, colon biopsy 
homogenates and serum was determined using a CBA kit according to the manufacturer’s 
instructions (BD Biosciences, San Jose, CA).
  Study design
Patients received 2 doses of MSCs, 7 days apart, at week 0 and 1. Just before clinical appli-
cation, cryopreserved cells were thawed and cells were infused intravenously at a target 
dose of 1-2x10^6 cells/kg bodyweight. Patients were clinically assessed at weeks 0, 1, 2, 4, 
6, and 14. At each visit, adverse events were ascertained, concomitant medications were 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































obtained. Colonoscopies were performed at week 0 and 6, and mucosal inflammation was 
assessed using the Crohn’s disease endoscopic index of severity (CDEIS). The study flow 




  Statistical analysis
Data were analyzed using SPSS (SPSS Inc., Chicago, IL) or GraphPad (Graphpad software 
Inc., La Jolla, CA). Analyses included the Kruskall Wallis test followed by Dunn’s multiple 
comparisons (multiple comparisons), two-sided t-test and Wilcoxon signed-rank test for 
paired data. P-values <0.05 were considered significant.
  Results
  Patients
In total ten patients (eight females/two males, median age 32,5 and range 19-42 years) with 
moderate to severe Crohn’s disease (median CDAI score at screening of 299,5 and range 
255-442) were included in the study and underwent bone marrow aspiration under local 
anesthesia. Besides some local pain at the puncture site afterwards, bone marrow aspiration 
was well tolerated by all patients. Baseline characteristics are presented in table 1. The bone 
marrow aspiration procedure resulted in sufficient bone marrow to expand MSC up to the 
required therapeutic doses (supplementary Table 1).
One patient with a CDAI score of 255 at screening, showed no active disease on colonos-
copy and was therefore excluded for further MSC administration (patient 9). The baseline 
median CDAI score of the nine treated patients was 326 (range 224-378). During MSC infu-
sion, patients were closely monitored. MSC infusion was successful and without relevant 
side effects. In one patient a transient mild allergic reaction occurred which was probably 
due to the cryopreservant DMSO. Moreover, all patients noticed the typical smell and taste 
due to the DMSO up to 48 hours after infusion. Other adverse events in the first 6 weeks 
of the protocol were ruled unlikely to be associated with MSC treatment and included AEs 
such as common cold and headache (Table 2).
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Table 2 Adverse events in MSC treated patients (week 0-6).
n Patient number
Likely related to MSC infusion
Allergic reaction 1 4
Typical taste and smell 9 all
Headache 3 1,4,7
Unlikely related





Abdominal pain 3 3,5,8
Hemorrhoid 1 4
Fever 1 4
Lack of appetite 2 1,4
Fatigue 2 5,8
Diarrhea 1 8
Common cold 1 10
Otitis media acuta 1 2
Two serious adverse events (*) were reported due to worsening of disease requiring hospitalization
  Figure 2 Mesenchymal stromal cells (MSCs) from Crohn’s disease patients differentiate 
into mesenchymal lineages.
 (A) Adipocyte differentiation was demonstrated in MSCs cultured from a healthy donor (hd) and from a patient 
with Crohn’s disease (pt) after which cells were stained with Oil Red O to show lipid droplets in the cytoplasm 
of the cell.
(B) For osteoblast differentation MSCs were stained with fast blue to show alkaline phosphatase activity. Non-
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  bmMSC from refractory Crohn’s disease patients are comparable to MSCs from healthy 
donors
Approximately hundred milliliters of bone marrow was aspirated from each patient and 
bmMSCs were isolated and cultured. MSCs from Crohn’s disease patients showed the typi-
cal spindle-shaped morphology and similar growth potential and yield compared to MSCs 
from healthy donors (Supplementary Figure 1). Depending on the number of cells needed 
and the yield of cells, MSCs were harvested in the first, second or third passage (Supplemen-
tary Table 1). All MSC cultures showed normal karyotyping. Immunophenotypical charac-
terization was performed by FACS analysis, and showed similar phenotyping as described 
for healthy controls (Table 3).
Furthermore, CD MSCs were able to differentiate along the osteogenic and adipogenic line-
ages when cultured in appropriate culture medium (Figure 2).
  bmMSCs from refractory Crohn’s disease patients suppress immune responses in vitro
In the presence of autologous bmMSCs proliferation of PBMCs was reduced in a cell 
dose-dependent fashion (Figure 3A) and a decreased TNF-α production was observed. An 
increase of IL-1b, IL-6 was seen, as well as an increase in the regulatory cytokine IL-10 (Fig-
ure 3B). MSC proliferation was not affected by co-medication (infliximab, adalimumab, dex-
Figure 3 Mesenchymal stromal cells (MSCs) from Crohn’s disease patients significantly inhibit 
the proliferation of peripheral blood mononuclear cells (PBMCs) and this inhibition is dose-
dependent.
(A) 100 000 PBMCs cells were stimulated with anti-CD3/CD28 beads in the absence (white column) or pres-
ence (black columns) of indicated numbers of autologous MSCs. Proliferation measured by 3H-thymidine uptake 
in counts per minute was expressed as a percentage of PBMCs proliferation without MSCs for each individual 
patient. (B) Cytocine production in the supernatants of PBMC cultures and 10 000MSC/100 000 PBMC cocul-
tures. MSCS alone produce IL-6 (lower right). In the presence of MSCs, TNF-α production is lowered, whereas 
IL-1b and IL-10 production is increased. Bars represent the mean and SEM of data from 10 patients in triplo. *p< 
0.05 for significant differences
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amethasone, azathioprine, 6-mercaptopurine and methotrexate) in vitro (data not shown). 
However, MSCs do have an additive effect on inhibition of PBMC proliferation by various 
Crohn’s disease medication in vitro (Figure 4).
Figure 4 Mesenchymal strom cells (MSCs) have an additive effect on the inhibition of PBMC 
proliferation by Crohn’s disease medication.
In the presence of indicated Crohn’s disease medication proliferation of 100 000 stimulated PBMCs added to 
1000 MSC (black bars) compared to PBMC without MSCs (white bars) was measured. Proliferation measured 
by 3H-thymidine uptake in counts per minute was expressed as a percentage relative to PBMC proliferation in 
control medium (set to 100%). Bars represent mean and SEM. *p< 0.05 for significant differences between test 
conditions based (two-sided t-test)
   
Clinical response
Clinical assessment was performed on all patients using CDAI scoring. Two patients were 
excluded before the primary endpoint was met. The first patient was a chronic severe ster-
oid refractory patient on the waiting list for surgery. Although an initial drop of CDAI score 
was seen, this patient was excluded when presented with a CDAI >450 due to poor general 
condition and persistent rectal blood loss. Patient 7 was withdrawn from the study four days 
after the first MSC infusion because of continuing abdominal aches and bloody diarrhea. 
In this case infliximab treatment was resumed. CDAI scores improved in 5 patients, clinical 
response (defined as a drop in CDAI>70) was seen in 3 patients at week 6 (Table 4).
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Table 4 Clinical scores of patients at week 0, 1, and 6.
Patient number





254 326 350 266 378 224 304
wk 1 Second infusion 305 281 182 318 306 247 #452 167 ND
wk 6 Primary endpoint #473 185 179 267 314 160 ND 340 354
Surgical resection
In week number 7 n n n 12 n n 14 n
In the 6 month follow up period, three patients underwent surgery in indicated week after MSC infusion. *base-
line, #withdrawn from study, ND not determined, n no
remission (CDAI <150) was not achieved in any of the patients. Three patients had a reduc-
tion of 70 points in CDAI score, this decrease could in most cases be ascribed to solid stools 
and a decrease in soft stool frequency. In a period of 14 weeks, three patients required 
surgery due to disease worsening (Table 4). No significant differences in C-reactive protein 
(CrP) levels were seen.
C
Figure 5 Endoscopy 0 (upper panels) and at 6 weeks (lower panels) after mesenchymal stromal cell (MSC) 
treatment (two administrations of 2x10^6 autologous bmMSCs) shows clear mucosal healing. 
Pictures A and B are from patient 2, pictures C and D from patient 3
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Figure 6
CD4+, CD8+ and CD4+CD127+ populations in biopsies of inflamed mucosa at week 0 and 6 (A, left panels).
Cytokine levels of TNF-α, IL-1b, IL-10 and IL-6 were determined in mucosal biopsies (A, right panels) and serum 
(B) at week 0 and 6. Bars represent mean and SEM. *p< 0.05 for significant differences
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  Endoscopy
Endoscopic improvement, observed by a drop in CDEIS of 10,0 and 24,7 points, was seen 
in two patients with extensive CD localized in the colon (Figure 5). 
In the other five patients no significant endoscopic improvement was seen between base-
line and six weeks post-infusion. At week 0 and 6, levels of CD4+, CD8+ and CD4+CD127+ 
populations were determined in biopsies of inflamed mucosa (fig 6A left panels). Lower 
CD4+ T cells and higher CD4+CD127+ regulatory T cells were observed at week 6 when 
compared to week 0. Cytokine levels of TNF-α, IL-1b, IL-10 and IL-6 were determined in 
mucosal biopsies and serum at week 0 and 6. In general, cytokine levels went down in the 
mucosa (Figure 6A right panels), whereas an increase of cytokine levels in the serum was 
seen (Figure 6B).
  Discussion
This phase I study shows that bone marrow harvesting and expansion of bmMSCs from 
refractory Crohn’s disease patients is feasible and that MSCs cultured from Crohn’s disease 
patients are similar to MSCs from healthy donors, in for example plastic adherence, spindle-
shaped morphology, growth potential (Supplementary Figure 1), surface marker expression, 
lack of hematopoietic markers (Table 3) and differentiation capability (Figure 2). In addition, 
MSCs from refractory Crohn’s disease patients are able to inhibit autologous PBMC prolif-
eration and inhibit TNF-α production in vitro (Figure 3). Furthermore, autologous bmMSC 
infusion appears to be safe as intravenous MSC infusions were clinically well tolerated. 
reported adverse events directly related to MSC infusion were a mild and transient allergic 
reaction in one patient and the typical taste and smell of the cryopreservant DMSO noticed 
by all patients (Table 2).
Although the design of this study does not allow conclusions on efficacy, after two infu-
sions with autologous bmMSCs, endoscopic improvement was seen in two patients (Figure 
5), while three patients required surgery due to worsening of disease (Table 4). Patients 
included were chronic active patients refractory to all currently available medical therapeu-
tic options. One could speculate that the immunomodulatory effect of MSCs might not be 
sufficient to induce clinical remission in this category of patients. Further (randomized) 
trials in also less refractory patients are therefore warranted
In order to study the biologic effects of systemic MSC infusion in refractory CD patients 
we analyzed CD4+CD127+ expression on T cells obtained from colonic biopsies and deter-
mined cytokine production in both colon homogenates and serum. We observed a trend of 
lower CD4+ T cells and higher CD4+CD127+ regulatory T cells at week 6 when compared to 
week 0, although the number of patients in this study was not enough to reach statistical sig-
nificance. In addition, cytokine levels went down in mucosal biopsies, indicating a decrease 
in intestinal inflammation (Figure 6A right panels). The apparent reciprocal increase in 
serum cytokine levels (Figure 6B) may be the result of altered distribution of inflammatory 
cells. Due to the decreased local inflammation, leukocytes are no longer recruited to the 
intestine, but remain in the circulation, thus increasing the systemic cytokine levels. Similar 
findings have been observed for regulatory T cells in CD 18 and plasmacytoid dendritic cells 
in dermal inflammation. 19
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The intravenous route of administration and target dose of 1-2x10^6 cells/kg bodyweight 
were based on experience with other protocols in GvHD. Intravenous infusion of cells is 
an easy, minimal invasive and routinely performed procedure with proven safety so far. 
Although it has been suggested that MSCs home to sites of inflammation, it is unknown 
how many cells will eventually reach the intestine in CD patients. In a case report, Dinesen 
et al. 20 showed that MSCs administration via selective mesenteric artery cannulation was 
safe and feasible. This approach may possibly increase the number of cells reaching the 
affected organ.
In the case of autologous MSCs, an ongoing discussion is whether MSCs are affected by or 
may contribute to the underlying disease. For instance, MSCs from patients with systemic 
lupus erythematosus are difficult to expand in culture and yield low cell numbers 21 and 
those from patients with multiple myeloma have been shown to be impaired and possibly 
contribute to the pathogenesis of the disease. 22 In this study we demonstrate that MSCs 
obtained from refractory Crohn’s disease patients show similar growth potential, yield and 
properties when studied in vitro in comparison to MSCs from healthy donors. Our data sup-
ports work published recently 23 and suggests that bmMSCs from patients with refractory 
Crohn’s disease are not affected by the disease. Unfortunately, there is no golden standard 
test to assess the functionality of MSCs and it has not been demonstrated that in vitro effec-
tiveness of MSCs can be translated to clinical effectiveness, making true extrapolation of 
this topic difficult.
Another important issue is the effect of MSCs on concomitant medication. 24 To address this 
matter, we studied the effect of MSCs on various routinely used CD medications in vitro. We 
found that adding various CD medications to MSC cultures did not affect cell proliferation. 
Furthermore, adding MSCs to proliferating PBMCs in the presence of tested medications, 
gave a cumulative effect on the inhibition of PBMC proliferation (Figure 4), suggesting that 
MSCs can be used in addition to concomitant CD medication.
A concern in cell based therapies with ex vivo expanded cells is the formation of tumors. Pre-
vious work indicated that in mice, MSCs stimulate the growth of cancers 25, 26 and promote 
metastasis. 27 Additionally, extensive in vitro expansion of cells may induce genetic instabil-
ity. Although an increased risk on tumor formation has never been confirmed in humans, 
patients with a history of malignancy were excluded from this study. To minimize the risk 
of transformation of cells we have expanded MSCs in the absence of growth factors, plated 
MSCs in moderate cell concentrations and used only low passage numbers. Furthermore, 
we karyotype the MSC product before clinical release to confirm normal karyotyping and 
did not observe any aberrancies.
In conclusion, our data suggests that intravenous application of autologous bmMSCs is fea-
sible and well tolerated. Furthermore, bmMSC administration may produce clinical bene-
fits in severe refractory Crohn’s disease. Therefore, further studies should be designed to 
examine MSCs as a potential treatment for Crohn’s disease.
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  Supplementary files
Supplementary figure 1.
MSC expansion of CD patients (red) and healthy volunteers (black) expressed as theoretical cumu lative cell 




ml bone marrow 
collected Days of culture Passage number
Number of cells 
(x10^6)/kg/
infusion
Total number of 
cells infused 
1 120 15 1 1,9 220
2 97 24 2 1,9 260
3 106 24 2 2,0 300
4 114 16 1 2,0 400
5 106 24 2 1,6 150
6 111 31 3 0,9 146
7 96 23 2 1,1 240
8 109 34 3 1,5 346
9 100 16 1 NA NA
10 102 27 2 2,1 220
Overview of bone marrow collection, time needed for MSC culture and final MSC product infused. NA not appli-
cable
C
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  Abstract
Immune suppressant medications such as thiopurines and anti-tumor necrosis factor 
agents are important for maintaining disease control in most patients with inflammatory 
bowel diseases (IBD), however, their use have been associated with the development of 
malignant lymphoma. The purpose of this Dutch nationwide study was to estimate the rela-
tive risk of malignant lymphoma in IBD patients.
IBD patients who developed a lymphoma between 1997 and 2004 were identified using 
the Dutch National Database of PALGA. Data from confirmed cases were collected from 
individual hospitals, including data on Epstein Barr virus. The age-adjusted 8-years inci-
dence of malignant lymphoma in the Netherlands was retrieved from the Central Bureau 
of Statistics. 
Forty-two hospitals were visited and 285 matches evaluated in the total cohort of 17834 IBD 
patients. Forty-four lymphomas were observed resulting in a relative risk of 1.27 (95% CI: 
0.92 – 1.68). Only 19 of 44 patients (43%) were exposed to AZA/6-MP. remarkably, 92% 
of patients (11/12) with EBV positive lymphoma used AZA/6-MP, in contrast to only 19% 
patients (4/21) with EBV negative lymphoma, suggesting a strong relation between EBV 
positive lymphoma and thiopurine use. 
This nationwide study does not suggest a significant overall increased risk for lymphoma 
in IBD patients. A distinct correlation between EBV positive lymphoma and AZA/6MP use 
was observed.
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  Introduction
An approximate fourfold increased risk of a malignant lymphoma in inflammatory bowel 
disease (IBD) patients treated with azathioprine/6-mercaptopurine (AZA/6MP) was 
observed in a meta-analysis several years ago. 1 Since the absolute risk was considered low 
and not affecting the risk-benefit ratio, global IBD guidelines continued to endorse the use 
of AZA/6MP as maintenance therapy for IBD. Two recent developments have occurred that 
could potentially challenge this. First, reports on cases with hepatosplenic T-cell lymphoma 
suggested a role for thiopurines possibly in combination with anti-TNF therapy. 2 Second, a 
recent French prospective nationwide study from the Cesame Study Group involving almost 
twenty thousand IBD patients, demonstrated a significant increased risk for lymphoma 
development in patients receiving thiopurine therapy. 3 
IBD lymphoma cases have typically involved post-transplant lymphoproliferative disorder-
like B-cell disorders associated with Epstein-Barr virus suggesting a causal role for immu-
nosuppression. However, inflammation itself might contribute to the excess lymphoma 
risk. Indeed, a longer duration of IBD was an independent risk factor for developing a 
lymphoma in the Cesame study. Also, in rheumatoid arthritis it has been evident that severe 
disease can be associated with an increased risk for lymphoproliferative disease irrespective 
of immunomodulatory therapy. 4, 5
Although the cumulative absolute risk for developing lymphoproliferative disorders in 
patients receiving thiopurine therapy appears to be low, we investigated the lymphoma 
incidence in a Dutch nationwide study. Specifically, we were interested in the association 
between the use of thiopurines and the development of lymphoproliferative disorder-like 
B-cell disorders in IBD patients associated with EBV.
  Methods
  Cases
To identify all IBD patients in the Netherlands who developed a malignant lymphoma, the 
PALGA database was used. PALGA is the Dutch nationwide network and registry of histo- 
and cytopathology, which contains standardized abstracts of all 16 million inhabitants of 
the Netherlands since 1990. 6 Patients in this registry are identified by date of birth, gender 
and the first 4 characters of their family name. The abstracts contain encrypted patient 
information, demographic data and a summary of the pathology report coded in accord 
with Systematized Nomenclature of Medicine (SNOMED) terminology issued by the Col-
lege of American Pathologists. We queried the PALGA database according to a standard-
ized procedure, after which an independent review committee consented to this search and 
subsequent identification of cases. The PALGA case-numbers were generated in an anony-
mous way. Subsequently, local pathologists were contacted to identify the associated medical 
files. Local gastroenterologists or treating physicians assisted to retrieve the required data-
sets. Finally, participating hospitals were visited and anonymized datasets of case reports 
matched by PALGA were entered in the case report forms (CrFs) using unique study num-
bers. 
132 Chapter 7
  Dutch lymphoma incidence and expected number
Age-adjusted incidence numbers of Hodgkin Lymphoma (HL) and Non-Hodgkin Lym-
phoma (NHL) in the general population in the Netherlands were obtained from the Central 
Bureau for Statistics (2000 – 2004) and used to calculate the 8-years incidence and subse-
quently the expected number in our IBD-cohort. The total number of the cohort was calcu-
lated using the estimated sum of patients per participating hospital and was estimated at 
23216. Because 23% of the case histories was not available for full analysis, the final cohort 
size was estimated at 17834 IBD patients (77% * 23216).  Forty-two medical centers were 
participating in this study, both academic and peripheral, and we used the Dutch age and 
gender specific incidence numbers from the Central for Statistics to calculate the number 
of IBD patients in each age and gender group.
Subsequently, the expected number of lymphomas in IBD patients was calculated using the 
8-years age-adjusted incidence numbers. 
  Design of the study
From the PALGA registry all patients with both IBD and lymphoma were selected between 
1997 and 2004. This time window was chosen since thiopurine therapy management 
became more prominent and more generally applied around 1995. Criteria adopted for the 
data base search were based on the association of the term “ulcerative colitis”, “Crohn’s dis-
ease”, “inflammatory bowel disease”, “inflammation”, with “malignancy” and “malignant 
lymphoma” coupled to “oesophagus”, “stomach”, “small intestine” or “colon”. The search 
disclosed only cases recorded between 1st January 1997 and 31st December 2004. Lesions 
histologically diagnosed as “multiple myeloma”, or “adenomatous polyposis coli” as well 
as “colorectal carcinoma” were excluded from the study. When it wasn’t clear whether the 
diagnosis was UC or CD, the diagnosis of the latest pathology report and/or medical file was 
recorded as definite diagnosis. When the diagnosis was “nonspecific colitis”, and the patient 
used immunosuppressive agents, it was assumed that the patient had either CD or UC, and 
was recorded in the CrF as “IBD” and was subsequently verified in the individual medical 
file. The final selection of the cases was done after an analysis of the medical records in the 
participating hospitals. Cases were excluded if the objective diagnosis of lymphoma or IBD 
was lacking. 
  Data management and statistical analysis
From all cases an a priori defined dataset was retrieved and entered in a dedicated Excel 
database. The dataset included both general information such as gender, age, height and 
weight, as well as details on disease duration, medication, onset of disease, and phenotypic 
characteristics such as stenoses, fistulas, surgery, complications and family history of IBD. 
In addition, the year of diagnosis of malignant lymphoma, location and type of lymphoma, 
treatment, patient survival and the presence of EBV were retrieved. Descriptive and ana-
lytical statistics were performed using Microsoft Excel. The relation between EBV positive 
lymphoma and azathioprine was calculated using Fisher exact test. 
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Results
Cases
The PALGA database search identified a total of 371 cases with both IBD and lymphoma 
between 1997 and 2004. Figure 1 depicts the search and selection algorithm. Eighty-six case 
histories (86/371, 23%) proofed not to be present for full analysis and could therefore not be 
analyzed. Subsequently, 42 Dutch medical centers were visited to analyze the medical files 
of in total 285 matches. In 241 cases, an objective diagnosis of IBD or malignant lymphoma 
could not be confirmed. Thus, 44 cases of malignant lymphoma in a cohort of 17834 IBD 
patients were included for final analysis. Table 1 shows the number of cases and patient 
characteristics. 
Figure 1 Search and selection strategy.
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  Lymphoma risk
Since 44 cases were observed in a total IBD population of 17834, and 34.63 cases were 
expected (Table 2), the relative risk (rr) of developing a malignant lymphoma was 1.27 
(95% CI 0.92 – 1.68). Hence, no overall increased risk was observed. However, a statisti-
cally significant increased risk was observed in the age categories 35 – 39 (rr 9.32, 95% CI: 
3.89 – 17.07) and 45 – 49 (rr 3.99, 95% CI: 1.22 – 8.36). The increased rr in these two 
groups suggests an association between lymphoma and a diagnosis of IBD for patients of 
these ages. 
Also, a gender specific analysis was performed, since the lymphoma incidence numbers 
in males are higher than in females and therefore, the expected number of lymphoma in 
males would be higher. In line with this, more lymphomas were observed in males (27/44, 
61%) than in females (17/44, 39%). In all age groups taken together, the risk in males and 
females was similar, and there was no significant increased risk for either males or females 
for lymphoma in IBD (males: rr: 1.21 95% CI 0.79 – 1.72; females: rr: 1.23 95% CI: 0,70 
– 1,89). However, in both males and females, a statistically significant risk was found in 
the age group 35 – 39 y and this increased relative risk was particularly outspoken in males 
(males: rr: 10.25 95% CI: 2.56 – 23.05; females: rr: 6.74 95% CI: 1.20 – 16.77). In all other 
EBV positive EBV negative EBV status unknown Total 
number of cases 12/44 (27%) 21/44 (48%) 11/44 (25%) 44
Age 
mean ± SD (y) 
median (range, y)
 
46.75 ± 17.56 
37.5 (24 – 78)
 
53.62 ± 14.31 
58 (21 – 74)
 
61.64 ± 13.74 
63 (36 – 79)
 
53.75 ± 15.74 
56.5 (21 – 79)




















Duration between IBD and 
lymphoma  




12.05  ± 6.75* 
13 (2.5 – 25)
 
 
13.76 ± 10.97 
12 (0.5 – 36)
 
 
12.73 ± 8.21  
11 (1 – 31)
 
 
13.06 ± 9.21 
12 (0.5 – 36)
AZA/6MP use (%) 11/12 (92%)** 4/21 (19%)** 4/11 (36%) 19/44 (43%)
Duration of AZA/6MP use mean 
± SD (y) 
median (range, y)
 
4.32 ± 4.08  
3 (0.25 – 12)
 
3.63 ± 1.7   
3.25 (2 – 6)
 
1.3  ± 0.71*** 
1.33 (0.58 – 2)
 
3.58 ± 3.3 
2.5 (0.25 – 12)
Table 1 Characteristics of cases.
 EBV = Epstein Barr virus, CD = Crohn’s disease, UC = ulcerative colitis, IBDU = unspecified IBD, AZA = azathio-
prine,  6MP = 6-mercaptopurine
* of 1 patient in this group the time between IBD diagnosis and lymphoma was unknown; ** medication use of 1 
patient in both groups was unknown; *** of 1 patient in this group the duration of azathioprine use was unknown
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Age Expected number of cases Observed number of cases
(EBV positive lymphoma)
RR (95% CI)
0 – 4 0.002 0
5 – 9 0.013 0
10 – 14 0.044 0
15 – 19 0.318 0
20 – 24 0.748 2 (1) 2.67 (0.23 – 7.79)
25 – 29 0.975 0
30 – 34 0.783 2 (1) 2.56 (0.22 – 7.45)
35 – 39 0.858 8 (5) 9.32 (3.89 – 17.07)*
40 – 44 1.188 1 0.84 (0 – 3.37)
45 – 49 1.252 5 (1) 3.99 (1.22 – 8.36)*
50 – 54 1.834 3 1.64 (0.29 – 4.07)
55 – 59 1.924 5 (1) 2.60 (0.79 – 5.44)
60 – 64 2.136 6 (1) 2.81 (0.98 – 5.57)
65 – 69 3.370 4 1.19 (0.30 – 2.67)
70 – 74 4.913 4 0.81 (0.20 – 1.83)
75 – 79 5.729 4 (2) 0.70 (0.17 – 1.57)
80 – 84 5.022 0
85 – 89 2.833 0
> 90 0.788 0
Total 34.63 44 1.27 (0.92 – 1.68)
age groups, the relative risk for both males and females was similar and not significantly 
increased. In conclusion, males initially have a higher risk of developing lymphoma, and 
the fact that we observed more male than female cases, is therefore probably not related to 
IBD or treatment. 
EBV associated lymphomas
Of the 44 lymphoma specimens, 12 were EBV positive and 21 negative. In 11 cases the EBV 
status could not be ascertained. Table 3 depicts the 12 individual IBD cases with an EBV-
related lymphoma in detail. Of these, 11 patients were treated with thiopurines in combina-
tion with 5-ASA and prednisone. One case is supposed to be related to immunosuppression 
after liver transplantation. Six patients were diagnosed with CD (4 female and 2 male), 6 
with UC (3 female, 3 male). None of the patients used anti-TNF compounds. Nine out of 
twelve lymphomas were localized in the gastrointestinal tract and all EBV+ lymphomas but 
one were of the diffuse large B cell type. A considerable variation was found in the dose and 
duration of the thiopurine use (duration ranging from months to 12 years, dose ranging 
from 50 – 350 mg/day), and in time between onset of IBD and lymphoma diagnosis (2.5 – 
25 years).
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Twenty-one EBV negative lymphomas were observed (Table 4). Of these, four patients 
used azathioprine. Nineteen patients used mesalazine, prednisone or a combination, one 
patient didn’t receive any therapy at all and from one patient the prescribed medication was 
unknown. Of these 21 lymphomas, 10 lymphomas were diffuse large B cells lymphomas, 
so there was more variation in the type of lymphoma. Twelve out of 21 lymphomas were 
localized in the gastrointestinal tract. Twelve patients were diagnosed with UC (8 male, 4 
female), six with CD (4 male, 2 female) and three with unspecified IBD (IBDU). The time 
between IBD and lymphoma diagnosis ranged from 6 months to 36 years. 
  Association between azathioprine/6-MP use and EBV positive lymphomas
Of the 44 cases, 19 patients were exposed to AZA/6MP (range: 3 months –12 yrs), 23 
patients never used AZA/6MP and from two patients it was unknown whether they used 
AZA/6-MP. Of the 19 lymphomas in thiopurine users, 15 were tested for EBV. remarkably, 
11 lymphomas were EBV positive (73%) and 4 were EBV negative (27%), and there was 
a significant association between thiopurine use and EBV positive lymphoma (p<0,001). 
Twenty-three patients didn’t use AZA/6MP, and in this group 16 lymphomas were tested 
for EBV status. No EBV positive lymphomas were found. From 2 patients it was unknown 
whether they used AZA/6-MP, one tested negative for EBV and one was positive for EBV. 
The latter case, however, was thought to be related to immunosuppression following liver 
transplantation (Figure 2 and table 5). Most EBV positive lymphomas were diffuse large B 
cell lymphomas. Ten out of 21 EBV negative lymphomas were diffuse large B cell lympho-
mas. Whether these lymphomas arose as a result of the disease itself or because of the use 
of immune suppressive agents has not been elucidated yet. Since EBV positive lymphomas 
arise especially in the setting of immunosuppression, the occurrence of these lymphomas 
suggested a strong relation with the use of immunosuppressive drugs, especially thiopu-
rines, in IBD patients.
Figure 2 Thiopurine use in EBV positive and EBV negative lymphomas.









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 5 Thiopurine use and EBV status.
EBV status Thiopurine use + Thiopurine use - Thiopurine use 
unknown
Total
Positive 11** 0 1* 12
Negative 4 16 1 21
Unknown 4 7 0 11
Total 19 23 2 44
* In this case the lymphoma could also be related to immunosuppression after liver transplantation 
** A significant association between EBV+ lymphoma and thiopurine use was found (p ≤ 0.001)
  Discussion
This nationwide study in the Netherlands suggests that there is no overall statistically signif-
icant increased risk of malignant lymphoma in IBD patients (rr 1.27, 95% CI: 0.92 – 1.68). 
Two relevant additional observations were made: 1) almost all patients with an EBV positive 
lymphoma used AZA/6-MP, and 2) these EBV post-transplant like lymphomas were partic-
ularly prevalent in the younger aged adult patients (< 50 years). This was a remarkable find-
ing since the expected number of lymphomas increases with age and is quite low in younger 
age categories of the normal population. Therefore, these data suggest that younger aged 
adult patients may have an increased risk. Although more lymphomas were observed in 
males (61%), more lymphomas were expected since the lymphoma incidence in males is 
higher than in females. Both in males and females no significant increased risk for lym-
phoma was found, except in the age group 35 – 39. risks were similar and not significantly 
increased for males and females in other age groups. Lymphomas of different origin were 
found in the study population, which included both CD and UC patients in different age 
categories. Since the study population is a mixed population and not all patients received 
immunomodulators, it is possible that the calculated risk underestimates the actual risk in 
patients receiving immunomodulators, and overestimates the risk in patients that do not. 
The current literature does not offer clear and conclusive answers on the risk of predis-
posing factors for lymphoma development in IBD. It seems that our results are comparable 
to those of reported population based studies. Two large population based studies including 
16996 IBD patients in the UK 7 and 47679 IBD patients in Sweden 8 failed to show a sig-
nificant increased risk of lymphoma (rr for CD 1.4 and 1.3, rr for UC 1.2 and 1.0 resp.). In 
addition, other population based studies did not show a significant increased risk. 9-11
In contrast, one population-based, retrospective Canadian IBD study did observe an 
increased risk of 2.4 in CD patients but not in UC. 12 In 2000, Farrell et al. observed a small 
increased risk in a cohort of 782 IBD patients. 13 In 2002, Dayharsh et al. observed in 10,000 
IBD patients from a tertiary center a two-fold risk, also including EBV positive lymphomas. 
14 Also, two other studies found a significant increased risk. 1, 3 reasons for the conflicting 
results of the different studies could be the design of the study, selection of patients, referral 
bias, or a different incidence of NHL and HL in the general population. For instance, it is 
possible that single center studies experience referral bias, and meta-analyses performed on 
the cases reported in single center studies might overestimate the actual risk. In addition, 
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the prospective study performed by Beaugerie et al. showed a significant increased risk but 
was also designed differently; the investigators aimed to evaluate the lymphoma risk in thio-
purine users versus non users. Because of differences in design and patient recruitment, it 
is complicated to compare the outcomes of different studies.  
Furthermore, we found that especially younger aged adult patients are at risk. This observa-
tion is in line with another study 15 and rather interesting, since lymphoma incidence in the 
general population increases with age, and therefore the increased risk in the younger aged 
adult patients suggests that the lymphoma is more likely related to the disease or the treat-
ment. However, it is not known why this age group might have an increased risk. Future 
studies are needed to elucidate why this particular group has an increased risk, and how this 
vulnerable group can be protected from an increased risk.  Also, we confirmed a significant 
association between EBV positive lymphoma and the use of thiopurines. This was observed 
previously in other studies and case reports. 1, 16-18
There has been a longstanding concern regarding anti-TNF therapy and the risk of lym-
phoma. Anti-TNFs were introduced in the Netherlands in the late ‘90s so anti-TNF was 
introduced during our study period (1997 – 2004). None of our cases used anti-TNF ther-
apy, and the issue of anti-TNF therapy and the risk of lymphoma was not addressed in this 
study. 
It is unclear to what extent disease severity plays a role in the development of malignant 
lymphoma in IBD. In rheumatoid arthritis (rA), a strong relation between disease activity 
and lymphoma risk has been reported. 4, 19 One particular problem with such an assumption 
is the selection bias of patients because association evidently does not imply causation. It is 
likely that use of thiopurine derivatives also reflects severity of the disease, which in itself 
could well be part of the pathogenesis of lymphoma development. This concern has also 
been voiced by others. 20
A few limitations of this study should be noted. First of all, most medical centers in the 
Netherlands do not register their IBD patients in research dedicated databases. Conse-
quently, the size of the total IBD patient cohort in our study is an estimation drawn from 
hospital information systems. Second, a considerable number of case histories could not 
be retrieved or were incomplete. As a result, we were unable to fully evaluate 23% of the 
possible cases. Although this a large percentage, the missing case reports were both in ter-
tiary centers as well as peripheral centers and distributed over 21 medical centers, arguing 
against the idea of selection bias or over- or under presentation of a certain patient group 
and suggesting that the missing case reports over 21 medical centers are caused by random 
inaccuracies. In addition, given the number of medical centers included in our study (42 in 
total), the representativeness of our cohort and nationwide design of the study, this study 
provides a valid estimation of the relative risk of malignant lymphoma among IBD patients. 
We were unable to identify specific risk factors other than age in this study, since the design 
of this study is not eligible for the identification of other risk factors. Future studies are 
needed to identify other risk factors, such as disease severity, and to find out which patient 
groups are at risk. 
In conclusion, we report no statistically significant overall increased relative risk for malig-
nant lymphoma development in IBD patients, and a significant association of thiopurine 
derivative use and development of EBV-positive lymphoma. Furthermore, a significantly 
increased risk was found in younger aged adult patients. Should we now be reluctant to 
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prescribe thiopurines in our IBD population? Probably not, since thiopurine use has been 
so successful in maintenance therapy and in avoidance of corticosteroids, its benefit is well 
appreciated. In risk-benefit models, it has been suggested that a 10-fold risk is necessary for 
the overall effect of thiopurines in IBD to be detrimental. 21
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This thesis focuses on various strategies towards disease control in IBD; new treatment tar-
gets, working mechanism of established therapies, side effects and future therapy. A better 
understanding of disease pathology and the working mechanism of IBD therapy, could help 
to find new treatment targets, disease markers and novel therapies. Also, this would allow 
the selection of patients for a certain therapy based on genotype or phenotype. 
An overview of a selection strategy based on disease phenotype is provided in chapter two. 
It has been shown that patients with young age at onset of disease, presence of perianal dis-
ease, stricturing disease and initial need for corticosteroids have a high risk at developing a 
complicated disease course. In addition, CD typically evolves from an inflammatory disease 
to a fibrotic disease. At this stage, the disease is difficult to treat and response rates to vari-
ous therapies, among which anti-TNF, are lower than in patients with recently diagnosed 
disease. It is suggested that patients with a high risk of developing complicated disease 
would particularly benefit from a “top-down” approach. Importantly, side effects need to be 
weighed against the benefits, and strong genetic or phenotypic factors in order to predict 
disease course, therapeutic response and risk of side effects are still lacking but would be 
highly valuable. 
  A new role for autophagy in CD pathogenesis:  clinical implications 
Since autophagy has been described as a degradation mechanism, 1, 2 many studies on the 
role of autophagy in CD pathogenesis focused on its role in the clearance of pathogens. 3-5 A 
defect in the autophagy pathway could lead to impaired clearance of intracellular organisms, 
and in that way contribute to uncontrolled microbial expansion and excessive immunity. 
Likely, these mechanisms contribute to disease pathogenesis, but the results described in 
chapter three provide new insight into the role of autophagy in the absence of pathogens. 
We found that autophagy is important in the breakdown of the immunological synapse, and 
in that way identified a role of autophagy in tolerance and immunity in general. Importantly, 
we also confirmed these findings in patients carrying the autophagy SNP, and these data 
may explain the aberrant immune response observed in these patients. The identification 
of a new role for autophagy in the pathogenesis of CD may provide new therapeutic tar-
gets in patients carrying this SNP. Interestingly, azathioprine has been described to sup-
press APC-T cell interactions, 6 and therefore patients carrying the autophagy risk allele 
may bene fit from azathioprine therapy in particular. In addition, other autophagy inducing 
drugs may be effective in this specific patient group, such as rapamycin, which inhibits 
mammalian target of rapamycin (mTOr) and thereby induces autophagy. Indeed, two case 
reports show an impressive effect of this drug, 7, 8 but this has not been tested in patients 
with the risk allele specifically. In addition, the efficacy of this drug has not been evaluated 
in clinical trials. Yet, selecting patients based on genotype for a certain therapy might be a 
promising future strategy. 
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  Relevance of Mφ2 induction and future implications 
In chapter four we describe the Fc region dependent induction of regulatory macrophages in 
vitro by anti-TNF antibodies and we further show their immunosuppressive features. Both 
the presence of monocytes and T cells was required in order to induce Mφ2. Interestingly, 
this induction was only observed when mixed lymphocyte reaction cultures were treated 
with agents that have the ability to bind to mTNF and have an Fc region to interact with Fc 
receptors. Anti-TNF agents that do not bind to mTNF (etanercept, onercept) and anti-TNF 
agents that do not interact with Fc receptors (certolizumab, CDP571) did not induce Mφ2 in 
vitro. These agents are also the ones that failed to show efficacy in clinical practice, and it is 
tempting to speculate that the induction of Mφ2 is crucial in this process.
Mucosal healing is nowadays an important treatment goal, since it has been shown that 
mucosal healing is associated with less surgery, less hospitalization, less corticosteroid 
use and improved quality of life. 9-11 The factors that contribute to mucosal healing are not 
completely understood, but the role of regulatory macrophages (Mφ2) in wound healing 
in general has been extensively studied before. 12, 13 Next to wound healing properties, Mφ2 
have immunosuppressive effects. They produce mainly anti-inflammatory cytokines, 14 have 
minor ability to respond to bacterial stimuli, 15 and inhibit proliferation of activated T cells. 16 
Since IBD is thought to result from loss of tolerance towards the mucosal environment, the 
induction of this cell type might be of particular interest in restoring the balance and induc-
ing mucosal healing. Indeed, decreased numbers of this cell type are found in the mucosa 
of IBD patients. 17 Since the successful introduction of anti-TNF agents during the late ‘90s 
in terms of mucosal healing and improved quality of life, 18-21 much research has focused on 
the mechanisms of action to elucidate factors involved in mucosal healing. In addition, the 
inefficacy of several anti-TNF agents in the clinic suggested that neutralization of TNFα was 
not the most important aspect.   
In chapter five, we confirmed the induction of Mφ2 in vivo and showed that patients respond-
ing to infliximab therapy have increased numbers of CD206+/CD68+ cells after 4 weeks of 
induction therapy compared to baseline. Since we used endoscopic and histologic healing as 
a definition of response, these data suggest that the induction of Mφ2 may be important in 
the process of mucosal healing. Also, we demonstrated the wound healing capacity in vitro, 
which further suggests a critical role of this cell type in mucosal healing. 
The induction of Mφ2 by anti-TNFα antibodies provides a model which helps to elucidate 
several other features related to anti-TNF treatment. Not only may this hypothesis help to 
explain why certain anti-TNF agents have not succeeded in clinical practice, also the supe-
riority of infliximab/azathioprine combination treatment observed in the clinic in terms of 
remission induction and maintenance and mucosal healing 22 may be explained. The results 
obtained with combination treatment in the clinic correlate properly with the results we 
observed in vitro. We found increased numbers of Mφ2 upon combination treatment, and 
interestingly, these macrophages also displayed stronger immunosuppressive properties. 
In addition, this hypothesis may help to resolve several side effect issues, for instance the 
increased risk of tuberculosis which is observed with anti-TNF antibodies. 23, 24 remarkably, 
this increased risk is only observed with the anti-TNF antibodies, and not with the soluble 
TNF receptor etanercept, both in human 25 and in mice. 26 It has been shown that mycobac-
teria like M. tuberculosis bind stronger to Mφ2 than Mφ1, 27 and that the mannose receptor 
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CD206 plays a role in the phagocytosis of M. tuberculosis. 28 Interestingly, we only found an 
induction of Mφ2 only in the conditions treated with anti-TNF antibodies, and in addition 
we observed an upregulation of CD206 on these induced cells. The results we obtained in 
vitro fit properly with the observations in vivo, and insight into these mechanisms provides 
new opportunities to challenge this problem in the future. 
The immunosuppressive effect of Mφ2 is probably mediated by a soluble factor, as we 
observe strong dose-dependent inhibition of T cell proliferation when we culture T cells 
with Mφ2-conditioned medium (data not shown). However, we did not find wound-heal-
ing effects of Mφ2-conditioned medium (data not shown) and this might suggest that the 
immunosuppressive properties and wound healing properties of Mφ2 are mediated by dis-
tinct factors. Therefore, the exact mechanisms that underlie Mφ2-induced effects are yet 
to be defined, but likely both soluble factors and cell-cell interactions are involved in the 
various processes. IL-10 has been proposed as a responsible factor in Mφ2-induced ame-
lioration of colonic disease in mice, 17 but it is less likely that IL-10 is the key factor leading 
to the results we observed in vitro. In our hands, Mφ2 mainly produce large amounts of 
IL-10 in response to LPS, but we observed strong immunosuppressive and wound healing 
properties in the absence this stimulus. Therefore, we think that IL-10 may contribute to 
the effects, but is unlikely to be the key mediator. Several other factors have been described 
in the literature, including the induction of Treg, 29 but this mechanism was not involved in 
our in vitro experiments. 
We found that patients that do not respond to infliximab therapy have lower amounts of 
Mφ2 at baseline, and it is possible that these patients have a defect in the differentiation 
or the recruitment of Mφ2. Identifying factors involved in this defect and Mφ2 differentia-
tion in general would allow the selection of patients for a certain therapeutic strategy. A 
recent paper showed that UC patients with high IL13rα2 expression at baseline, show poor 
response to infliximab therapy. 30 IL13rα2 has been described to function as a decoy recep-
tor, and thereby prevents proper IL-13 signaling. 31 Interestingly, IL-13 in combination with 
IL-4 is a known inducer of regulatory macrophages, 32, 33 and disturbed IL-13 signaling might 
therefore result in reduced induction of regulatory macrophages. 
It would be of great value to identify the factors that are responsible for the induction and 
function of Mφ2, since this would facilitate the identification of a marker that reflects dis-
ease severity and therapy efficacy. In addition, the identification of responsible factors would 
possibly provide new treatment targets. 
The findings described in chapter 4 and 5 may have further implications. The idea that bind-
ing to Fc receptors is a critical step in the induction of Mφ2 suggests that the generation of 
an anti-TNF antibody with stronger affinity to the Fc receptor might have enhanced efficacy. 
Indeed, antibodies with higher affinity to Fc receptors have been developed in other fields 
of medicine in order to augment efficacy, 34, 35 and this approach may be promising in the 
development of new therapies with greater efficacy for the treatment of IBD as well. 
Although the introduction of anti-TNF agents was an important development in the treat-
ment of IBD, about 30% do not respond to this therapy, and about 30% lose response after 
a certain period of time. Because side effects and occasionally limited efficacy are still obsta-
cles in the treatment of IBD, there is need for new therapies with less toxicity and higher 
efficacy. Mesenchymals stem cells (MSCs) are multipotential nonhematopoetic progenitor 
cells that can be isolated from various tissues, including the bone marrow. Like Mφ2, MSCs 
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have immunomodulatory 36, 37 and wound healing 38-40 properties. Several mechanisms have 
been suggested that may be involved in these processes, including cell-cell dependent mech-
anisms as well as soluble factors. Interestingly, it has been described that MSCs are able 
to induce Mφ2. 41-43 Because of their wound healing and immunomodulatory properties, 
these cells are of particular interest in various fields of medicine, including in the treatment 
of IBD. In chapter six we described the treatment of CD patients with autologous MSC 
in a Phase I trial. Importantly, MSCs from CD patients showed the same characteristics 
and immunomodulatory properties as MSCs from healthy controls. No serious side effects 
were reported during the study period, and a clinical response was observed in 3 patients; 3 
patients needed surgery. Since all patients had severe refractory disease, it is complicated to 
speculate on efficacy. MSCs seem to have high potential to serve as an efficacious cell based 
therapy in IBD, and currently numerous studies are underway to further evaluate this. 
  Side effects and risk profiles: current therapy and future implications
As mentioned before, the drugs used for the treatment of IBD are not without risk. There-
fore, a better understanding of the mechanism of action of IBD drugs enables the identifi-
cation of factors leading to side effects. In addition, a careful evaluation of side effects and 
defining specific risk groups is important to limit side effects as much as possible. Cancer, 
and especially lymphoma, is a long-standing concern in patients treated with immunosup-
pressive agents. 
In chapter seven we aimed to assess the risk of lymphoma in IBD patients and to find 
specific patient groups at risk. Also, we investigated whether we could establish an associa-
tion between azathioprine use and lymphoma. In this retrospective, nation-wide study, we 
observed 44 lymphomas in a cohort of approximately 18000 IBD patients. Compared to 
lymphoma risk in the general population, the risk of lymphoma in IBD patients was not 
increased in this study. However, a clear increased risk was observed in patients in the age 
groups 35 – 39 and 45 – 49 and a significant correlation was found between thiopurine use 
and the development of EBV+ lymphoma. None of the 44 cases used anti-TNF agents, but 
it is risky to draw any conclusions from that observation since this study was not designed 
to specifically study lymphoma risk in anti-TNF treated patients. Our data are in line with 
other population-based studies, 44-47 but in contrast to data from a meta-analysis 48 and a 
recent prospective study. 49 Discrepancies in outcome may result from differences in patient 
recruitment, study design and a different lymphoma incidence in the general population. 
The latter determines the calculated expected number and in that way the relative risk. 
Nevertheless, it has been estimated that only a ten-fold increased risk would outweigh the 
benefit of thiopurine treatment, 50 so although a slightly increased risk is found in some 
studies, this would still have limited clinical implications. On the other hand, since it 
appears that particularly patients ≤ 50 years have an increased risk, and patients with young 
onset of disease more often require intensive therapy, watchfulness is warranted in this 
vulnerable group. It is yet unknown why younger patients might have an increased risk, 
and which factors may be involved. In addition, it remains to be determined to what extent 
disease severity and disease duration contribute to lymphoma development, or whether this 
simply results from immunosuppression in general, or azathioprine in particular. Other 
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aspects like medication dose, therapy duration, and disease-related factors like disease loca-
tion and age at onset of disease also may play a role. Although our study involved approxi-
mately 18000 IBD patients in the Netherlands, the relative small number of 44 lymphomas 
does not provide the power which is needed to calculate the contribution of these specific 
factors. This would further allow the stratification of patients for a certain therapy, especially 
with regard to side effects. 
In summary, the studies described in this thesis provide new insight into our current knowl-
edge of IBD therapy. Increasing knowledge of the working mechanism of anti-TNF agents, 
safety profiles, cell-based therapy and the identification of new possible drug targets, could 
eventually lead to personalized treatment with higher efficacy and less toxicity. 
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  Inflammatoire darmziekten
Crohn’s disease (CD, ook wel ziekte van Crohn genoemd) en ulcerative colitis (UC, coli-
tis ulcerosa) zijn chronische inflammatoire darmziekten (IBD, inflammatory bowel disea-
ses). Patiënten hebben doorgaans klachten als buikpijn, diarree, bloed bij de ontlasting, 
gewichtsverlies en algehele malaise. De ziekte is chronisch, en is op dit moment helaas 
niet te genezen. De ziekte heeft een grote invloed op de kwaliteit van leven van de patiënt, 
en veel patiënten gebruiken chronisch medicatie die het immuunsysteem onderdrukken 
(immuunsuppressiva) en ondergaan een of meerdere operaties. Bij CD kan het hele spijs-
verteringsstelsel zijn aangedaan (dat wil zeggen van mond tot anus); UC betreft alleen de 
dikke darm. Zowel UC als CD kunnen op elke leeftijd voorkomen, maar de meeste nieuwe 
gevallen worden vastgesteld tussen het 20e en 40e levensjaar. 
In de darm leven miljoenen bacteriën (de darmflora) die belangrijk zijn voor verschillende 
processen, en die ook een rol spelen in het afweersysteem. In de normale situatie reageert 
het afweersysteem niet op de darmflora, omdat dit zou leiden tot een ontsteking (een pro-
ces dat tolerantie wordt genoemd). In het geval van IBD reageert het afweersysteem toch 
op de darmflora, waardoor een afweerreactie in gang wordt gezet welke resulteert in een 
chronische ontsteking. Hoewel er veel onderzoek wordt verricht naar het ontstaan van beide 
ziekten, is het niet geheel duidelijk waarom de tolerantie wordt doorbroken. Het is bekend 
dat zowel CD als UC een sterke genetische component heeft, aangezien mensen die een 
familielid hebben met de ziekte, een grotere kans hebben om de ziekte ook te krijgen dan 
mensen die geen familielid hebben met de ziekte. Verschillende grote studies (Genome 
Wide Association Studies, GWAS) zijn uitgevoerd om defecten in genen op te sporen die 
mogelijk geassocieerd zijn met CD en/of UC. Er zijn defecten gevonden in genen die een 
rol spelen in verschillende componenten van het immuunsysteem, maar ook defecten in 
genen waarvan minder goed bekend is hoe dit geassocieerd is met de ziekte. Hoewel deze 
GWAS studies weliswaar aanwijzingen verschaffen over welke genen mogelijk betrokken 
zijn, blijken daarnaast ook omgevingsfactoren een belangrijke rol te spelen. Zowel UC als 
CD zijn dus ziekten die multifactorieel van aard zijn; dat wil zeggen dat er op dit moment 
niet duidelijk een verantwoordelijke factor aangewezen kan worden die leidt tot de ziekte. 
De behandeling is voornamelijk gericht op het verbeteren van de kwaliteit van leven, het ver-
minderen van hospitalisatie, operaties en steroïde-gebruik, en het behouden van klinische 
remissie. Vaak gebeurt dit met immuunsuppressiva, zodat de afweerreactie onderdrukt 
wordt. De medicatie die gebruikt wordt om de ziekte onder controle te krijgen is echter niet 
zonder bijwerkingen. De medicamenten die op dit moment deel uit maken van de behan-
deling van UC en CD, zijn onder andere 5-ASA, steroiden, methotrexaat, ciclosporine, aza-
thioprine en anti-tumor-necrosis-factor-alpha (anti-TNFα) waaronder infliximab en adali-
mumab. Laatstgenoemden zijn antilichamen gericht tegen TNFα, een pro-inflammatoir 
stofje (cytokine) dat in grote mate aanwezig is in de darm van IBD patienten. Een anti-TNFα 
bindt TNFα en kan op deze manier TNFα neutraliseren. 
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Idealiter is een behandeling 100% effectief en zijn er geen bijwerkingen. Dit is zelden het 
geval. Tevens zou het in de ideale situatie mogelijk zijn om patiënten op basis van hun 
ziektekarakteristieken en/of genetisch profiel een behandeling-op-maat aan te bieden. Op 
de wijze zou een hogere effectiviteit bereikt kunnen worden en nadelige bijeffecten gemini-
maliseerd. Om dit in de toekomst te bewerkstelligen, is het belangrijk dat er meer bekend is 
over hoe CD en UC precies ontstaan, zodat gezocht kan worden naar nieuwe aangrijpings-
mechanismen. Daarnaast is het van belang dat er meer inzicht wordt verkregen in het wer-
kingsmechanisme van bestaande therapieën, opdat deze verder geoptimaliseerd kunnen 
worden. Verder is het noodzakelijk dat nadelige bijeffecten goed in kaart worden gebracht 
en dat mogelijke risicogroepen geïdentificeerd kunnen worden. Tot slot moet gezocht blij-
ven worden naar nieuwe behandelingsstrategieën met mogelijk minder bijwerkingen die 
een uitkomst kunnen bieden voor patiënten die niet of slecht reageren op de huidige the-
rapieën. 
In dit proefschrift worden verschillende aspecten van huidige en toekomstige therapie bij 
IBD belicht. 
In hoofdstuk 2 worden verschillende behandelstrategieën besproken. Hierbij wordt onder-
scheid gemaakt tussen de step-up en top-down benadering. Bij een step-up behandeling 
wordt de behandeling op geleide van klachten en symptomen aangepast; indien de ziekte 
verslechterd wordt er een “sterker” medicijn aan de behandeling toegevoegd. recente 
onderzoeken tonen echter aan dat in een bepaalde groep CD patienten het de voorkeur 
geniet om top-down te behandelen. Dit houdt in dat in een vroeg stadium van de ziekte 
wordt behandeld (early intervention) met medicijnen die anders pas later in de behande-
ling geintroduceerd zouden worden, dit betreft met name behandeling met infliximab en 
azathioprine. Vooral patienten die een verhoogd risico hebben op een gecompliceerd ziekte-
beloop zouden van de early intervention benadering kunnen profiteren. Een overzicht van 
de verschillende aspecten van deze behandelingsstrategieen alsmede mogelijke factoren die 
patienten met verhoogde risico op een gecompliceerd ziektebeloop kunnen identificeren 
worden in dit hoofdstuk besproken. 
In hoofdstuk 3 wordt een nieuwe rol voor autofagie in het ontstaan van de ziekte van Crohn 
beschreven. Autofagie (“autophagos” – zelf-eten) is van oorsprong een proces dat een 
belangrijke rol speelt bij de overleving van een cel. Uit verschillende GWAS bleek dat een 
bepaalde mutatie in het gen ATG16L1 geassocieerd is met het ontstaan van CD.  Het is 
bekend dat ATG16L1 belangrijk is voor het proces van autofagie, maar nog onvoldoende hoe 
dit mogelijk gerelateerd is aan CD. In dit hoofdstuk onderzoeken wij hoe een defect in dit 
gen kan leiden tot een overmatige afweerreactie. Verlaagde levels van ATG16L1 in dendriti-
sche cellen (DCs, cellen die belangrijk zijn in de herkenning van een pathogeen en voor de 
aansturing van het adaptieve afweersysteem) bleek te resulteren in een hyperactieve DCs. 
Hierdoor werden T cellen extra geactiveerd hetgeen kan resulteren in een afweerreactie. Dit 
mechanisme zou in de toekomst meer inzicht kunnen verschaffen in nieuwe aangrijpings-
punten bij patienten die een mutatie in dit gen hebben, bijvoorbeeld met medicijnen die het 
autofagieproces stimuleren of die de DC – T cel interactie verkorten. 
In hoofdstuk 4 wordt een nieuw werkingsmechanisme van infliximab beschreven. Het 
belangrijkste werkingsmechanisme van infliximab lijkt niet te berusten op de neutralisa-
tie van TNFα, aangezien andere medicijnen die TNFα kunnen neutraliseren niet effectief 
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zijn gebleken in de behandeling van IBD. In dit hoofdstuk beschrijven we de inductie van 
macrophagen met wondgenezende eigenschappen die een rol kunnen spelen bij het gene-
zen van ulcers in de darm. Deze inductie bleek afhankelijk te zijn van het Fc gedeelte van 
infliximab. Het Fc gedeelte is de “achterkant” van het antilichaam (dus niet de kant waar 
TNFα wordt gebonden en geneutraliseerd), en kan een interactie aangaan met Fc recepto-
ren op onder andere monocyten. Deze interactie bleek cruciaal te zijn in de inductie van 
regulatoire macrophagen. Tevens kan dit model verklaren waarom sommige anti-TNFs wel 
effectief zijn in IBD en anderen niet. Deze observatie verschaft meer inzicht in de factoren 
die belangrijk zijn voor de effectiviteit van anti-TNF en kan mogelijk in de toekomst leiden 
tot een nieuwe generatie anti-TNF met grotere effectiviteit. 
In hoofdstuk 5 wordt verder gekeken naar de rol van infliximab-geinduceerde regulatoire 
macrophagen in het proces van wond genezing. We laten zien dat patiënten die een goede 
respons hebben op infliximab, grotere hoeveelheden regulatoire macrophagen in hun darm 
hadden na infliximab therapie dan patiënten die niet reageerden op infliximab. Tevens zijn 
infliximab-geinduceerde regulatoire macrophagen in staat om wondgenezing te bevorderen 
in een in vitro-model. Deze data suggereren dat regulatoire macrophagen geïnduceerd door 
infliximab inderdaad een rol spelen bij de wond genezing. Tevens is het bekend dat een 
hogere effectiviteit bereikt wordt indien infliximab in combinatie met azathioprine wordt 
gebruikt. In dit hoofdstuk laten wij zien dat er grotere hoeveelheden regulatoire macropha-
gen ontstaan indien azathioprine wordt toegevoegd aan infliximab. Daarnaast hebben de 
macrophagen die geïnduceerd zijn door de combinatietherapie sterkere immuunsuppres-
sieve eigenschappen. 
In hoofdstuk 6 wordt een Fase I studie beschreven waarin 9 CD patiënten behandeld wer-
den met mesenchymale stamcellen (MSC). Het doel van deze studie was om te onderzoe-
ken of het haalbaar en veilig was om patiënten met MSCs te behandelen. MSCs zijn rela-
tief gemakkelijk te isoleren en op te kweken, en hebben, net als regulatoire macrophagen, 
immuunsuppressieve eigenschappen. Door deze kenmerken zijn MSCs een potentiële 
kandidaat voor een nieuwe behandeling van CD. De behandeling met MSCs bleek haalbaar 
en veilig te zijn. Omdat deze studie patiënten includeerde die niet meer reageerden op de 
gangbare therapieën, is het moeilijk om te speculeren over effectiviteit; meer inzicht in de 
effectiviteit zal verkregen moeten worden uit toekomstige studies. 
In hoofdstuk 7 wordt onderzocht of patiënten met IBD een vergrote kans hebben op het 
ontstaan van kwaadaardige (maligne) lymfomen. In deze studie die ongeveer 18000 IBD 
patiënten includeert, werd geen algeheel verhoogd risico op lymfoom in IBD patiënten 
gevonden. Wel werd een verhoogd risico waargenomen in de leeftijdscategorieën 35 – 39 
en 45 – 49.  Daarnaast bleek er een sterke associatie te zijn tussen het ontstaan van EBV+ 
(Epstein-Barr positieve) lymfomen en het gebruik van azathioprine. 
Samengevat, verschaffen de resultaten beschreven in dit proefschrift nieuwe inzichten in 
verschillende aspecten van de behandeling van IBD, welke besproken worden in hoofdstuk 
8. De beschreven rol van autofagie in het ontstaan van CD en de inductie van regulatoire 
macrophagen door infliximab en infliximab/azathioprine combinatie therapie, kunnen lei-
den tot nieuwe aangrijpingspunten in de behandeling. Tevens is het risico op maligne lym-
foom bij de IBD-patienten in kaart gebracht; welke in het algemeen niet verhoogd is maar 
in bepaalde leeftijdsgroepen toch moet leiden tot awareness. Tot slot is de experimentele 
behandeling met MSCs haalbaar en veilig gebleken, hetgeen aanleiding geeft tot verder 
onderzoek naar de effectiviteit van MSCs in de behandeling van CD. 
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